{
    "questions": [
        {
            "body": "Can sorafenib activate AMPK?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23963659",
                "http://www.ncbi.nlm.nih.gov/pubmed/25080865",
                "http://www.ncbi.nlm.nih.gov/pubmed/25349646"
            ],
            "ideal_answer": [
                "Sorafenib induces persisten AMPK activation"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4243524",
                "http://www.biosemantics.org/jochem#4243524",
                "http://amigo.geneontology.org/amigo/term/GO:0031588"
            ],
            "type": "yesno",
            "id": "56c8318f5795f9a73e00000f",
            "snippets": [
                {
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 452,
                    "text": "Here, we identify sorafenib as an activator of AMP-activated protein kinase (AMPK), in a manner that involves either upstream LKB1 or CAMKK2. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25080865",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1271,
                    "text": "Persistent activation of AMPK by sorafenib finally led to the impairment of glucose metabolism both in MCF-7 and SKBR3 cells as well as in the highly glycolytic MDA-MB-231 cells, resulting in cell death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963659",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 450,
                    "text": "Here, we identify sorafenib as an activator of AMP-activated protein kinase (AMPK), in a manner that involves either upstream LKB1 or CAMKK2",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25080865",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25080865",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1069,
                    "offsetInEndSection": 1396,
                    "text": "Persistent activation of AMPK by sorafenib finally led to the impairment of glucose metabolism both in MCF-7 and SKBR3 cells as well as in the highly glycolytic MDA-MB-231 cells, resulting in cell death. This previously unrecognized long-term effect of sorafenib was mediated by AMPK-dependent inhibition of the mTORC1 pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963659",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is olaparib effective for prostate cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23847380",
                "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                "http://www.ncbi.nlm.nih.gov/pubmed/25616434",
                "http://www.ncbi.nlm.nih.gov/pubmed/25583815",
                "http://www.ncbi.nlm.nih.gov/pubmed/24789362",
                "http://www.ncbi.nlm.nih.gov/pubmed/24225019",
                "http://www.ncbi.nlm.nih.gov/pubmed/25127709",
                "http://www.ncbi.nlm.nih.gov/pubmed/25366685"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0106149",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0090893",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0106148",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0091054",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0290426",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0290427",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0290428",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0290425",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7786660",
                    "o": "D011471"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0667486",
                    "o": "D011471"
                }
            ],
            "ideal_answer": [
                "Yes, olaparib was shown to be effective for treatment of prostate cancer. Olaparib led to stable disease or tumor regressions of prostate cancer patients.",
                "Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:10283",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011471",
                "http://www.disease-ontology.org/api/metadata/DOID:10286"
            ],
            "type": "yesno",
            "id": "56c1f01eef6e394741000046",
            "snippets": [
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 496,
                    "text": "We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.METHODS: We conducted a phase 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2035,
                    "offsetInEndSection": 2244,
                    "text": "CONCLUSIONS: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 768,
                    "text": " In addition, phase III trials in breast, gastric and pancreatic cancer are underway/planned, and phase I/II investigation is being conducted in other malignancies, including prostate cancer, non-small cell lung cancer, Ewing's sarcoma and advanced cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616434",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in BRCA1 or BRCA2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25583815",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 647,
                    "text": "Eligibility included ovarian cancer resistant to prior platinum; breast cancer with \u2265 three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 1427,
                    "text": "The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, respectively. Stable disease \u2265 8 weeks was observed in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, respectively. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 1301,
                    "text": "It is increasingly clear that there are molecularly distinct subtypes of various common cancers, with different therapeutic approaches required for each subtype, for example, the use of the monoclonal antibodies (trastuzumab and cetuximab) in HER2-positive breast cancer and wild-type KRAS colorectal cancer; tyrosine kinase inhibitors (imatinib, gefitinib, erlotinib and crizotinib) in chronic myeloid leukaemia, gastrointestinal stromal tumours and non-small-cell lung cancer and intracellular agents (vemurafenib and olaparib) in metastatic malignant melanoma and ovarian, breast and prostate cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24789362",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 703,
                    "text": "Olaparib, one of the most studied PARPis, has demonstrated activity in BRCA1/2(MUT+) and BRCA-like sporadic ovarian and breast cancers, and looks promising in prostate and pancreatic cancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225019",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 828,
                    "text": "Prostate cancer cells cotreated with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) and the PARPi, olaparib, demonstrated a synergistic decrease in cell viability compared with single-agent treatment (combination index<0.9), whereas normal prostatic cells did not.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2035,
                    "offsetInEndSection": 2243,
                    "text": "CONCLUSIONS: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 704,
                    "text": "Olaparib, one of the most studied PARPis, has demonstrated activity in BRCA1/2(MUT+) and BRCA-like sporadic ovarian and breast cancers, and looks promising in prostate and pancreatic cancers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24225019",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 62,
                    "text": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 1093,
                    "text": "Prostate cancer cells cotreated with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) and the PARPi, olaparib, demonstrated a synergistic decrease in cell viability compared with single-agent treatment (combination index < 0.9), whereas normal prostatic cells did not.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 501,
                    "text": "We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 303,
                    "text": "A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23847380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 496,
                    "text": "BACKGROUND: Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.METHODS: We conducted a phase 2 trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "text": "Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1398,
                    "offsetInEndSection": 1646,
                    "text": "Silencing RAD51 sensitized prostate cancer cells to SAHA and olaparib alone. Collectively, cotreatment with HDACi and PARPi downregulated HR-related protein expression and concomitantly increased DNA damage, resulting in prostate cancer cell death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 829,
                    "text": "Prostate cancer cells cotreated with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) and the PARPi, olaparib, demonstrated a synergistic decrease in cell viability compared with single-agent treatment (combination index<0.9), whereas normal prostatic cells did not. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1809,
                    "offsetInEndSection": 2244,
                    "text": "The specificity of the biomarker suite was 94%. Anemia (in 10 of the 50 patients [20%]) and fatigue (in 6 [12%]) were the most common grade 3 or 4 adverse events, findings that are consistent with previous studies of olaparib.CONCLUSIONS: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26510020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 822,
                    "text": "Prostate cancer cells cotreated with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA) and the PARPi, olaparib, demonstrated a synergistic decrease in cell viability compared with single-agent treatment (combination index &lt; 0.9), whereas normal prostatic cells did not.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25127709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 768,
                    "text": "In addition, phase III trials in breast, gastric and pancreatic cancer are underway/planned, and phase I/II investigation is being conducted in other malignancies, including prostate cancer, non-small cell lung cancer, Ewing's sarcoma and advanced cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25616434",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is vorinostat effective for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29016887",
                "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                "http://www.ncbi.nlm.nih.gov/pubmed/22923449",
                "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                "http://www.ncbi.nlm.nih.gov/pubmed/29133513",
                "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                "http://www.ncbi.nlm.nih.gov/pubmed/22028388"
            ],
            "ideal_answer": [
                "No. Although vorinostat is well tolerated it does not improve survival of glioblastoma patients."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5a7615af83b0d9ea6600001f",
            "snippets": [
                {
                    "offsetInBeginSection": 1630,
                    "offsetInEndSection": 1906,
                    "text": "Conclusions: Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma. Although the primary efficacy endpoint was not met, vorinostat sensitivity and resistance signatures could facilitate patient selection in future trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29016887",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "LESSONS LEARNED: Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29133513",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1772,
                    "offsetInEndSection": 1961,
                    "text": "CONCLUSION: Combination treatment of BEV and VOR was well tolerated. This combination therapy for this study population did not improve PFS6 or median OS when compared with BEV monotherapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29133513",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 1042,
                    "text": "We present two patients with glioblastoma multiforme who developed severe hemolytic anemia shortly after initiating therapy with vorinostat, a pan-active histone deacetylase inhibitor, while on prophylactic dapsone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24576944",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1289,
                    "text": "Vorinostat is the most advanced HDAC inhibitor that entered clinical trials in glioblastoma, showing activity in recurrent disease. Multiple phase II trials with vorinostat in combination with targeted agents, temozolomide and radiotherapy are currently recruiting. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838514",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1601,
                    "text": ". On the basis of the results of this phase II study, further evaluation of the vorinostat-bortezomib combination in GBM patients in this dose and schedule is not recommended.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22090453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1283,
                    "offsetInEndSection": 1552,
                    "text": "ith the increased toxicities associated with CPT-11 coupled with its unclear clinical significance, investigating the efficacy of vorinostat combined with bevacizumab alone may represent a more promising strategy to evaluate in the context of a phase II clinical trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22028388",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1637,
                    "text": "CONCLUSION: Vorinostat in combination with temozolomide is well tolerated in patients with HGG. A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22923449",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there evidence for somatic mosaicism in Tuberous Sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9361032",
                "http://www.ncbi.nlm.nih.gov/pubmed/16237225"
            ],
            "ideal_answer": [
                "Yes, somatic mosaicism in Tuberous Sclerosis has been documented with the use of mutation identification, and subsequent linkage analysis in the affected families. In a large family with both parents unaffected, 3 affected children and 5 unaffected siblings, a 4 bp insertion in TSC2 gene was shown to be inherited from the mother."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033596",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009030",
                "http://www.disease-ontology.org/api/metadata/DOID:13515",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014402",
                "http://www.uniprot.org/uniprot/TSC1_HUMAN",
                "http://www.biosemantics.org/jochem#4266396",
                "http://www.uniprot.org/uniprot/TSC2_HUMAN"
            ],
            "type": "yesno",
            "id": "53177803b166e2b80600000e",
            "snippets": [
                {
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 330,
                    "text": "There are several case reports of solitary SEGA without any other manifestations of TSC. Usually these cases are thought to be forme fruste of TSC due to somatic mosaicism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16237225",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9361032",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1297,
                    "offsetInEndSection": 1559,
                    "text": "This is the first case of germline mosaicism in tuberous sclerosis proven by molecular genetic analysis and also the first example of female germline mosaicism for a characterized autosomal dominant gene mutation apparently not associated with somatic mosaicism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9361032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 560,
                    "offsetInEndSection": 1296,
                    "text": "Mutation screening by RT-PCR and direct sequencing of the TSC2 gene identified a 4 bp insertion TACT following nucleotide 2077 in exon 18 which was present in the three affected children but not in five unaffected siblings or the parents. This mutation would cause a frameshift and premature termination at codon 703. Absence of the mutation in lymphocyte DNA from the parents was consistent with germline mosaicism and this was confirmed by our finding of identical chromosome 16 haplotypes in affected and unaffected siblings, providing unequivocal evidence of two different cell lines in the gametes. Molecular analysis of the TSC2 alleles present in the affected subjects showed that the mutation had been inherited from the mother.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9361032",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is dupilumab effective for treatment of asthma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27334730",
                "http://www.ncbi.nlm.nih.gov/pubmed/29355679",
                "http://www.ncbi.nlm.nih.gov/pubmed/29782217",
                "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                "http://www.ncbi.nlm.nih.gov/pubmed/28979129",
                "http://www.ncbi.nlm.nih.gov/pubmed/28547386",
                "http://www.ncbi.nlm.nih.gov/pubmed/30167841",
                "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
                "http://www.ncbi.nlm.nih.gov/pubmed/29036019",
                "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
                "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
                "http://www.ncbi.nlm.nih.gov/pubmed/23688323",
                "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
                "http://www.ncbi.nlm.nih.gov/pubmed/29939132",
                "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
                "http://www.ncbi.nlm.nih.gov/pubmed/29782224",
                "http://www.ncbi.nlm.nih.gov/pubmed/28478972"
            ],
            "ideal_answer": [
                "Yes, dupilumab is effective for treatment of asthma. It works by simultaneous targeting of both IL-4 and IL-13 by blocking IL-4 receptor \u03b1."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c6b7bee7c78d6947100002a",
            "snippets": [
                {
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 773,
                    "text": "The appropriate use of these biologics, and of those in development (e.g., benralizumab and dupilumab), should be aided by further understanding of asthma phenotypes and endotypes, utilizing appropriate biomarkers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29059087",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 890,
                    "text": "Simultaneous targeting of both IL-4 and IL-13 by blocking IL-4 receptor \u03b1 using dupilumab has yielded more consistent results in reducing asthma exacerbations and improving lung function, especially in patients with increased blood eosinophils.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036019",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 452,
                    "text": "In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting \u03b22-agonists.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355679",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1705,
                    "offsetInEndSection": 1856,
                    "text": "CONCLUSIONS: Dupilumab 300\u00a0mg q2w significantly improved AR-associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid PAR.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355679",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 771,
                    "text": "Small molecules (e.g. ligustrazine and SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, dupilumab) are being considered as novel agents for the pharmacotherapy of asthma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28971769",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29782217",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2062,
                    "offsetInEndSection": 2267,
                    "text": "CONCLUSIONS: In this trial, patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29782217",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "text": "Dupilumab for the treatment of asthma.Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 383,
                    "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 869,
                    "text": "If confirmed, efficacy of dupilumab in both eosinophilic and non-eosinophilic severe asthma phenotype might represent an advantage over approved biologics for asthma, including omalizumab, mepolizumab, and reslizumab.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1127,
                    "offsetInEndSection": 1391,
                    "text": "In this review, we focused on IL-4 and IL-13, as these interleukins are considered to play a key role in the pathophysiology of asthma, and on dupilumab, an anti-IL-4 receptor human mAb, as a forthcoming treatment for uncontrolled severe asthma in the near future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28979129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 724,
                    "offsetInEndSection": 956,
                    "text": "Expert opinion: Supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1462,
                    "offsetInEndSection": 1570,
                    "text": "All drugs decreased asthma exacerbations but the results were only significant for reslizumab and dupilumab.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30167841",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1158,
                    "text": "Anti-IL-4 and IL-13 agents (dupilumab, lebrikizumab, and tralokinumab) which block different Th-2 inflammatory pathways and agents targeting the Th-17 inflammatory pathway in severe refractory asthma are under development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27334730",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 38,
                    "text": "Dupilumab for the treatment of asthma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 872,
                    "text": "In addition, dupilumab is currently under phase\u00a0III development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28547386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "BACKGROUND\nDupilumab (an anti-interleukin-4-receptor-\u03b1 monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28478972",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 40,
                    "text": "Dupilumab: a novel treatment for asthma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 38,
                    "text": "Dupilumab for the treatment of asthma.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 798,
                    "offsetInEndSection": 1062,
                    "text": "The efficacy and safety profile of dupilumab in the treatment of allergic diseases has been tested for more than 10 years in a variety of large clinical trials in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29939132",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 495,
                    "text": "Areas covered: Pathophysiological role of IL-4 and IL-13 in asthma; mechanism of action of dupilumab; pharmacology of IL-4 receptor; phase I and phase II studies with dupilumab; regulatory affairs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 651,
                    "text": "Expert opinion: Patients with severe asthma who are not sufficiently controlled with standard-of-care represent the target asthma population for dupilumab.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1952,
                    "offsetInEndSection": 2147,
                    "text": "CONCLUSIONS In patients with glucocorticoid-dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the FEV1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29782224",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1832,
                    "offsetInEndSection": 2207,
                    "text": "CONCLUSIONS In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688323",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 672,
                    "text": "Expert opinion: Patients with severe asthma who are not sufficiently controlled with standard-of-care represent the target asthma population for dupilumab.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28085503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 391,
                    "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 977,
                    "text": "Expert opinion: Supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28990423",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 242,
                    "offsetInEndSection": 370,
                    "text": "Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26428945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 850,
                    "offsetInEndSection": 1133,
                    "text": "A recent trial showed that in patients with difficult-to-control asthma, dupilumab can markedly decrease asthma exacerbations and improve respiratory symptoms and lung function; these effects were paralleled by significant reductions in T-helper 2-associated inflammatory biomarkers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25214796",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Baloxavir effective for influenza?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30395523",
                "http://www.ncbi.nlm.nih.gov/pubmed/30316915",
                "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
                "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
                "http://www.ncbi.nlm.nih.gov/pubmed/30476172",
                "http://www.ncbi.nlm.nih.gov/pubmed/30396860",
                "http://www.ncbi.nlm.nih.gov/pubmed/30203386",
                "http://www.ncbi.nlm.nih.gov/pubmed/29941893"
            ],
            "ideal_answer": [
                "Yes. Baloxavir is approved for influenza A or B virus infections."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c58a74e86df2b917400000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 358,
                    "text": "Baloxavir marboxil (Xofluza\u2122; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 595,
                    "text": "This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "Baloxavir acid (BXA), derived from the prodrug baloxavir marboxil (BXM), potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29941893",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29941893",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "text": "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "text": "BACKGROUND: Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1917,
                    "offsetInEndSection": 2209,
                    "text": "CONCLUSIONS: Single-dose baloxavir was without evident safety concerns, was superior to placebo in alleviating influenza symptoms, and was superior to both oseltamivir and placebo in reducing the viral load 1 day after initiation of the trial regimen in patients with uncomplicated influenza.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184455",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 469,
                    "text": "A single oral dose of baloxavir is usually well tolerated; it hastens alleviation of influenza symptoms and shortens the duration of viral shedding.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 156,
                    "text": "Japan was the first country to approve baloxavir marboxil as a treatment for influenza.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30396860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 599,
                    "text": "This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 357,
                    "text": "In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29623652",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Dexmecamylamine effective for depression?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
                "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
                "http://www.ncbi.nlm.nih.gov/pubmed/25514064"
            ],
            "ideal_answer": [
                "No. Antidepressant effect of Dexmecamylamine (TC-5214) was not observed in clinical trials."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e4b62946d0a277941000024",
            "snippets": [
                {
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1277,
                    "text": "At treatment end, no significant differences were seen for change in MADRS total score with TC-5214 versus placebo. Furthermore, there were no significant differences in any of the secondary endpoints. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1389,
                    "offsetInEndSection": 1700,
                    "text": "In these 2 flexibly-dosed studies, no specific therapeutic effects were observed for TC-5214 (1-4 mg BID) adjunct to antidepressant in the primary endpoint or any secondary endpoint; however, TC-5214 was generally well tolerated. In conclusion, no antidepressant effect of TC-5214 was observed in these studies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1718,
                    "offsetInEndSection": 1819,
                    "text": "No notable differences were observed between dexmecamylamine and placebo for any secondary end point.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514064",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "TC-5214 ( dexmecamylamine ) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder ( MDD ) and is currently being evaluated by Targacept as a treatment for overactive bladder . ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "TC-5214 (dexmecamylamine) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder (MDD) and is currently being evaluated by Targacept as a treatment for overactive bladder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24408516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1191,
                    "text": "At treatment end, no significant differences were seen for change in MADRS total score with TC-5214 versus placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1389,
                    "offsetInEndSection": 1619,
                    "text": "In these 2 flexibly-dosed studies, no specific therapeutic effects were observed for TC-5214 (1-4 mg BID) adjunct to antidepressant in the primary endpoint or any secondary endpoint; however, TC-5214 was generally well tolerated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24507016",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is corpus callosum involved in the Mowat\u2013Wilson syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17958891",
                "http://www.ncbi.nlm.nih.gov/pubmed/23531534",
                "http://www.ncbi.nlm.nih.gov/pubmed/19842203",
                "http://www.ncbi.nlm.nih.gov/pubmed/15065106",
                "http://www.ncbi.nlm.nih.gov/pubmed/17203459",
                "http://www.ncbi.nlm.nih.gov/pubmed/23523603",
                "http://www.ncbi.nlm.nih.gov/pubmed/23243526",
                "http://www.ncbi.nlm.nih.gov/pubmed/12746390",
                "http://www.ncbi.nlm.nih.gov/pubmed/23427518",
                "http://www.ncbi.nlm.nih.gov/pubmed/23322667",
                "http://www.ncbi.nlm.nih.gov/pubmed/16053902",
                "http://www.ncbi.nlm.nih.gov/pubmed/22486326",
                "http://www.ncbi.nlm.nih.gov/pubmed/19215041",
                "http://www.ncbi.nlm.nih.gov/pubmed/20301585",
                "http://www.ncbi.nlm.nih.gov/pubmed/22246645",
                "http://www.ncbi.nlm.nih.gov/pubmed/20428734",
                "http://www.ncbi.nlm.nih.gov/pubmed/24282181",
                "http://www.ncbi.nlm.nih.gov/pubmed/17103451",
                "http://www.ncbi.nlm.nih.gov/pubmed/21957361",
                "http://www.ncbi.nlm.nih.gov/pubmed/18792984",
                "http://www.ncbi.nlm.nih.gov/pubmed/21893004",
                "http://www.ncbi.nlm.nih.gov/pubmed/24401652",
                "http://www.ncbi.nlm.nih.gov/pubmed/23466526",
                "http://www.ncbi.nlm.nih.gov/pubmed/14681759",
                "http://www.ncbi.nlm.nih.gov/pubmed/16088920"
            ],
            "ideal_answer": [
                "Yes, agenesis of the corpus callosum is common patients with Mowat\u2013Wilson syndrome. Other characteristic features of Mowat\u2013Wilson syndrome include typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, and eye defects."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003337",
                "http://www.disease-ontology.org/api/metadata/DOID:225"
            ],
            "type": "yesno",
            "id": "5314896adae131f847000001",
            "snippets": [
                {
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 430,
                    "text": " The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24282181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Mowat-Wilson syndrome in a fetus with antenatal diagnosis of short corpus callosum: advocacy for standard autopsy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523603",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 375,
                    "text": "It is mainly characterized by moderate-to-severe intellectual disability, epilepsy, facial dysmorphism and various malformations including Hirschsprung disease and corpus callosum anomalies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 614,
                    "text": "The association of a corpus callosum hypoplasia with a histological Hirschsprung disease and a typical facial gestalt allowed the guiding of genetic testing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23523603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 290,
                    "text": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "Mowat-Wilson syndrome (MWS) is characterized by severe mental retardation with seizures, specific facial dysmorphism, Hirschsprung disease, anomalies of the corpus callosum, and genitourinary and cardiac malformations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23427518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 284,
                    "text": "Mowat-Wilson syndrome (MWS) is a genetic disease caused by heterozygous mutations or deletions of the ZEB2 gene and is characterized by distinctive facial features, epilepsy, moderate to severe intellectual disability, corpus callosum abnormalities and other congenital malformations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23322667",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 491,
                    "text": "The striking facial phenotype in addition to other features such as severely impaired speech, hypotonia, microcephaly, short stature, seizures, corpus callosum agenesis, congenital heart defects, hypospadias, and Hirschsprung disease are particularly important clues for the initial clinical diagnosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23243526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "text": "Mowat-Wilson syndrome is a genetic disorder characterized by a distinct facial appearance, moderate-to-severe mental retardation, microcephaly, agenesis of the corpus callosum, Hirschsprung disease, congenital heart disease, and genital anomalies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22486326",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 372,
                    "text": "It is characterized by a distinctive facial appearance in association with intellectual disability (ID) and variable other features including agenesis of the corpus callosum, seizures, congenital heart defects, microcephaly, short stature, hypotonia, and Hirschsprung disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246645",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "text": "Mowat-Wilson syndrome (MWS) is an autosomal dominant intellectual disability syndrome characterised by unique facial features and congenital anomalies such as Hirschsprung disease, congenital heart defects, corpus callosum agenesis and urinary tract anomalies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21893004",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 294,
                    "text": "Mowat-Wilson syndrome (MWS) is a recently delineated mental retardation; a multiple congenital anomaly syndrome characterised by a typical facial gestalt, Hirschsprung disease or severe constipation, genitourinary anomaly, congenital heart defects, agenesis of corpus callosum and eye defects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20428734",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 374,
                    "text": "Agenesis or hypogenesis of the corpus callosum.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301585",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 396,
                    "text": "The anomalies may include Hirschsprung disease, heart defects, structural eye anomalies including microphthalmia, agenesis of the corpus callosum, and urogenital anomalies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19842203",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 410,
                    "text": "Mowat-Wilson syndrome (MWS; OMIM #235730) is a genetic condition caused by heterozygous mutations or deletions of the ZEB2 gene, and characterized by typical face, moderate-to-severe mental retardation, epilepsy, Hirschsprung disease, and multiple congenital anomalies, including genital anomalies (particularly hypospadias in males), congenital heart defects, agenesis of the corpus callosum, and eye defects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19215041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1035,
                    "offsetInEndSection": 1418,
                    "text": "In 11 of the 28 patients with ACC, the following diagnoses could be established: Mowat-Wilson syndrome (n = 2), Walker-Warburg syndrome (n = 1), oro-facial-digital syndrome type 1 (n = 1), and chromosomal rearrangements (n = 7), including a patient with an apparently balanced reciprocal translocation, which led to the disruption and a predicted loss of function in the FOXG1B gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18792984",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 756,
                    "text": "Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly syndrome characterized by a distinct facial phenotype (high forehead, frontal bossing, large eyebrows, medially flaring and sparse in the middle part, hypertelorism, deep set but large eyes, large and uplifted ear lobes, with a central depression, saddle nose with prominent rounded nasal tip, prominent columella, open mouth, with M-shaped upper lip, frequent smiling, and a prominent but narrow and triangular pointed chin), moderate-to-severe intellectual deficiency, epilepsy and variable congenital malformations including Hirschsprung disease (HSCR), genitourinary anomalies (in particular hypospadias in males), congenital heart defects, agenesis of the corpus callosum and eye anomalies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17958891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 305,
                    "text": "Mowat-Wilson syndrome is a mental retardation-multiple congenital anomaly syndrome characterized by a typical facies, developmental delay, epilepsy, and variable congenital malformations, including Hirschsprung disease, urogenital anomalies, congenital heart disease, and agenesis of the corpus callosum. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21957361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 341,
                    "text": "Mowat-Wilson syndrome (MWS) is a recently delineated mental retardation (MR)-multiple congenital anomaly syndrome, characterized by typical facies, severe MR, epilepsy, and variable congenital malformations, including Hirschsprung disease (HSCR), genital anomalies, congenital heart disease (CHD), and agenesis of the corpus callosum (ACC). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17203459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 858,
                    "offsetInEndSection": 1342,
                    "text": "Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17103451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 309,
                    "text": "Mowat-Wilson syndrome (MWS) is a mental retardation syndrome associated with distinctive facial features, microcephaly, epilepsy, and a variable spectrum of congenital anomalies, including Hirschsprung disease (HSCR), agenesis of the corpus callosum, genitourinary abnormalities, and congenital heart disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16088920",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 377,
                    "text": "ACC is found in 40% of the cases of Mowat-Wilson syndrome (MWS), a polytopic embryonic defect including a distinctive facial gestalt, severe mental retardation, epilepsy and postnatal microcephaly as constant features. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15065106",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1301,
                    "offsetInEndSection": 1450,
                    "text": "However, analysis of MWS should be considered in the differential diagnosis of ACC, especially when the facial features raise the possibility of MWS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15065106",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Frameshift mutation of the zinc finger homeo box 1 B gene in syndromic corpus callosum agenesis (Mowat-Wilson syndrome).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681759",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "We report a girl who had Hirschsprung disease in association with distinct facial appearance, microcephaly, agenesis of the corpus callosum and mental retardation (Mowat-Wilson syndrome).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14681759",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 470,
                    "text": "Congenital anomalies, including Hirschsprung disease (HSCR), congenital heart disease, hypospadias, genitourinary anomalies, agenesis of the corpus callosum, and short stature are common. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12746390",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the protein ABCG2 transmembrane?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30021380",
                "http://www.ncbi.nlm.nih.gov/pubmed/29514827",
                "http://www.ncbi.nlm.nih.gov/pubmed/29407974"
            ],
            "ideal_answer": [
                "Yes,\nthe protein ABCG2 is transmembrane."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e5b60adb761aafe0900000b",
            "snippets": [
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 74,
                    "text": "the transmembrane ATP-binding cassette transporter G2",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29407974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "ATP-binding cassette (ABC) transporters are transmembrane efflux transporters mediating the extrusion of an array of substrates ranging from amino acids and lipids to xenobiotics, and many therapeutic compounds, including anticancer drugs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29514827",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "The ATP-binding cassette (ABC) transporter family is a large class of ATP energy-dependent transmembrane proteins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021380",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is subacute sclerosing panencephalitis caused by the Measles vaccine?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28750182",
                "http://www.ncbi.nlm.nih.gov/pubmed/26765654",
                "http://www.ncbi.nlm.nih.gov/pubmed/28116334",
                "http://www.ncbi.nlm.nih.gov/pubmed/21311432",
                "http://www.ncbi.nlm.nih.gov/pubmed/15464644",
                "http://www.ncbi.nlm.nih.gov/pubmed/26587021",
                "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                "http://www.ncbi.nlm.nih.gov/pubmed/29062617",
                "http://www.ncbi.nlm.nih.gov/pubmed/23188587",
                "http://www.ncbi.nlm.nih.gov/pubmed/2019970",
                "http://www.ncbi.nlm.nih.gov/pubmed/27777245",
                "http://www.ncbi.nlm.nih.gov/pubmed/25761293",
                "http://www.ncbi.nlm.nih.gov/pubmed/29112137",
                "http://www.ncbi.nlm.nih.gov/pubmed/1468866",
                "http://www.ncbi.nlm.nih.gov/pubmed/6685828",
                "http://www.ncbi.nlm.nih.gov/pubmed/15566859",
                "http://www.ncbi.nlm.nih.gov/pubmed/2807674",
                "http://www.ncbi.nlm.nih.gov/pubmed/15246492",
                "http://www.ncbi.nlm.nih.gov/pubmed/21245918",
                "http://www.ncbi.nlm.nih.gov/pubmed/2774513",
                "http://www.ncbi.nlm.nih.gov/pubmed/6879001",
                "http://www.ncbi.nlm.nih.gov/pubmed/18037676",
                "http://www.ncbi.nlm.nih.gov/pubmed/22408143",
                "http://www.ncbi.nlm.nih.gov/pubmed/27634625",
                "http://www.ncbi.nlm.nih.gov/pubmed/25802788",
                "http://www.ncbi.nlm.nih.gov/pubmed/11545478",
                "http://www.ncbi.nlm.nih.gov/pubmed/28387784",
                "http://www.ncbi.nlm.nih.gov/pubmed/15557053"
            ],
            "ideal_answer": [
                "Subacute sclerosing panencephalitis is caused by the Measles and can be prevented by the measles vaccine.",
                "Subacute sclerosing panencephalitis (SSPE) is a potentially fatal complication of measles. "
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D008458",
                "http://www.disease-ontology.org/api/metadata/DOID:8970",
                "https://meshb.nlm.nih.gov/record/ui?ui=D013344",
                "https://meshb.nlm.nih.gov/record/ui?ui=D022542",
                "https://meshb.nlm.nih.gov/record/ui?ui=D008457"
            ],
            "type": "yesno",
            "id": "5aa3fa73d6d6b54f79000008",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 103,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a potentially fatal complication of measles. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28116334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 155,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a fatal complication of measles. We reviewed California cases from 1998-2015 to understand risk f",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28387784",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Subacute sclerosing panencephalitis should be eliminated by measles vaccination",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28750182",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 974,
                    "offsetInEndSection": 1102,
                    "text": "The mean interval between measles infection and onset of subacute sclerosing panencephalitis was 6.5 years (range = 3-11 years).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15246492",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1231,
                    "offsetInEndSection": 1429,
                    "text": "Active surveillance of subacute sclerosing panencephalitis for those with measles infection during the 1988 outbreak is necessary to conduct multicenter drug trials for this devastating disease.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15246492",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1230,
                    "text": "There has been an increasing trend of subacute sclerosing panencephalitis in southern China after the measles outbreak in 1988.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15246492",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 532,
                    "text": "The prevalence rate of subacute sclerosing panencephalitis in Hong Kong and Macau in 2002 was 1 per million total population or 5.5 per million children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15246492",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 825,
                    "text": "Because a positive correlation was found between the prevalence of measles and the onset of subacute sclerosing panencephalitis, particularly among children infected at an early age, it is vital to eradicate measles infection by vaccination.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22408143",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Incidence of subacute sclerosing panencephalitis following measles and measles vaccination in Japan.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2807674",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "UNLABELLED Subacute sclerosing panencephalitis (SSPE), in the majority of cases, is caused by the wild measles virus, although there are some reports relating SSPE to vaccination.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurodegenerative disease caused by the measles (rubeola) virus and is most often seen in children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2019970",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 888,
                    "text": "There was no indication that measles vaccine can induce SSPE.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6685828",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Subacute Sclerosing Panencephalitis (SSPE), a rare lethal disease of children and young adults due to persistence of measles virus (MeV) in the brain, is caused by wild type (wt) MeV.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587021",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurological disorder of childhood and early adolescence caused by persistent defective measles virus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21311432",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a devastating disease of the central nervous system (CNS) caused by persistent mutant measles virus infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25802788",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Subacute sclerosing panencephalitis (SSPE) caused by persistent defective measles virus strains, is a progressive neurological disorder of children and adolescents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23188587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Subacute sclerosing panencephalitis (SSPE), in the majority of cases, is caused by the wild measles virus, although there are some reports relating SSPE to vaccination.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Measles can persist in the central nervous system and cause subacute sclerosing panencephalitis (SSPE), a progressive disease that is almost always fatal.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6879001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1117,
                    "offsetInEndSection": 1198,
                    "text": "However, because of the median 8-year interval between measles and onset of SSPE,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1468866",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1261,
                    "text": "The prevention of endemic circulation of measles virus in England and Wales through the high coverage achieved with MMR vaccine, together with the measles/rubella vaccination campaign of 1994, has resulted in the near elimination of SSPE.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15557053",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 1276,
                    "text": "We applied the polymerase chain reaction (PCR) to detect the measles virus genome in specimens from a 12-year-old boy with SSPE who had received measles vaccine 10 years before and had no history of apparent natural measles. The oligonucleotide primers for PCR were prepared based on the nucleotide sequence of the F and NP genes of the measles virus Edmonston strain.RESULTS: F and NP genes were detected in both the cerebrospinal fluid and peripheral blood lymphocytes. Nucleotide and deduced amino acid sequence analysis of the F gene showed that the patient's virus was different from that of the vaccine strain. Judging from these results, it was likely that the SSPE-associated strain in this case was derived from the wild-type rather than the vaccine strain",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15566859",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 125,
                    "text": "subacute sclerosing panencephalitis (SSPE) is a late, rare and usually fatal complication of measles infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21245918",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 130,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a chronic central nervous (CNS) system infection caused by measles virus",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11545478",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1745,
                    "offsetInEndSection": 1832,
                    "text": " Epidemiological and virological data suggest that measles vaccine does not cause SSPE.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18037676",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Subacute sclerosing panencephalitis, a rare, progressive, fatal central nervous system disease of children, is caused by measles virus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2774513",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "Subacute sclerosing panencephalitis is a form of chronic persistent measles encephalitis in childhood which rarely manifests after wild virus infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15464644",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Subacute sclerosing panencephalitis is a fatal infectious disease of childhood caused by persistence of the measles virus in the brain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27777245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 144,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a fatal encephalitis manifesting a number of years after a primary measles infection. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25761293",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a fatal complication of measles infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27634625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "In 2015, the Oregon Health Authority was notified of the death of a boy with subacute sclerosing panencephalitis (SSPE), a rare and fatal complication of measles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26765654",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a rare progressive neurological disorder of early adolescence caused by persistent infection of the measles virus, which remains prevalent worldwide despite an effective vaccine. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29112137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Subacute Sclerosing Panencephalitis (SSPE) is a debilitating disorder associated with the measles infection in childhood.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29062617",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Could plasmepsins be used as targets for developing anti-malaria drugs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12767832",
                "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
                "http://www.ncbi.nlm.nih.gov/pubmed/21334328",
                "http://www.ncbi.nlm.nih.gov/pubmed/11841219",
                "http://www.ncbi.nlm.nih.gov/pubmed/17727268",
                "http://www.ncbi.nlm.nih.gov/pubmed/16838300",
                "http://www.ncbi.nlm.nih.gov/pubmed/15181345",
                "http://www.ncbi.nlm.nih.gov/pubmed/19472268",
                "http://www.ncbi.nlm.nih.gov/pubmed/21136953",
                "http://www.ncbi.nlm.nih.gov/pubmed/14636976",
                "http://www.ncbi.nlm.nih.gov/pubmed/8816746",
                "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
                "http://www.ncbi.nlm.nih.gov/pubmed/24975562",
                "http://www.ncbi.nlm.nih.gov/pubmed/23466235",
                "http://www.ncbi.nlm.nih.gov/pubmed/16054370",
                "http://www.ncbi.nlm.nih.gov/pubmed/12435452",
                "http://www.ncbi.nlm.nih.gov/pubmed/16138859",
                "http://www.ncbi.nlm.nih.gov/pubmed/15011947",
                "http://www.ncbi.nlm.nih.gov/pubmed/25719272",
                "http://www.ncbi.nlm.nih.gov/pubmed/22242846",
                "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
                "http://www.ncbi.nlm.nih.gov/pubmed/20056606",
                "http://www.ncbi.nlm.nih.gov/pubmed/24468190",
                "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
                "http://www.ncbi.nlm.nih.gov/pubmed/19437467",
                "http://www.ncbi.nlm.nih.gov/pubmed/9561244",
                "http://www.ncbi.nlm.nih.gov/pubmed/21760810",
                "http://www.ncbi.nlm.nih.gov/pubmed/17585371",
                "http://www.ncbi.nlm.nih.gov/pubmed/24983235",
                "http://www.ncbi.nlm.nih.gov/pubmed/27718413",
                "http://www.ncbi.nlm.nih.gov/pubmed/21428877",
                "http://www.ncbi.nlm.nih.gov/pubmed/18442137"
            ],
            "ideal_answer": [
                "Yes, plasmepsins, which are essential Plasmodium proteases, could be highly promising anti-malarial drug targets."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000962",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015195",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008288",
                "http://www.disease-ontology.org/api/metadata/DOID:12365",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016780"
            ],
            "type": "yesno",
            "id": "58a6d89660087bc10a00002b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 274,
                    "text": "Given that the parasite needs the resulting amino acid building blocks for its growth and development, plasmepsins are an important antimalarial drug target. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25719272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 1056,
                    "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e. Plm I, II, IV and V. With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "text": "Plasmepsin V, an essential aspartyl protease of malaria parasites, has a key role in the export of effector proteins to parasite-infected erythrocytes. Consequently, it is an important drug target for the two most virulent malaria parasites of humans, Plasmodium falciparum and Plasmodium vivax.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 388,
                    "text": "Plasmepsin V (PmV) is an essential Plasmodium protease and a highly promising antimalarial target, which still lacks molecular characterization and drug-like inhibitors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1375,
                    "offsetInEndSection": 1503,
                    "text": "Our inhibitors act 'on-target', confirmed by cellular interference of PmV function and biochemical interaction with inhibitors. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1826,
                    "offsetInEndSection": 2191,
                    "text": "Our work disclosed novel pursuable drug design strategies for highly efficient PmV inhibition highlighting novel molecular elements necessary for picomolar activity against PmV. All the presented data are discussed in respect to human aspartic proteases and previously reported inhibitors, highlighting differences and proposing new strategies for drug development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26566224",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 458,
                    "text": "High binding likeness on antimalarial target plasmepsin was detected through molecular docking. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24975562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1303,
                    "text": "This provides the first direct evidence that PMV activity is essential for protein export in Plasmodium spp. and for parasite survival in human erythrocytes and validates PMV as an antimalarial drug target.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 310,
                    "text": "The export mechanism involves the Plasmodium export element (PEXEL), which is a cleavage site for the parasite protease, Plasmepsin V (PMV). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983235",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "Plasmepsin II (PM II) is an attractive target for anti-malaria drug discovery, which involves in host hemoglobin degradation in the acidic food vacuole.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23466235",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 480,
                    "text": "These methods are utilized to search for inhibitors of the aspartyl proteases, plasmepsin II and cathepsin D. Plasmepsin II, a protease found in the malaria parasite, hydrolyzes human hemoglobin, the nutrient source for the parasite and is a new target for anti-malaria therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9561244",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 1040,
                    "text": "Given recent advances in understanding the fundamental roles of the various plasmepsins, it is likely that the most effective antimalarial plasmepsin targets will be the non-digestive vacuole plasmepsins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets for developing drugs against malaria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19472268",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 274,
                    "text": "Therefore, the plasmepsins of malaria parasites have been recognized as attractive antimalarial drug targets.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21334328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 201,
                    "text": "As inhibition of plasmepsins leads to the parasite's death, these enzymes can be utilized as potential drug targets.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16138859",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 377,
                    "offsetInEndSection": 515,
                    "text": "falciparum plasmepsins II and IV make structure-based drug design of antimalarial compounds that focus on inhibiting plasmepsins possible.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 250,
                    "offsetInEndSection": 462,
                    "text": "The malarial parasite encodes two homologous aspartic proteases, plasmepsins I and II, which are essential components of its hemoglobin-degradation pathway and are novel targets for antimalarial drug development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8816746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1906,
                    "offsetInEndSection": 2052,
                    "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 155,
                    "offsetInEndSection": 345,
                    "text": "In P.falciparum, plasmepsins I, II, IV and HAP have been directly implicated in hemoglobin degradation during malaria infection, and are now considered targets for anti-malarial drug design.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12767832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1531,
                    "offsetInEndSection": 1743,
                    "text": "These results shed light on the role of V105 and T108 residues in plasmepsin specificities, and they should be useful in structure-based design of novel, selective inhibitors that may serve as antimalarial drugs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18442137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 245,
                    "text": "The aspartic proteases plasmepsins, whose inhibition leads to parasite death, are classified as targets for the design of potent drugs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21760810",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 818,
                    "offsetInEndSection": 994,
                    "text": "A large compound library of about 1 million chemical compounds was docked on 5 different targets of plasmepsins using two different docking software, namely FlexX and AutoDock.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17727268",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 281,
                    "text": "Plasmodium aspartic proteases known as plasmepsins play an important role on haemoglobin degradation and are being studied as drug targets for chemotherapy of malaria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14636976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 815,
                    "text": "Our study revealed about 100 parasite-coded gene products that included many known drug targets such as Pf hypoxanthine guanine phosphoribosyl transferase, Pf L-lactate dehydrogenase, and Plasmepsins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21136953",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 295,
                    "text": "The two aspartic proteases, plasmepsins I and II, from Plasmodium falciparum have recently emerged as potential targets.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16054370",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 303,
                    "text": "Plasmepsins are highly promising as drug targets, especially when combined with the inhibition of falcipains that are also involved in hemoglobin catabolism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17585371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 984,
                    "offsetInEndSection": 1133,
                    "text": "Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains (cysteine proteases) are highly promising antimalarial drug targets.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21428877",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 703,
                    "offsetInEndSection": 878,
                    "text": "The high sequence conservations between the plasmepsins from the isolates support the notion that the enzymes could be reliable targets for new antimalarial chemotherapeutics.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15181345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 652,
                    "offsetInEndSection": 877,
                    "text": "Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 469,
                    "offsetInEndSection": 651,
                    "text": "Plasmepsin, an aspartic protease, which is involved in the hemoglobin breakdown into smaller peptides emerged as a crucial target to develop new chemical entities to counter malaria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1160,
                    "offsetInEndSection": 1233,
                    "text": "were employed in order to develop new chemical entities targeting Plm II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 899,
                    "offsetInEndSection": 1055,
                    "text": "With the advancements in drug discovery, several computational and synthetic approaches were employed in order to develop novel inhibitors targeting Plm II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827401",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1906,
                    "offsetInEndSection": 2053,
                    "text": "vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 422,
                    "text": "We developed a potent inhibitor of plasmepsin V, called WEHI-842, which directly mimics the Plasmodium export element (PEXEL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26214367",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1768,
                    "offsetInEndSection": 1905,
                    "text": "In order to validate appropriate use of PM4 as potential anti-malarial drug target, studies on genetic and structural variations among P.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21382523",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 642,
                    "text": "Over the past decade, much effort has been placed towards developing plasmepsin inhibitors as antimalarial agents, particularly targeting the digestive vacuole.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242846",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a relationship between junctin and ryanodine receptors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19230141",
                "http://www.ncbi.nlm.nih.gov/pubmed/22025663",
                "http://www.ncbi.nlm.nih.gov/pubmed/24257462",
                "http://www.ncbi.nlm.nih.gov/pubmed/19448693",
                "http://www.ncbi.nlm.nih.gov/pubmed/11162129",
                "http://www.ncbi.nlm.nih.gov/pubmed/19398037"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400276",
                    "o": "C498842"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1454076",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400276"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400276",
                    "o": "Calsequestrin binding protein, rabbit"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1454076",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400589"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1454076",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400589"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400589",
                    "o": "Junctin protein, Oryctolagus cuniculus"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400589",
                    "o": "C498842"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400276",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400589",
                    "o": "MeSH"
                },
                {
                    "p": "http://purl.uniprot.org/core/sequence",
                    "s": "http://purl.uniprot.org/uniprot/Q12797",
                    "o": "http://purl.uniprot.org/isoforms/Q12797-4"
                },
                {
                    "p": "http://purl.uniprot.org/core/shortName",
                    "s": "http://linkedlifedata.com/resource/#_513132373937001E",
                    "o": "ASP beta-hydroxylase"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/isoforms/Q12797-4",
                    "o": "Junctin-2"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513132373937001E",
                    "o": "Aspartate beta-hydroxylase"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513132373937001D",
                    "o": "Aspartyl/asparaginyl beta-hydroxylase"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_513132373937001F",
                    "o": "Peptide-aspartate beta-dioxygenase"
                },
                {
                    "p": "http://purl.uniprot.org/core/sequence",
                    "s": "http://purl.uniprot.org/uniprot/Q12797",
                    "o": "http://purl.uniprot.org/isoforms/Q12797-3"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/isoforms/Q12797-3",
                    "o": "Cardiac junctin"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/isoforms/Q12797-3",
                    "o": "Junctin-1"
                },
                {
                    "p": "http://purl.uniprot.org/core/basedOn",
                    "s": "http://purl.uniprot.org/isoforms/Q12797-3",
                    "o": "http://purl.uniprot.org/isoforms/Q12797-1"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/isoforms/Q12797-1",
                    "o": "1"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6808855",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6808855",
                    "o": "aspartate beta-hydroxylase protein, human"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1432044",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6983105"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1432044",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6812955"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1432044",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6808855"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1432044",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6819849"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6986254",
                    "o": "junctin protein, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6983105",
                    "o": "calsequestrin binding protein, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6819849",
                    "o": "ASPH protein, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1432044",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6986254"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6812955",
                    "o": "junctate protein, human"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6812955",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6819849",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6983105",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6986254",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6808855",
                    "o": "C419389"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6812955",
                    "o": "C419389"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6819849",
                    "o": "C419389"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6983105",
                    "o": "C419389"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6986254",
                    "o": "C419389"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400212",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401237",
                    "o": "aspartate-beta-hydroxylase protein, mouse"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8401402"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400590",
                    "o": "Junctin protein, mouse"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400271"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400212",
                    "o": "Asph protein, mouse"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400271",
                    "o": "CSQ binding protein, mouse"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401262",
                    "o": "calsequestrin binding protein, mouse"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400590"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401402",
                    "o": "junctate protein, mouse"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8401237"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400590"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8401262"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400212"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400271",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400590",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401237",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401262",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401402",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400212",
                    "o": "C498841"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400271",
                    "o": "C498841"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400590",
                    "o": "C498841"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401237",
                    "o": "C498841"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401262",
                    "o": "C498841"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8401402",
                    "o": "C498841"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11655911",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000929",
                    "o": "JUNCTIN"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11986511"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11957838",
                    "o": "ASPARTYL/ASPARAGINYL-BETA-HYDROXYLASE"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12000927"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11675087"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12000929"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16688957"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16700759",
                    "o": "junctate"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11703532",
                    "o": "CASQ2BP1"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12014935",
                    "o": "BAH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16700758",
                    "o": "humbug"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12014935"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11703532"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11674202"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11655911"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11943486"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12000928"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000927",
                    "o": "ASPARTATE BETA-HYDROXYLASE"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11665411"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12014936",
                    "o": "HUMBUG"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16688957",
                    "o": "junctin"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000928",
                    "o": "ASPH"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17713684"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11655911",
                    "o": "aspartate beta-hydroxylase"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17713684",
                    "o": "ASPH gene"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16700759"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11957838"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12014936"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16700758"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6898590"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11674202",
                    "o": "HAAH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11943486",
                    "o": "JUNCTATE"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1412592",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17721534"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11665411",
                    "o": "JCTN"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11665411",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11674202",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11675087",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11703532",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16688957",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16700758",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16700759",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17713684",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17721534",
                    "o": "HUGO"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11943486",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11957838",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11986511",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000927",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000928",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000929",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12014935",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12014936",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11655911",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11665411",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11674202",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11675087",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11703532",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16688957",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16700758",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16700759",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17713684",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17721534",
                    "o": "757"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#broader",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1454076",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0026832"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18022868",
                    "o": "Muscle Proteins [Chemical/Ingredient]"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0436569",
                    "o": "Muscle proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7572292",
                    "o": "Muscle Protein"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17975416",
                    "o": "Proteins, Muscle"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17903060",
                    "o": "Protein, Muscle"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0088740",
                    "o": "Muscle Proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0484290",
                    "o": "muscle protein"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11943486",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11957838",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11986511",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000927",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000928",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000929",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12014935",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12014936",
                    "o": "600582"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#broader",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1432044",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0026832"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#broader",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1384568",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0026832"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#broader",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1454076",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0025252"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0106726",
                    "o": "Proteins, Surface"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0106545",
                    "o": "Protein, Membrane"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0106681",
                    "o": "Proteins, Membrane-Associated"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17878805",
                    "o": "Proteins, Membrane"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7572056",
                    "o": "Membrane Protein"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17975235",
                    "o": "Membrane Associated Proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0483564",
                    "o": "membrane protein"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A1395117",
                    "o": "membrane proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0434758",
                    "o": "Membrane proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0121434",
                    "o": "Surface Proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17999026",
                    "o": "Membrane-Associated Proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0084559",
                    "o": "Membrane Proteins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17950981",
                    "o": "Membrane Proteins [Chemical/Ingredient]"
                }
            ],
            "ideal_answer": [
                "Yes, junctin binds to ryanodine receptors within the junctional sarcoplasmic reticulum of calcium release units, and normally acts as an activator of RyR channels at low luminal [Ca(2+)], and as an inhibitor at high luminal [Ca(2+)]."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/RYR1_RABIT",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019837",
                "http://www.uniprot.org/uniprot/RYR3_MOUSE",
                "http://www.uniprot.org/uniprot/RYR2_RABIT",
                "http://www.uniprot.org/uniprot/RYR2_MOUSE",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005219",
                "http://www.uniprot.org/uniprot/RYR1_RAT",
                "http://www.uniprot.org/uniprot/RYR2_RAT",
                "http://www.uniprot.org/uniprot/RYR1_HUMAN",
                "http://www.uniprot.org/uniprot/RYR1_PIG",
                "http://www.uniprot.org/uniprot/RYR3_HUMAN",
                "http://www.uniprot.org/uniprot/RYR2_HUMAN",
                "http://www.uniprot.org/uniprot/RYR1_MOUSE",
                "http://www.uniprot.org/uniprot/RYR3_RABIT"
            ],
            "type": "yesno",
            "id": "52b2f3b74003448f5500000c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Junctin, a 26 kDa intra-sarcoplasmic reticulum (SR) protein, forms a quaternary complex with triadin, calsequestrin and the ryanodine receptor (RyR) at the junctional SR membrane. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22025663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 919,
                    "text": "Junctin ablation appears to affect how RyRs 'sense' SR Ca(2+) load, resulting in decreased diastolic SR Ca(2+) leak despite an elevated [Ca(2+)](SR). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22025663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1120,
                    "offsetInEndSection": 1804,
                    "text": "Single channel recordings of RyRs from WT and JCN-KO cardiac SR indicate that the absence of junctin produces a dual effect on the normally linear response of RyRs to luminal [Ca(2+)]: at low luminal [Ca(2+)] (<1 mmol l(-1)), junctin-devoid RyR channels are less responsive to luminal [Ca(2+)]; conversely, high luminal [Ca(2+)] turns them hypersensitive to this form of channel modulation. Thus, junctin produces complex effects on Ca(2+) sparks, transients, and leak, but the luminal [Ca(2+)]-dependent dual response of junctin-devoid RyRs demonstrates that junctin normally acts as an activator of RyR channels at low luminal [Ca(2+)], and as an inhibitor at high luminal [Ca(2+)].",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22025663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 287,
                    "text": "Normal Ca(2+) signalling in skeletal muscle depends on the membrane associated proteins triadin and junctin and their ability to mediate functional interactions between the Ca(2+) binding protein calsequestrin and the type 1 ryanodine receptor in the lumen of the sarcoplasmic reticulum.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398037",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 1212,
                    "text": "We show here that purified skeletal ryanodine receptors are similarly activated by purified triadin or purified junctin added to their luminal side, although a lack of competition indicated that the proteins act at independent sites. Surprisingly, triadin and junctin differed markedly in their ability to transmit information between skeletal calsequestrin and ryanodine receptors. Purified calsequestrin inhibited junctin/triadin-associated, or junctin-associated, ryanodine receptors and the calsequestrin re-associated channel complexes were further inhibited when luminal Ca(2+) fell from 1mM to",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398037",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 797,
                    "text": "By fusing GCaMP6f to the N-terminus of triadin 1 or junctin, GCaMP6f-T/J was targeted to dyadic junctions, where it colocalized with t-tubules and RyRs after adenovirus-mediated gene transfer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257462",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 532,
                    "text": "The junctional face of the jSR, facing the transverse tubules, is occupied by a molecular complex composed of the transmembrane Ca2+ release channels (ryanodine receptors); the luminal protein calsequestrin (CSQ); the 2 membrane proteins, junctin (Jct), and triadin (Tr), which mediate CSQ-ryanodine receptor interactions; and several other components.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19448693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 581,
                    "text": "Calsequestrin, the main calcium buffer in the sarcoplasmic reticulum, provides a pool of calcium for release through the ryanodine receptor and acts as a luminal calcium sensor for the channel via its interactions with triadin and junctin. We examined the influence of phosphorylation of calsequestrin on its ability to store calcium, to polymerise and to regulate ryanodine receptors by binding to triadin and junctin. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19230141",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Junctin is a 26 kDa membrane protein that binds to calsequestrin, triadin, and ryanodine receptors (RyRs) within the junctional sarcoplasmic reticulum of calcium release units. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11162129",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does Apolipoprotein E (ApoE) have anti-inflammatory activity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23963646",
                "http://www.ncbi.nlm.nih.gov/pubmed/22197603",
                "http://www.ncbi.nlm.nih.gov/pubmed/22326991"
            ],
            "ideal_answer": [
                "Yes. ApoE has anti-inflammatory activity"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/APOE_CANFA",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0050727",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0050728",
                "http://www.uniprot.org/uniprot/APOE_MACMU",
                "http://www.uniprot.org/uniprot/APOE_RABIT",
                "http://www.uniprot.org/uniprot/APOE_GORGO",
                "http://www.uniprot.org/uniprot/APOE_HUMAN",
                "http://www.uniprot.org/uniprot/APOE_SAISC",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001057",
                "http://www.uniprot.org/uniprot/APOE_HYLLA",
                "http://www.uniprot.org/uniprot/APOE_PANTR",
                "http://www.uniprot.org/uniprot/APOE_PONPY",
                "http://www.uniprot.org/uniprot/APOE_TUPGL",
                "http://www.uniprot.org/uniprot/APOE_MOUSE",
                "http://www.uniprot.org/uniprot/APOE_PAPAN",
                "http://www.uniprot.org/uniprot/APOE_RAT",
                "http://www.uniprot.org/uniprot/APOE_MACFA",
                "http://www.uniprot.org/uniprot/APOE_CAVPO",
                "http://www.uniprot.org/uniprot/APOE_PIG",
                "http://www.uniprot.org/uniprot/APOE_ZALCA",
                "http://www.uniprot.org/uniprot/APOE_BOVIN",
                "http://www.uniprot.org/uniprot/APOE_SHEEP"
            ],
            "type": "yesno",
            "id": "530cf4fe960c95ad0c000002",
            "snippets": [
                {
                    "offsetInBeginSection": 2,
                    "offsetInEndSection": 396,
                    "text": " have previously reported that apolipoprotein E (apoE), a protein component of very-low-density lipoproteins (VLDL) and high-density lipoproteins and a potent plasma-borne atheroprotective factor, exerts anti-inflammatory activity in macrophages by switching the activation profile from M1 (\"classic\") to M2 (\"alternative\") in a process involving signaling via low-density lipoprotein receptor ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963646",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 248,
                    "text": "anti-inflammatory activity in macrophages ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23963646",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 360,
                    "text": "Small peptides corresponding to the receptor-binding region of apoE mimic the anti-inflammatory activity of the apoE ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22326991",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 312,
                    "text": "Apolipoprotein (apo) E-containing high-density lipoprotein (HDL) has antioxidant, anti-inflammatory and anti-atherogenic properties",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22197603",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a relation between ANP and transcapillary albumin escape?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2952859",
                "http://www.ncbi.nlm.nih.gov/pubmed/9815090",
                "http://www.ncbi.nlm.nih.gov/pubmed/1320716",
                "http://www.ncbi.nlm.nih.gov/pubmed/7579054",
                "http://www.ncbi.nlm.nih.gov/pubmed/2173580",
                "http://www.ncbi.nlm.nih.gov/pubmed/2148510",
                "http://www.ncbi.nlm.nih.gov/pubmed/12087555",
                "http://www.ncbi.nlm.nih.gov/pubmed/2148091",
                "http://www.ncbi.nlm.nih.gov/pubmed/2958207",
                "http://www.ncbi.nlm.nih.gov/pubmed/2142858",
                "http://www.ncbi.nlm.nih.gov/pubmed/15481764",
                "http://www.ncbi.nlm.nih.gov/pubmed/2210073",
                "http://www.ncbi.nlm.nih.gov/pubmed/8065837",
                "http://www.ncbi.nlm.nih.gov/pubmed/10405209",
                "http://www.ncbi.nlm.nih.gov/pubmed/9338510",
                "http://www.ncbi.nlm.nih.gov/pubmed/2956451",
                "http://www.ncbi.nlm.nih.gov/pubmed/1837999",
                "http://www.ncbi.nlm.nih.gov/pubmed/8853382",
                "http://www.ncbi.nlm.nih.gov/pubmed/17070433",
                "http://www.ncbi.nlm.nih.gov/pubmed/10092997",
                "http://www.ncbi.nlm.nih.gov/pubmed/2526450",
                "http://www.ncbi.nlm.nih.gov/pubmed/9702472",
                "http://www.ncbi.nlm.nih.gov/pubmed/23927843",
                "http://www.ncbi.nlm.nih.gov/pubmed/8432776"
            ],
            "ideal_answer": [
                "A possible role of ANP gene in conferring protection from nephropathy and microvascular damage in type 1 diabetes is present.\nANP infusion in healthy subjects caused a shift of plasma water and electrolytes from the circulation, with albumin escape as a secondary phenomenon"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017461",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013668",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012709",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009320",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000418"
            ],
            "type": "yesno",
            "id": "5321b8a39b2d7acc7e000009",
            "snippets": [
                {
                    "offsetInBeginSection": 2008,
                    "offsetInEndSection": 2257,
                    "text": "Thus, in a large ethnically homogeneous cohort of diabetic subjects, our data show: (1) a significant association of C708/T polymorphism with microalbuminuria in long-term diabetes and with both lower plasma ANP levels and widespread albumin leakage",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10405209",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2376,
                    "offsetInEndSection": 2511,
                    "text": "hese results suggest a possible role of PND gene in conferring protection from nephropathy and microvascular damage in type 1 diabetes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10405209",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1247,
                    "offsetInEndSection": 1462,
                    "text": "Moreover, the increased susceptibility of the glomerular capillaries in diabetics to ANP seems to be part of a more generalized capillary abnormality, because ANP also increases the transcapillary escape of albumin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7579054",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1263,
                    "offsetInEndSection": 1433,
                    "text": "In summary, low dose ANP infusion in healthy subjects caused a shift of plasma water and electrolytes from the circulation, with albumin escape as a secondary phenomenon.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8432776",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can botulism poisoning of a pregnant woman harm her fetus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23735780",
                "http://www.ncbi.nlm.nih.gov/pubmed/24235190"
            ],
            "ideal_answer": [
                "Botulinum toxin, which causes botulism, is not expected to be present in systemic circulation following proper intramuscular or intradermal injection. Moreover, botulinum toxin has a high molecular weight, and does not appear to cross the placenta. Based on the study cases reported in the literature, botulism poisoning during pregnancy does not appear to increase the risk of adverse outcome in the fetus."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:11976",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005333",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014930",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011042",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011041",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037841"
            ],
            "type": "yesno",
            "id": "554763f0f35db75526000002",
            "snippets": [
                {
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 871,
                    "text": "Two botulism outbreaks were attributed to commercial ready-to-eat meat products and 3 to foods served in restaurants; several cases were attributed to non-Native home-prepared foods. Three affected pregnant women delivered healthy infants.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 610,
                    "text": "Botulinum toxin is not expected to be present in systemic circulation following proper intramuscular or intradermal injection. Moreover, BTX-A, which has a high molecular weight, does not appear to cross the placenta. From the 38 pregnancies reported in the literature, including women who had botulism poisoning during pregnancy, exposure to BTX-A does not appear to increase the risk of adverse outcome in the fetus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24235190",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 593,
                    "text": "From the 38 pregnancies reported in the literature, including women who had botulism poisoning during pregnancy, exposure to BTX-A does not appear to increase the risk of adverse outcome in the fetus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24235190",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does low T3 negatively affect prognosis of patients after cardiac surgery?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12475369",
                "http://www.ncbi.nlm.nih.gov/pubmed/4057698",
                "http://www.ncbi.nlm.nih.gov/pubmed/2627465",
                "http://www.ncbi.nlm.nih.gov/pubmed/12165116",
                "http://www.ncbi.nlm.nih.gov/pubmed/14500064",
                "http://www.ncbi.nlm.nih.gov/pubmed/19448543",
                "http://www.ncbi.nlm.nih.gov/pubmed/23958074",
                "http://www.ncbi.nlm.nih.gov/pubmed/9078538",
                "http://www.ncbi.nlm.nih.gov/pubmed/15868525",
                "http://www.ncbi.nlm.nih.gov/pubmed/21248453",
                "http://www.ncbi.nlm.nih.gov/pubmed/16719939"
            ],
            "ideal_answer": [
                "Low cardiac output syndrome after cardiac surgery for congenital heart diseases is associated with decreased T3\nLow T3 concentrations are associated with occurrence of post operative atrial fibrillation\nLow T3 concentrations are inversely correlated with the days of post operative hospitalization"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011379",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013903",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002303",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005067"
            ],
            "type": "yesno",
            "id": "53302bced6d3ac6a34000039",
            "snippets": [
                {
                    "offsetInBeginSection": 1819,
                    "offsetInEndSection": 2049,
                    "text": "ur findings suggest that the development of LCOS after congenital heart surgery is associated with decreased total and free T3, and increased IL-8 levels at 48 hours, and preoperative tT4 level is an independent predictor of LCOS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21248453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 1575,
                    "text": "Low basal fT3 concentration can reliably predict the occurrence of postoperative AF in CABG patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14500064",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1295,
                    "text": "A relevant finding was that the days of post-operative hospitalization (10+/-3 days, means+/-S.D.) was inversely correlated with the slope of the recovery of T3 concentration (P<0.001) or with the area under the plasma curves of T3 (P=0.024, time range 72-144 h) and the FT3/FT4 ratio (P=0.037, time range 72-144 h) during the post-operative period. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12475369",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there clinical trials on stem cells in multiple sclerosis",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18562508",
                "http://www.ncbi.nlm.nih.gov/pubmed/21366911",
                "http://www.ncbi.nlm.nih.gov/pubmed/23197667",
                "http://www.ncbi.nlm.nih.gov/pubmed/23124791",
                "http://www.ncbi.nlm.nih.gov/pubmed/12376881",
                "http://www.ncbi.nlm.nih.gov/pubmed/15764028",
                "http://www.ncbi.nlm.nih.gov/pubmed/23331685",
                "http://www.ncbi.nlm.nih.gov/pubmed/20413685",
                "http://www.ncbi.nlm.nih.gov/pubmed/22359549",
                "http://www.ncbi.nlm.nih.gov/pubmed/21440544",
                "http://www.ncbi.nlm.nih.gov/pubmed/22561409"
            ],
            "ideal_answer": [
                "Yes.  Human multipotent mesenchymal stem cell (MSC) therapies are currently being tested in clinical trials for multiple sclerosis. Several small pilot clinical trials in subjects with advanced MS have demonstrated that MSC administration is safe and provided an early signal of clinical effectiveness. The current aim of clinicians and scientists interested in the development of MSC-based strategies for the treatment of MS is to have the ultimate demonstration in large clinical trials that MSC can inhibit CNS inflammation and foster tissue repair."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013234",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D049109",
                "http://www.disease-ontology.org/api/metadata/DOID:2377",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103"
            ],
            "type": "yesno",
            "id": "515df5b2298dcd4e5100002c",
            "snippets": [
                {
                    "offsetInBeginSection": 1033,
                    "offsetInEndSection": 1180,
                    "text": "Cells are generally given intravenously. Multiple sclerosis, rheumatoid arthritis and lupus have been successfully treated in human clinical trials",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23331685",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "text": "Human multipotent mesenchymal stem cell (MSC) therapies are currently being tested in clinical trials for Crohn's disease, multiple sclerosis, graft-versus-host disease, type 1 diabetes, bone fractures, cartilage damage, and cardiac diseases.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23197667",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 1028,
                    "text": "Based on these results, several small pilot clinical trials in subjects with advanced MS have demonstrated that MSC administration is safe and provided an early signal of clinical effectiveness. The current aim of clinicians and scientists interested in the development of MSC-based strategies for the treatment of MS is to have the ultimate demonstration in large clinical trials that MSC can inhibit CNS inflammation and foster tissue repair",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23124791",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "Mesenchymal stem cells (MSC) promote functional recovery in experimental models of central nervous system (CNS) pathology and are currently being tested in clinical trials for stroke, multiple sclerosis and CNS injury.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22561409",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 319,
                    "text": "Autologous bone marrow stromal cells (BMSCs) offer significant practical advantages for potential clinical applications in multiple sclerosis (MS). Based on recent experimental data, a number of clinical trials have been designed for the intravenous (IV) and/or intrathecal (ITH) administration of BMSCs in MS patients.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21440544",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 341,
                    "offsetInEndSection": 520,
                    "text": "Fingolimod is a S1P receptor modulator in MS clinical trials due to systemic anti-inflammatory properties, yet may impact cells within the CNS by crossing the blood-brain barrier.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20413685",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 477,
                    "text": "Their development in vitro and their use in vivo in animal models of degenerative neurological disease and recent first efforts in human clinical trials were the topics of a recent international meeting sponsored by the Multiple Sclerosis International Federation and the National Multiple Sclerosis Society on \"Stem Cells & MS: Prospects and Strategies\"",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18562508",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 287,
                    "text": "Here we discuss key observations and questions emerging from clinical trials of hematopoietic stem cell transplantation for MS",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15764028",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 731,
                    "text": "Another possibility to achieve remyelination is the transplantation of myelinating cells into the central nervous system. Proof of principle and demonstration of the functionality were shown in numerous experiments, and a first clinical trial in patients with MS has started",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12376881",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 850,
                    "offsetInEndSection": 997,
                    "text": "This first trial will show if cell transplantation is a feasible concept in MS and whether the transplanted cells will survive and form new myelin.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12376881",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Does MicroRNA-21 (miR-21) contribute to cardiovascular disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22859901",
                "http://www.ncbi.nlm.nih.gov/pubmed/22960625",
                "http://www.ncbi.nlm.nih.gov/pubmed/20649511",
                "http://www.ncbi.nlm.nih.gov/pubmed/20980922",
                "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                "http://www.ncbi.nlm.nih.gov/pubmed/19336275",
                "http://www.ncbi.nlm.nih.gov/pubmed/20219857",
                "http://www.ncbi.nlm.nih.gov/pubmed/20959496",
                "http://www.ncbi.nlm.nih.gov/pubmed/20015039",
                "http://www.ncbi.nlm.nih.gov/pubmed/23691029",
                "http://www.ncbi.nlm.nih.gov/pubmed/21712654",
                "http://www.ncbi.nlm.nih.gov/pubmed/19043405",
                "http://www.ncbi.nlm.nih.gov/pubmed/19706597",
                "http://www.ncbi.nlm.nih.gov/pubmed/22882958",
                "http://www.ncbi.nlm.nih.gov/pubmed/21464712"
            ],
            "ideal_answer": [
                "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683",
                "http://www.disease-ontology.org/api/metadata/DOID:1287"
            ],
            "type": "yesno",
            "id": "54f4703764850a5854000008",
            "snippets": [
                {
                    "offsetInBeginSection": 1167,
                    "offsetInEndSection": 1329,
                    "text": "The synergistic effect of miR-21 and miR-1 were functionally validated for their significant influences on myocardial apoptosis, cardiac hypertrophy and fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23691029",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1435,
                    "offsetInEndSection": 1682,
                    "text": "Taken together, we found a novel reciprocal loop between miR-21 and TGF\u03b2RIII in cardiac fibrosis caused by myocardial infarction in mice, and targeting this pathway could be a new strategy for the prevention and treatment of myocardial remodeling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 316,
                    "text": "It is still controversial whether microRNA-21 (miR-21) participates in the process of cardiac fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 288,
                    "text": "In mice, myocardial miR-21 overexpression is related to cardiac fibrosis elicited by pressure overload. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882958",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1135,
                    "text": "The myocardial and plasma levels of miR-21 were significantly higher in the AS patients compared with the controls and correlated directly with the echocardiographic mean transvalvular gradients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882958",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1751,
                    "text": "Our results support the role of miR-21 as a regulator of the fibrotic process that occurs in response to pressure overload in AS patients and underscore the value of circulating miR-21 as a biomarker for myocardial fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882958",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1736,
                    "offsetInEndSection": 1914,
                    "text": "Ad-miR-21 improves LV remodeling and decreases the apoptosis of myocardial cells, suggesting the possible mechanism by which Ad-miR-21 functions in protecting against I/R injury.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22859901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1131,
                    "offsetInEndSection": 1309,
                    "text": "In the Ad-miR-21 group, LV dimensions, myocardial infarct size, LV/BW, collagen type \u2160, type \u2162 and PCNA positive cells all significantly decreased compared with the Ad-GFP group.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22859901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 825,
                    "text": "While miR-21, -133, -150, -195, and -214 regulate cardiomyocyte hypertrophy, miR-1/-133 and miR-208 have been elucidated to influence myocardial contractile function. In addition, miR-21, -24, -133, -210, -494, and -499 appear to protect myocytes against I/R-induced apoptosis, whereas miR-1, -29, -199a, and -320 promote apoptosis. Myocardial fibrosis can be regulated by the miR-29 family and miR-21.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "The small regulatory RNA microRNA-21 (miR-21) plays a crucial role in a plethora of biological functions and diseases including development, cancer, cardiovascular diseases and inflammation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712654",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 723,
                    "offsetInEndSection": 907,
                    "text": "During recent years, additional roles of miR-21 in cardiovascular and pulmonary diseases, including cardiac and pulmonary fibrosis as well as myocardial infarction have been described.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712654",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 758,
                    "text": "On the other hand, miR-21, miR-199a, miR-210, and miR-494 have been proven critical for the myocytes' adaptation and survival during hypoxia/ischemia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21464712",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 858,
                    "text": "Studies have shown that several miRs, including miR-1, miR-133, miR-21, miR-126, miR-320, miR-92a, and miR-199a, are regulated after preconditioning and play an active role in protecting the heart against ischemia/reperfusion injury.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20980922",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1053,
                    "text": "Studies using various in vivo, ex vivo, and in vitro models have suggested the possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in ischemia-reperfusion injury and/or remodeling after myocardial infarction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20959496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 672,
                    "text": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system. Recent studies have revealed that its expression is deregulated in heart and vasculature under cardiovascular disease conditions such as proliferative vascular disease, cardiac hypertrophy and heart failure, and ischemic heart disease. miR-21 is found to play important roles in vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. Accordingly, miR-21 is proven to be involved in the pathogenesis of the above-mentioned cardiovascular diseases as demonstrated by both loss-of-function and gain-of-function approaches.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 993,
                    "text": "miR-21 might be a novel therapeutic target in cardiovascular diseases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 994,
                    "offsetInEndSection": 1103,
                    "text": "This review article summarizes the research progress regarding the roles of miR-21 in cardiovascular disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 1173,
                    "text": "Remarkably, miR-21 was one of most upregulated miRNAs in hearts after IP. In vivo, IP-mediated cardiac protection against ischaemia/reperfusion injury was inhibited by knockdown of cardiac miR-21. In cultured cardiac myocytes, we identified that miR-21 also had a protective effect on hypoxia/reoxygenation-induced cell apoptosis that was associated with its target gene, programmed cell death 4. The protective effect of miR-21 on cardiac cell apoptosis was further confirmed in rat hearts after ischaemia/reperfusion injury in vivo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 747,
                    "text": "Lately, some highlight articles revealed that the altered expression of miRNAs such as miR-1, miR-133, miR-21, miR-208 etc in hearts also contributed to cardiovascular diseases, such as heart ischemia, cardiac hypertrophy, and arrhythmias.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20015039",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 495,
                    "offsetInEndSection": 1537,
                    "text": "Remarkably, miR-21 expression was significantly down-regulated in infarcted areas, but was up-regulated in border areas. The down-regulation of miR-21 in the infarcted areas was inhibited by ischemic preconditioning, a known cardiac protective method. Overexpression of miR-21 via adenovirus expressing miR-21 (Ad-miR-21) decreased myocardial infarct size by 29% at 24 h and decreased the dimension of left ventricles at 2 weeks after AMI. Using both gain-of-function and loss-of-function approaches in cultured cardiac myocytes, we identified that miR-21 had a protective effect on ischemia-induced cell apoptosis that was associated with its target gene programmed cell death 4 and activator protein 1 pathway. The protective effect of miR-21 against ischemia-induced cardiac myocyte damage was further confirmed in vivo by decreased cell apoptosis in the border and infarcted areas of the infarcted rat hearts after treatment with Ad-miR-21. The results suggest that miRNAs such as miR-21 may play critical roles in the early phase of AMI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19706597",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1792,
                    "text": "The results suggest that miR-21 is sensitive to H(2)O(2) stimulation. miR-21 participates in H(2)O(2)-mediated gene regulation and functional modulation in cardiac myocytes. miR-21 might play an essential role in heart diseases related to ROS such as cardiac hypertrophy, heart failure, myocardial infarction, and myocardial ischemia/reperfusion injury.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19336275",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043405",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22882958",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22859901",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19336275",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043405",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "MicroRNA-21 (miR-21) is a highly expressed microRNA (miRNA) in cardiovascular system",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 992,
                    "text": "miR-21 might be a novel therapeutic target in cardiovascular diseases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20560046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "MicroRNA-21 as therapeutic target in cancer and cardiovascular disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20649511",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1163,
                    "offsetInEndSection": 1273,
                    "text": "These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1451,
                    "text": "Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19043405",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does teplizumab hold promise for diabetes prevention?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
                "http://www.ncbi.nlm.nih.gov/pubmed/30569273",
                "http://www.ncbi.nlm.nih.gov/pubmed/25941654",
                "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
                "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                "http://www.ncbi.nlm.nih.gov/pubmed/31523950",
                "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
                "http://www.ncbi.nlm.nih.gov/pubmed/23231526",
                "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                "http://www.ncbi.nlm.nih.gov/pubmed/21719095"
            ],
            "ideal_answer": [
                "Yes, teplizumab is promising for diabetes prevention."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e30f638fbd6abf43b000045",
            "snippets": [
                {
                    "offsetInBeginSection": 2377,
                    "offsetInEndSection": 2474,
                    "text": "Anti-CD3 teplizumab and anti-CD3 otelixizumab have been shown to provide C-peptide preservation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941654",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1284,
                    "text": "Underway are secondary prevention studies with teplizumab and with abatacept.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2371,
                    "offsetInEndSection": 2731,
                    "text": "INTERPRETATION: Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 39,
                    "text": "Teplizumab therapy for type 1 diabetes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Teplizumab for treatment of type 1 diabetes mellitus.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 950,
                    "text": "TAKE HOME MESSAGE\n\nIn Phase I/II randomized control trials, in patients with new onset T1D, teplizumab slowed the rate of loss of beta-cell function over 2 years of follow-up.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2377,
                    "offsetInEndSection": 2737,
                    "text": "INTERPRETATION\n\nFindings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 983,
                    "text": "AREAS COVERED\n\nIn this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1783,
                    "offsetInEndSection": 1906,
                    "text": "CONCLUSIONS Teplizumab is an anti-CD3 human monoclonal antibody with promising activity in treatment of patients with T1DM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 891,
                    "text": "The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2377,
                    "offsetInEndSection": 2737,
                    "text": "INTERPRETATION\nFindings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 883,
                    "text": "The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2343,
                    "offsetInEndSection": 2687,
                    "text": "Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 571,
                    "text": "Despite decades of research and clinical trials, no treatment exists yet to prevent or cure T1D. A recent prevention trial using the anti-CD3 antibody teplizumab in individuals at a high risk of developing T1D has provided the first piece of evidence that a safe and transient intervention may be able to delay disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523950",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 953,
                    "text": "In this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7\u00a0years from diagnosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30569273",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Do cephalopods use RNA editing less frequently than other species?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25775132",
                "http://www.ncbi.nlm.nih.gov/pubmed/28855414",
                "http://www.ncbi.nlm.nih.gov/pubmed/29048557",
                "http://www.ncbi.nlm.nih.gov/pubmed/26268193",
                "http://www.ncbi.nlm.nih.gov/pubmed/28388405",
                "http://www.ncbi.nlm.nih.gov/pubmed/24205087"
            ],
            "ideal_answer": [
                "Extensive messenger RNA editing generates transcript and protein diversity in genes involved in neural excitability, as previously described, as well as in genes participating in a broad range of other cellular functions. ",
                "No. Extensive messenger RNA editing generates transcript and protein diversity in cephalopod genes involved in neural excitability, as previously described, as well as in genes participating in a broad range of other cellular functions",
                "Extensive messenger RNA editing generates transcript and protein diversity in genes involved in neural excitability, as previously described, as well as in genes participating in a broad range of other cellular functions"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "58e8a2fc3e8b6dc87c00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1237,
                    "text": "Extensive messenger RNA editing generates transcript and protein diversity in genes involved in neural excitability, as previously described, as well as in genes participating in a broad range of other cellular functions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268193",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 491,
                    "text": "By adopting a method originally designed to detect linkage disequilibrium of DNA mutations, we examined the editomes of ten metazoan species and detected extensive linkage of editing in Drosophila and cephalopods.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29048557",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 476,
                    "text": "We here show that RNA editing is particularly common in behaviorally sophisticated coleoid cephalopods, with tens of\u00a0thousands of evolutionarily conserved sites.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1280,
                    "text": "Even for the subset of RNA editing sites shared by deeply divergent cephalopod lineages, the primary effect of nuclear editing is an increase-not a decrease-in protein divergence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28855414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Coleoid cephalopods (octopus, squid and cuttlefish) are active, resourceful predators with a rich behavioural repertoire.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268193",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1239,
                    "offsetInEndSection": 1419,
                    "text": "We identified hundreds of cephalopod-specific genes, many of which showed elevated expression levels in such specialized structures as the skin, the suckers and the nervous system.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268193",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1552,
                    "offsetInEndSection": 1838,
                    "text": "Our analysis suggests that substantial expansion of a handful of gene families, along with extensive remodelling of genome linkage and repetitive content, played a critical role in the evolution of cephalopod morphological innovations, including their large and complex nervous systems.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26268193",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is microRNA(miRNA) 30 involved in post-ischemic cardiac remodeling?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22352753",
                "http://www.ncbi.nlm.nih.gov/pubmed/21434842",
                "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                "http://www.ncbi.nlm.nih.gov/pubmed/19096030"
            ],
            "ideal_answer": [
                "Myocardial remodeling after an ischemic insult involves extracellular matrix proteins with increased fibrosis\nInitial experimental data indicate that miRNA 30 decreases CTGF a key molecule in the process of fibrosis, by directly downregulating the production of CTGF"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010586",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
            ],
            "type": "yesno",
            "id": "513f4249bee46bd34c000012",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "The myocardium of the failing heart undergoes a number of structural alterations, most notably hypertrophy of cardiac myocytes and an increase in extracellular matrix proteins, often seen as primary fibrosi",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 345,
                    "text": "Connective tissue growth factor (CTGF) is a key molecule in the process of fibrosis and therefore seems an attractive therapeutic target",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 659,
                    "text": "CTGF is importantly regulated by 2 major cardiac microRNAs (miRNAs), miR-133 and miR-30.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 1060,
                    "text": "the expression of both miRNAs was inversely related to the amount of CTGF in 2 rodent models of heart disease and in human pathological left ventricular hypertrophy. Second, in cultured cardiomyocytes and fibroblasts, knockdown of these miRNAs increased CTGF levels. Third, overexpression of miR-133 or miR-30c decreased CTGF levels, which was accompanied by decreased production of collagens.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1249,
                    "offsetInEndSection": 1296,
                    "text": "miR-30 importantly limit the production of CTGF",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1531,
                    "offsetInEndSection": 1733,
                    "text": "miR-30 directly downregulate CTGF, a key profibrotic protein, and thereby establish an important role for these miRNAs in the control of structural changes in the extracellular matrix of the myocardium.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is there a role for TET proteins in invariant natural killer T cells (iNKT) cell fate?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27869820"
            ],
            "ideal_answer": [
                "Yes. Tet2-TET proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells. TETs are ubiquitously expressed and play diverse roles in gene regulation, imprinting, insulation, intra/interchromosomal interactions, nuclear compartmentalisation, and alternative splicing. Depletion of Tet2 and its ligand, Tet3, from mouse CD4CD8 double-positive thymus-derived cardiomyocytes (iNKT) resulted in dysregulated development and proliferation, with increased expression of tumour suppressor genes and decreased",
                "Yes. TET proteins regulate iNKT cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the T cell antigen receptor (TCR).",
                "Yes. Tet2-Tet3 double-knocked-out (DKO) iNKT cells displayed pronounced skew toward the NKT17 lineage, with increased DNA methylation and impaired expression of genes encoding the key lineage-specifying factors T-bet and ThPok. Moreover, simultaneous deletion of Tet2 and Tet3 in mouse CD4CD8 double-positive thymocytes resulted in dysregulated development and proliferation of the non-classical major histocomponent complex (MHC) CD1d, which presents lipid antigens to T-cell-derived",
                "Yes. Tet2-Tet3 proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells. Indeed, deletion of Tet2 and Tet3 in mouse CD4CD8 double-positive thymus cells resulted in dysregulated development and proliferation of the non-classical major histocompromised T cell antigen receptor (MHC) protein CD1d, which presents lipid antigens to iNKB-derived cells. Moreover, overexpression of TET1 and TET3 in Drosophila melanogaster T cells (iN",
                "Yes. Tet2-Tet3 double-knockout (DKO) cells displayed pronounced skewing toward the NKT17 lineage, with increased DNA methylation and impaired expression of genes encoding the key lineage-specifying factors T-bet and ThPOK. Mutations in exon 2 interfere with the synthesis of the full-length isoform of Tet2 and lead to the production of a shortened isoform, Tet2s. These mutations have been found in human natural killer T cells (iNKTs), the most common type of innate immune cells."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e36994092b3349b55000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "TET proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869820",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 985,
                    "text": "We found that simultaneous deletion of Tet2 and Tet3 in mouse CD4+CD8+ double-positive thymocytes resulted in dysregulated development and proliferation of invariant natural killer T cells (iNKT cells). Tet2-Tet3 double-knockout (DKO) iNKT cells displayed pronounced skewing toward the NKT17 lineage, with increased DNA methylation and impaired expression of genes encoding the key lineage-specifying factors T-bet and ThPOK. Transfer of purified Tet2-Tet3 DKO iNKT cells into immunocompetent recipient mice resulted in an uncontrolled expansion that was dependent on the nonclassical major histocompatibility complex (MHC) protein CD1d, which presents lipid antigens to iNKT cells. Our data indicate that TET proteins regulate iNKT cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the T cell antigen receptor (TCR).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869820",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "TET proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells .",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27869820",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is indicated the use of antioxidant supplements in patients at risk for coronary artery disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19774218",
                "http://www.ncbi.nlm.nih.gov/pubmed/10575394",
                "http://www.ncbi.nlm.nih.gov/pubmed/8164066",
                "http://www.ncbi.nlm.nih.gov/pubmed/8650957",
                "http://www.ncbi.nlm.nih.gov/pubmed/23877741",
                "http://www.ncbi.nlm.nih.gov/pubmed/11944023",
                "http://www.ncbi.nlm.nih.gov/pubmed/9430400",
                "http://www.ncbi.nlm.nih.gov/pubmed/10329064",
                "http://www.ncbi.nlm.nih.gov/pubmed/12069675",
                "http://www.ncbi.nlm.nih.gov/pubmed/9877124",
                "http://www.ncbi.nlm.nih.gov/pubmed/18277182",
                "http://www.ncbi.nlm.nih.gov/pubmed/7695869",
                "http://www.ncbi.nlm.nih.gov/pubmed/10987596",
                "http://www.ncbi.nlm.nih.gov/pubmed/9193380",
                "http://www.ncbi.nlm.nih.gov/pubmed/8472392",
                "http://www.ncbi.nlm.nih.gov/pubmed/9746269",
                "http://www.ncbi.nlm.nih.gov/pubmed/10639540",
                "http://www.ncbi.nlm.nih.gov/pubmed/9723625",
                "http://www.ncbi.nlm.nih.gov/pubmed/9849356",
                "http://www.ncbi.nlm.nih.gov/pubmed/10077397",
                "http://www.ncbi.nlm.nih.gov/pubmed/22645453",
                "http://www.ncbi.nlm.nih.gov/pubmed/22293859",
                "http://www.ncbi.nlm.nih.gov/pubmed/15531665",
                "http://www.ncbi.nlm.nih.gov/pubmed/8479464",
                "http://www.ncbi.nlm.nih.gov/pubmed/18548846",
                "http://www.ncbi.nlm.nih.gov/pubmed/15567903",
                "http://www.ncbi.nlm.nih.gov/pubmed/15302616",
                "http://www.ncbi.nlm.nih.gov/pubmed/12968298",
                "http://www.ncbi.nlm.nih.gov/pubmed/11192356",
                "http://www.ncbi.nlm.nih.gov/pubmed/9659191",
                "http://www.ncbi.nlm.nih.gov/pubmed/10386507",
                "http://www.ncbi.nlm.nih.gov/pubmed/7977015",
                "http://www.ncbi.nlm.nih.gov/pubmed/8479463",
                "http://www.ncbi.nlm.nih.gov/pubmed/12204790",
                "http://www.ncbi.nlm.nih.gov/pubmed/18377792",
                "http://www.ncbi.nlm.nih.gov/pubmed/23335472",
                "http://www.ncbi.nlm.nih.gov/pubmed/19033020",
                "http://www.ncbi.nlm.nih.gov/pubmed/10711786",
                "http://www.ncbi.nlm.nih.gov/pubmed/8946266",
                "http://www.ncbi.nlm.nih.gov/pubmed/16603825",
                "http://www.ncbi.nlm.nih.gov/pubmed/15153272",
                "http://www.ncbi.nlm.nih.gov/pubmed/11089430",
                "http://www.ncbi.nlm.nih.gov/pubmed/12741415",
                "http://www.ncbi.nlm.nih.gov/pubmed/8602181",
                "http://www.ncbi.nlm.nih.gov/pubmed/12732794",
                "http://www.ncbi.nlm.nih.gov/pubmed/22254063",
                "http://www.ncbi.nlm.nih.gov/pubmed/20400494",
                "http://www.ncbi.nlm.nih.gov/pubmed/20350251",
                "http://www.ncbi.nlm.nih.gov/pubmed/10656300",
                "http://www.ncbi.nlm.nih.gov/pubmed/9164706",
                "http://www.ncbi.nlm.nih.gov/pubmed/19859067",
                "http://www.ncbi.nlm.nih.gov/pubmed/24489984",
                "http://www.ncbi.nlm.nih.gov/pubmed/15117174",
                "http://www.ncbi.nlm.nih.gov/pubmed/10812586",
                "http://www.ncbi.nlm.nih.gov/pubmed/23055813",
                "http://www.ncbi.nlm.nih.gov/pubmed/12675072",
                "http://www.ncbi.nlm.nih.gov/pubmed/15585762",
                "http://www.ncbi.nlm.nih.gov/pubmed/10600089",
                "http://www.ncbi.nlm.nih.gov/pubmed/15693087",
                "http://www.ncbi.nlm.nih.gov/pubmed/23833580",
                "http://www.ncbi.nlm.nih.gov/pubmed/21996047",
                "http://www.ncbi.nlm.nih.gov/pubmed/12492632",
                "http://www.ncbi.nlm.nih.gov/pubmed/18460663",
                "http://www.ncbi.nlm.nih.gov/pubmed/10498115",
                "http://www.ncbi.nlm.nih.gov/pubmed/8570438",
                "http://www.ncbi.nlm.nih.gov/pubmed/10696633",
                "http://www.ncbi.nlm.nih.gov/pubmed/12090883",
                "http://www.ncbi.nlm.nih.gov/pubmed/17275460",
                "http://www.ncbi.nlm.nih.gov/pubmed/11702901",
                "http://www.ncbi.nlm.nih.gov/pubmed/23022248",
                "http://www.ncbi.nlm.nih.gov/pubmed/21115589",
                "http://www.ncbi.nlm.nih.gov/pubmed/22342390"
            ],
            "ideal_answer": [
                "antioxidant supplementation \nHowever there are no clear evidencies on the clinical and prognostic benefit of this supplementation. \nCurrently there areno recommendation for the antioxidant therapy in patients with coronary artery disease.\nCurrently the American Heart Association recommends consumption of a balanced diet with emphasis on antioxidant-rich fruits and vegetables but does not recommend antioxidant supplementation for the general population."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000975",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054059",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023921",
                "http://www.disease-ontology.org/api/metadata/DOID:4248",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003324",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003327",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010361",
                "http://www.disease-ontology.org/api/metadata/DOID:3393",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019587"
            ],
            "type": "yesno",
            "id": "53329c84d6d3ac6a34000040",
            "snippets": [
                {
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 331,
                    "text": "We and others have published observational epidemiologic studies in support of vitamins in the primary prevention of CVD, but the results from intervention studies are mixed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18377792",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 1053,
                    "text": "For vitamin E, observational data suggest benefit at doses of 100 to 400 IU/d. Results from recent large-scale trials are mixed, with some showing modest benefit but others suggesting no benefit, especially for secondary prevention. Results for B vitamins are also mixed and further complicated by the recent folate fortification of the flour supply. If greater B vitamin intake does reduce CVD, the benefits are likely to be greatest for primary prevention and in populations with intake below dietary reference standards. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18377792",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1445,
                    "offsetInEndSection": 1911,
                    "text": "In the dose-response meta-analysis, each 30 mg/day increase in vitamin C, 30 IU/day increase in vitamin E, and 1 mg/day increase in beta-carotene yielded the estimated overall relative risk for CHD of 1.01 (95% CI, 0.99-1.02), 0.96 (95% CI, 0.94-0.99), and 1.00 (95% CI, 0.88-1.14), respectively. CONCLUSIONS: Our findings in this meta-analysis suggest that an increase in dietary intake of antioxidant vitamins has encouraging prospects for possible CHD prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18277182",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1183,
                    "offsetInEndSection": 1514,
                    "text": "High levels of \u03b1-tocopherol in serum were associated with 30% lower CAD risk in another study (HR 0.71; 95%CI 0.53-0.94). Among minerals (zinc, selenium, and chromium), an inverse association between zinc and CAD was observed; levels lower than 14.1 \u00b5mol/L were associated with an increased risk for CAD (RR 1.70; 95%CI 1.21-2.38).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1711,
                    "text": "The information available on this issue is scarce. Further prospective studies are needed to elucidate the role of these nutrients in the cardiovascular risk of patients with diabetes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23877741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1523,
                    "offsetInEndSection": 1644,
                    "text": "Coenzyme Q10 supplementation at a dosage of 150 mg appears to decrease the inflammatory marker IL-6 in patients with CAD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22342390",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1973,
                    "offsetInEndSection": 2237,
                    "text": " Coenzyme Q10 supplements at a dose of 150 mg can decrease oxidative stress and increase antioxidant enzyme activity in patients with CAD. A higher dose of coenzyme Q10 supplements (>150 mg/d) might promote rapid and sustainable antioxidation in patients with CAD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21996047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1267,
                    "offsetInEndSection": 1412,
                    "text": "Alpha-tocopherol or beta-carotene supplementation has no protective effect on macrovascular outcomes or total mortality of diabetic male smokers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20350251",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1589,
                    "offsetInEndSection": 1769,
                    "text": "Sodium selenite supplementation increases GPx-1 activity in endothelial cells and in CAD patients. Future studies have to demonstrate whether long-term CAD outcome can be improved.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19033020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2236,
                    "offsetInEndSection": 2474,
                    "text": "After 7.3 years of treatment and follow-up, a combination pill of folic acid, vitamin B6, and vitamin B12 did not reduce a combined end point of total cardiovascular events among high-risk women, despite significant homocysteine lowering.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18460663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1627,
                    "offsetInEndSection": 1885,
                    "text": " In this population-based study, vitamin E use was unrelated to mortality, but this apparently null finding seems to represent a combination of increased mortality in those with severe cardiovascular disease and a possible protective effect in those without.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17275460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1356,
                    "offsetInEndSection": 1572,
                    "text": " In this large cohort of apparently healthy US male physicians, self-selected supplementation with vitamin E, vitamin C, or multivitamins was not associated with a significant decrease in total CVD or CHD mortality. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090883",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1278,
                    "offsetInEndSection": 1712,
                    "text": "The American Heart Association has recommended consumption of a balanced diet with emphasis on antioxidant-rich fruits and vegetables but has made no recommendations regarding vitamin E supplementation for the general population. Although vitamin E supplementation seems to be safe for most people, recommendations from health care professionals should reflect the uncertainty of established benefit as demonstrated in clinical trials",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11702901",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 961,
                    "text": "Recent studies show that supplementation with antioxidant vitamins E and C have benefits in CHD prevention; however, supplementation with beta-carotene may have deleterious effects and is not recommended. Current evidence suggests that patients with CHD would probably benefit from taking vitamin E in a dosage of 400 IU per day and vitamin C in a dosage of 500 to 1,000 mg per day. Clinicians may also want to consider vitamin supplementation for CHD prevention in high-risk patients. Folate lowers elevated homocysteine levels, but evidence for routine supplemental use does not yet exist. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10498115",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1931,
                    "offsetInEndSection": 2082,
                    "text": "In patients at high risk for cardiovascular events, treatment with vitamin E for a mean of 4.5 years had no apparent effect on cardiovascular outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10639540",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are people with blood group O protected against severe Malaria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22771625",
                "http://www.ncbi.nlm.nih.gov/pubmed/15814030",
                "http://www.ncbi.nlm.nih.gov/pubmed/23071435",
                "http://www.ncbi.nlm.nih.gov/pubmed/22818742",
                "http://www.ncbi.nlm.nih.gov/pubmed/17959777"
            ],
            "ideal_answer": [
                "It appears that individuals who are of blood-group O are relatively resistant to the severe disease caused by P. falciparum infection."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:14067",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001769",
                "http://www.disease-ontology.org/api/metadata/DOID:4176",
                "http://www.disease-ontology.org/api/metadata/DOID:12365",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008288",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001789"
            ],
            "type": "yesno",
            "id": "551ae6c564b14b4618000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Differential carbonylation of cytoskeletal proteins in blood group O erythrocytes: potential role in protection against severe malaria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22771625",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1267,
                    "offsetInEndSection": 1460,
                    "text": ". Our findings indicate a possible correlation between the protection against severe malaria in blood group O individuals and a specific pattern of 4-HNE-carbonylation of cytoskeleton proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22771625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 314,
                    "text": "There is a predominance of blood group O in malaria-endemic regions, and several lines of evidence suggest that ABO blood groups may influence the outcome of P. falciparum infection",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071435",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1541,
                    "text": "These data provide the first evidence that ABO blood group antigens influence macrophage clearance of P. falciparum-infected erythrocytes and suggest an additional mechanism by which blood group O may confer resistance to severe malaria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071435",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Blood group phenotypes A and B are risk factors for cerebral malaria in Odisha, India.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818742",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 652,
                    "text": "type O is significantly associated with protection against CM, patients with type A and B group had increased risk for developing CM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959777",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 448,
                    "text": "Malaria has been a major selective force on the human population, and several erythrocyte polymorphisms have evolved that confer resistance to severe malaria. Plasmodium falciparum rosetting, a parasite virulence phenotype associated with severe malaria, is reduced in blood group O erythrocytes compared with groups A, B, and AB, but the contribution of the ABO blood group system to protection against severe malaria has received little attention",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959777",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 579,
                    "text": "We hypothesized that blood group O may confer resistance to severe falciparum malaria through the mechanism of reduced rosetting.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959777",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1142,
                    "text": "It appears that individuals who are of blood-group O are relatively resistant to the severe disease caused by P. falciparum infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814030",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does cucumber lower blood sugar in diabetics?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21264099",
                "http://www.ncbi.nlm.nih.gov/pubmed/937227",
                "http://www.ncbi.nlm.nih.gov/pubmed/19276533",
                "http://www.ncbi.nlm.nih.gov/pubmed/19854256",
                "http://www.ncbi.nlm.nih.gov/pubmed/2620957",
                "http://www.ncbi.nlm.nih.gov/pubmed/11451723",
                "http://www.ncbi.nlm.nih.gov/pubmed/17650589",
                "http://www.ncbi.nlm.nih.gov/pubmed/20614191",
                "http://www.ncbi.nlm.nih.gov/pubmed/22419465",
                "http://www.ncbi.nlm.nih.gov/pubmed/22416705",
                "http://www.ncbi.nlm.nih.gov/pubmed/8569244",
                "http://www.ncbi.nlm.nih.gov/pubmed/22897583",
                "http://www.ncbi.nlm.nih.gov/pubmed/16179750"
            ],
            "ideal_answer": [
                "Yes. Based on several scientific reports, ethanolic extract of cucumber and some other Cucurbitaceae plants are associated with a significant reduction of elevated blood glucose level, suggesting that cucumber could have antidiabetic activity."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003920",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001786",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018553"
            ],
            "type": "yesno",
            "id": "516c220e298dcd4e51000071",
            "snippets": [
                {
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 411,
                    "text": "The ethanolic extract of Cucumis sativus Linn, Cucumis melo utilissimum Roxb, Cucumis melo Linn, Benincasa hispida Thunb Cogn and Tricosanthes anguina Nees, when administered in 250 mg/kg dose, orally to rats failed to lower blood sugar or to depress the peak value, after glucose load.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2620957",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 952,
                    "text": "Ethanolic extract of Tricosanthes dioica Roxb plant caused a significant lowering of blood sugar in fasted rats and depressed the peak value in glucose loaded single and longterm fed groups of rats. The ethanolic extract of the aerial part of T. dioica also induced significant depression in the peak values in the glucose loaded models.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2620957",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 979,
                    "offsetInEndSection": 1087,
                    "text": "The amount of sucrose in ordinary marinated foods, such as herring, cucumber, and common beet was negligible",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/937227",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Dietary saponins of sea cucumber ameliorate obesity, hepatic steatosis, and glucose intolerance in high-fat diet-fed mice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897583",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 271,
                    "text": "In this study, we investigated the effects of saponins of sea cucumber (SSC) on high-fat diet-induced obesity, insulin resistance, and fatty liver in mice.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897583",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 879,
                    "text": "Mice administrated with 0.1% SSC had significantly decreased serum glucose and insulin levels, lower homeostatic model assessment for insulin resistance index, and area under the blood glucose curve, suggesting that insulin sensitivity is enhanced by dietary SSC.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22897583",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "[Effects of sea cucumber cerebroside and its long-chain base on lipid and glucose metabolism in obese mice].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419465",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "OBJECTIVE: To investigate the effect of sea cucumber cerebroside(SCC) and its long-chain base(LCB) on lipid and glucose metabolism in obese mice.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419465",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 907,
                    "text": "CONCLUSIONS: Sea cucumber cerebroside and its long-chain base can improve the glucose and lipid metabolism in obese mice.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22419465",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 380,
                    "text": "The hitherto unknown glucose regulating role of three vegetable peels from cucurbitaceae family was evaluated. In a preliminary study, effects of ethanolic extracts of Cucurbita pepo, Cucumis sativus and Praecitrullus fistulosus peels were studied at 250 and 500\u00a0mg\u00a0kg(-1)\u00a0d(-1) for 15\u00a0days in the alterations in serum glucose and in hepatic lipid peroxidation (LPO) in male mice.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20614191",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 900,
                    "offsetInEndSection": 1086,
                    "text": "All the three peel extracts nearly reversed most of these changes induced by alloxan suggesting their possible role in ameliorating diabetes mellitus and related changes in serum lipids.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20614191",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Antidiabetic activity of aqueous fruit extract of Cucumis trigonus Roxb. in streptozotocin-induced-diabetic rats.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 347,
                    "text": "Cucumis trigonus Roxb. (Cucurbitaceae) fruit is used in the Indian traditional medicine for the treatment of diabetes. Based on a number of reports on the blood glucose level reduction and the other complications of diabetes associated with some Cucurbitaceae plants, the antidiabetic effect of Cucumis trigonus fruit was investigated.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 490,
                    "offsetInEndSection": 632,
                    "text": "The antidiabetic activity of aqueous extract of Cucumis trigonus fruit was evaluated by using normal and streptozotocin-induced-diabetic rats.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1347,
                    "offsetInEndSection": 1512,
                    "text": "The aqueous fruit extract of Cucumis trigonus has had beneficial effects in reducing the elevated blood glucose level and lipid profile of STZ-induced-diabetic rats.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19854256",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "Possible amelioration of atherogenic diet induced dyslipidemia, hypothyroidism and hyperglycemia by the peel extracts of Mangifera indica, Cucumis melo and Citrullus vulgaris fruits in rats.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276533",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 261,
                    "text": "Hitherto unknown efficacy of the peel extracts of Mangifera indica (MI), Cucumis melo (CM) and Citrullus vulgaris (CV) fruits in ameliorating the diet-induced alterations in dyslipidemia, thyroid dysfunction and diabetes mellitus have been investigated in rats.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276533",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 919,
                    "offsetInEndSection": 1296,
                    "text": "Rats, treated simultaneously with either of the peel extracts reversed the CCT-diet induced increase in the levels of tissue LPO, serum lipids, glucose, creatinine kinase-MB and decrease in the levels of thyroid hormones and insulin indicating their potential to ameliorate the diet induced alterations in serum lipids, thyroid dysfunctions and hyperglycemia/diabetes mellitus.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19276533",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Role of pectin from cucumber (Cucumis sativus) in modulation of protein kinase C activity and regulation of glycogen metabolism in rats.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650589",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 518,
                    "text": "The regulatory role of protein kinase C (PKC) in glycogen metabolism in pectin fed rats was investigated. Administration of pectin (5 g/kg body wt/day) from cucumber (Cucumis sativius L.) led to inhibitory effects on PKC activity in the liver of rats. In the brain and pancreas, PKC activity was significantly higher in pectin-treated rats as compared to the control group. Level of blood glucose was significantly lowered and the level of glycogen in the liver was significantly increased in pectin-administered rats.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650589",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1386,
                    "offsetInEndSection": 1693,
                    "text": "Addition of fermented milk (yogurt) and pickled cucumber to a breakfast with a high-glycemic index bread significantly lowered postprandial glycemia and insulinemia compared with the reference meal. In contrast, addition of regular milk and fresh cucumber had no favorable effect on the metabolic responses.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11451723",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 461,
                    "text": "Tolbutamide, Cucurbita ficifolia, Phaseolus vulgaris, Opuntia streptacantha, Spinacea oleracea, Cucumis sativus and Cuminum cyminum decrease significantly the area under the glucose tolerance curve and the hyperglycemic peak.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8569244",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Two unsaturated fatty acids with potent \u03b1-glucosidase inhibitory activity purified from the body wall of sea cucumber (Stichopus japonicus).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416705",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1041,
                    "offsetInEndSection": 1361,
                    "text": "In this study, 2 fatty acids with strong \u03b1-glucosidase-inhibitory activity, 7(Z)-octadecenoic acid and 7(Z),10(Z)-octadecadienoic acid, were purified and identified from sea cucumber. Therefore, sea cucumber fatty acids can potentially be developed as a novel natural nutraceutical for the management of type-2 diabetes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416705",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Could the Menzerath-Altmann law be proved mathematically trivial in genomes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25503672"
            ],
            "ideal_answer": [
                "Yes. The view of Menzerath-Altmann law in genomes, as inevitable, is seriously flawed."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678"
            ],
            "type": "yesno",
            "id": "56bb1b4eac7ad10019000004",
            "snippets": [
                {
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 1101,
                    "text": "Here we review the statistical foundations of that test and consider three non-parametric tests based upon different correlation metrics and one parametric test to evaluate if Z \u223c 1/X in genomes. The most powerful test is a new non-parametric one based upon the correlation ratio, which is able to reject Z \u223c 1/X in nine out of 11 taxonomic groups and detect a borderline group. Rather than a fact, Z \u223c 1/X is a baseline that real genomes do not meet. The view of Menzerath-Altmann law as inevitable is seriously flawed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25503672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1095,
                    "offsetInEndSection": 1163,
                    "text": "The view of Menzerath-Altmann law as inevitable is seriously flawed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25503672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1033,
                    "offsetInEndSection": 1101,
                    "text": "The view of Menzerath-Altmann law as inevitable is seriously flawed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25503672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1039,
                    "offsetInEndSection": 1107,
                    "text": "The view of Menzerath-Altmann law as inevitable is seriously flawed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25503672",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Have Quantitative Trait Loci affecting splicing (splicing QTLs) been linked to disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21846806",
                "http://www.ncbi.nlm.nih.gov/pubmed/20707912",
                "http://www.ncbi.nlm.nih.gov/pubmed/22784570",
                "http://www.ncbi.nlm.nih.gov/pubmed/20856809"
            ],
            "ideal_answer": [
                "Yes, mutations in the DNA that affect the splicing pattern of genes have been linked in transcriptome population studies to a number of diseases."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056426",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000395",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000381",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040641",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017398",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D022821",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000389",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0000398",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0043484",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012326",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019655",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045291",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0045292",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0008380",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0006376"
            ],
            "type": "yesno",
            "id": "5158a5b8d24251bc05000097",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 616,
                    "text": "The spontaneously hypertensive rat (SHR) is a widely used rodent model of hypertension and metabolic syndrome. Previously we identified thousands of cis-regulated expression quantitative trait loci (eQTLs) across multiple tissues using a panel of rat recombinant inbred (RI) strains derived from Brown Norway and SHR progenitors. These cis-eQTLs represent potential susceptibility loci underlying physiological and pathophysiological traits manifested in SHR. We have prioritized 60 cis-eQTLs and confirmed differential expression between the parental strains by quantitative PCR in 43 (72%) of the eQTL transcripts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21846806",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1713,
                    "text": "These colocalizing correlated cis-eQTLs (c3-eQTLs) are highly attractive as primary susceptibility loci for the colocalizing pQTLs. Furthermore, sequence analysis of the c3-eQTL genes identified single nucleotide polymorphisms (SNPs) that are predicted to affect transcription factor binding affinity, splicing and protein function. These SNPs, which potentially alter transcript abundance and stability, represent strong candidate factors underlying not just eQTL expression phenotypes, but also the correlated metabolic and physiological traits. In conclusion, by integration of genomic sequence, eQTL and QTT datasets we have identified several genes that are strong positional candidates for pathophysiological traits observed in the SHR strain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21846806",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1107,
                    "text": "Identifying associations between genotypes and gene expression levels using microarrays has enabled systematic interrogation of regulatory variation underlying complex phenotypes. This approach has vast potential for functional characterization of disease states, but its prohibitive cost, given hundreds to thousands of individual samples from populations have to be genotyped and expression profiled, has limited its widespread application.RESULTS: Here we demonstrate that genomic regions with allele-specific expression (ASE) detected by sequencing cDNA are highly enriched for cis-acting expression quantitative trait loci (cis-eQTL) identified by profiling of 500 animals in parallel, with up to 90% agreement on the allele that is preferentially expressed. We also observed widespread noncoding and antisense ASE and identified several allele-specific alternative splicing variants.CONCLUSION: Monitoring ASE by sequencing cDNA from as little as one sample is a practical alternative to expression genetics for mapping cis-acting variation that regulates RNA transcription and processing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20707912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1263,
                    "offsetInEndSection": 1851,
                    "text": "The six genes corresponded to rat and mouse quantitative trait loci (QTLs) that had shown associations with the common traits such as the well characterized MS and even tumor susceptibility. Our findings suggest that the six genes may play important roles in the pleiotropic effects on lipid metabolism and the MS, which increase the risk of Type 2 Diabetes and cardiovascular disease. The use of the multivariate phenotypes can be advantageous in identifying genetic risk factors, accounting for the pleiotropic effects when the multivariate phenotypes have a common etiological pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22784570",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 693,
                    "text": "To elucidate mechanisms involved in multiple sclerosis (MS), we studied genetic regulation of experimental autoimmune encephalomyelitis (EAE) in rats, assuming a conservation of pathogenic pathways. In this study, we focused on Eae23, originally identified to regulate EAE in a (LEW.1AV1xPVG.1AV1)F2 cross. Our aim was to determine whether one or more genes within the 67 Mb region regulate EAE and to define candidate risk genes.METHODOLOGY/PRINCIPAL FINDINGS: We used high resolution quantitative trait loci (QTL) analysis in the 10th generation (G10) of an advanced intercross line (AIL) to resolve Eae23 into two QTLs that independently regulate EAE, namely Eae23a and Eae23b. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20856809",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29607687",
                "http://www.ncbi.nlm.nih.gov/pubmed/26697860"
            ],
            "ideal_answer": [
                "No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5ca0848aecadf2e73f000044",
            "snippets": [
                {
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 1222,
                    "text": "Treatment with memantine, a noncompetitive NMDA receptor antagonist which is an approved drug for treatment of Alzheimer's disease, rescued protein phosphatase-2A activity by decreasing its demethylation at Leu309 selectively and attenuated Alzheimer's disease-like pathology and cognitive impairment in adeno-associated virus vector-1-I1PP2A rats. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26697860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 626,
                    "text": "anti-Amyloid agents (13.30%)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29607687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 314,
                    "text": "no new drugs have been approved during the past 15\u00a0years; and the available medications are not cost-effective. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29607687",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Tecovirimat effective for smallpox?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20393639",
                "http://www.ncbi.nlm.nih.gov/pubmed/25480757",
                "http://www.ncbi.nlm.nih.gov/pubmed/23530860",
                "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                "http://www.ncbi.nlm.nih.gov/pubmed/24100494",
                "http://www.ncbi.nlm.nih.gov/pubmed/29773767",
                "http://www.ncbi.nlm.nih.gov/pubmed/25896687",
                "http://www.ncbi.nlm.nih.gov/pubmed/29982575",
                "http://www.ncbi.nlm.nih.gov/pubmed/29972742"
            ],
            "ideal_answer": [
                "Yes, tecovirimat FDA approved for treatment of smallpox."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c58923c86df2b9174000005",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 47,
                    "text": "Oral Tecovirimat for the Treatment of Smallpox.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972742",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2001,
                    "offsetInEndSection": 2206,
                    "text": "CONCLUSIONS: On the basis of its efficacy in two animal models and pharmacokinetic and safety data in humans, tecovirimat is being advanced as a therapy for smallpox in accordance with the FDA Animal Rule.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Background: Tecovirimat (ST-246) is being developed as an antiviral therapeutic for smallpox for use in the event of an accidental or intentional release. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29982575",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1384,
                    "text": "Conclusions: Tecovirimat treatment initiated up to 8 days following a lethal aerosol MPXV challenge improves survival and, when initiated earlier than 5 days after challenge, provides protection from clinical effects of disease, supporting the conclusion that it is a promising smallpox antiviral therapeutic candidate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29982575",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 35,
                    "text": "Tecovirimat: First Global Approval.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 618,
                    "text": "In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing \u2265\u00a013\u00a0kg.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 873,
                    "text": "An intravenous formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 1084,
                    "text": "Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo, has a different mechanism of action from tecovirimat (the only oral smallpox antiviral currently in the US Strategic National Stockpile), and has a resistance profile that reduces concerns in the scenario of a bioterror attack using genetically engineered smallpox.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29773767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25896687",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2035,
                    "offsetInEndSection": 2216,
                    "text": "Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100494",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does a linker histone exist in the yeast genome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22586276",
                "http://www.ncbi.nlm.nih.gov/pubmed/9516420",
                "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                "http://www.ncbi.nlm.nih.gov/pubmed/15046982",
                "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                "http://www.ncbi.nlm.nih.gov/pubmed/18687885",
                "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                "http://www.ncbi.nlm.nih.gov/pubmed/16342967",
                "http://www.ncbi.nlm.nih.gov/pubmed/11574687",
                "http://www.ncbi.nlm.nih.gov/pubmed/24023978",
                "http://www.ncbi.nlm.nih.gov/pubmed/15050829"
            ],
            "ideal_answer": [
                "Here, we present our results showing a connection between the linker histones, the higher-order chromatin structures, and the process of chronological lifespan of yeast cells. Characteristically, linker histone depleted chromatin generally exhibited longer chromatin loops than the wild-type. These results suggest that HHO1p may play a similar role to linker histones, but at restricted locations in the chromatin. The binding was structure specific, since the use of double-stranded DNA, or a mutant Hho1p in which the second DNA binding site of globular domain 1 was abolished, resulted in a significant decrease in bridged binding.",
                "Hho1p is a bona fide linker histone",
                "In Saccharomyces cerevisiae, HHO1 encodes a putative linker histone with very significant homology to histone H1. The putative linker histone in Saccharomyces cerevisiae, Hho1p, has two regions of sequence (GI and GII) that are homologous to the single globular domains of linker histones H1 and H5 in higher eukaryotes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015003",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012441",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678",
                "http://www.biosemantics.org/jochem#4278518",
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4278518",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006657"
            ],
            "type": "yesno",
            "id": "5709152ecf1c325851000014",
            "snippets": [
                {
                    "offsetInBeginSection": 999,
                    "offsetInEndSection": 1034,
                    "text": "Hho1p is a bona fide linker histone",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9516420",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 248,
                    "text": "In Saccharomyces cerevisiae, HHO1 encodes a putative linker histone with very significant homology to histone H1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11574687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1089,
                    "text": "HHO1p may play a similar role to linker histones, but at restricted locations in the chromatin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11574687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "The putative linker histone in Saccharomyces cerevisiae, Hho1p, has two regions of sequence (GI and GII) that are homologous to the single globular domains of linker histones H1 and H5 in higher eukaryotes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15046982",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "text": "The Saccharomyces cerevisiae homologue of the linker histone H1, Hho1p, has two domains that are similar in sequence to the globular domain of H1 (and variants such as H5)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050829",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Two homologous domains of similar structure but different stability in the yeast linker histone, Hho1p",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050829",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Saccharomyces cerevisiae encodes a single linker histone, Hho1p, with two globular domains. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16342967",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "The Saccharomyces cerevisiae linker histone Hho1p, with two globular domains, can simultaneously bind to two four-way junction DNA molecules",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16342967",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 272,
                    "text": "Here, we show in yeast, that the presence of yeast linker histone Hho1p represses expression of a pol II transcribed gene (MET15) embedded in the rDNA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18687885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Yeast linker histone Hho1p is required for efficient RNA polymerase I processivity and transcriptional silencing at the ribosomal DNA",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18687885",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Saccharomyces cerevisiae linker histone Hho1p is not essential for cell viability, and very little is known about its function in vivo. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "text": "Saccharomyces cerevisiae linker histone Hho1p functionally interacts with core histone H4 and negatively regulates the establishment of transcriptionally silent chromatin",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 813,
                    "offsetInEndSection": 1133,
                    "text": " Unlike canonical linker histones in higher eukaryotes that have a single conserved globular domain, Hho1p possesses two globular domains. We show that the carboxyl-terminal globular domain of Hho1p is dispensable for its function, suggesting that the mode of Hho1p action is similar to that of canonical linker histones",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19017647",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 440,
                    "text": "To identify new proteins involved in spore nuclear organization, we purified chromatin from mature spores and discovered a significant enrichment of the linker histone (Hho1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22586276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 621,
                    "offsetInEndSection": 837,
                    "text": "Hho1 chromatin immunoprecipitation followed by sequencing (ChIP-seq) revealed increased genome-wide binding in mature spores and provides novel in vivo evidence of the linker histone binding to nucleosomal linker DNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22586276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 327,
                    "text": "One of the peculiarities of S. cerevisiae cells is the unusual and less abundant linker histone, Hho1p.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Hho1p, the linker histone of Saccharomyces cerevisiae, is important for the proper chromatin organization in vivo",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 817,
                    "text": "Characteristically, linker histone depleted chromatin generally exhibited longer chromatin loops than the wild-type. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22200500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Saccharomyces cerevisiae linker histone-Hho1p maintains chromatin loop organization during ageing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023978",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 583,
                    "text": "Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 361,
                    "text": "Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 361,
                    "text": "Biochemical studies to date have not been able to identify the linker histone H1 protein in the budding yeast Saccharomyces cerevisiae. Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 361,
                    "text": "Database homology searching against the complete yeast genome has identified a gene, HHO1, (or YPL127C, formerly LPI17) which encodes a protein that has two regions that show similarity to the pea histone H1 globular domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11471242",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Fibroblast Growth Factor 23 a phosphaturic hormone?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24991914",
                "http://www.ncbi.nlm.nih.gov/pubmed/24466013",
                "http://www.ncbi.nlm.nih.gov/pubmed/25380933",
                "http://www.ncbi.nlm.nih.gov/pubmed/24434184",
                "http://www.ncbi.nlm.nih.gov/pubmed/25007710",
                "http://www.ncbi.nlm.nih.gov/pubmed/24980542",
                "http://www.ncbi.nlm.nih.gov/pubmed/25636143",
                "http://www.ncbi.nlm.nih.gov/pubmed/25404658",
                "http://www.ncbi.nlm.nih.gov/pubmed/26131357"
            ],
            "ideal_answer": [
                "Yes, fbroblast growth factor 23 (FGF23) is a phosphaturic hormone."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "570a5c27cf1c325851000023",
            "snippets": [
                {
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 609,
                    "text": "PTH can induce skeletal synthesis of another potent phosphaturic hormone, fibroblast growth factor 23 (FGF23), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26131357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 978,
                    "offsetInEndSection": 1114,
                    "text": " Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that has recently been identified as a CKD-related factor affecting CRS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25636143",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1148,
                    "text": " circulating phosphaturic hormone fibroblast growth factor-23 levels",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 199,
                    "text": " Fibroblast growth factor (FGF) 23 is one of the most recently discovered FGFs. This phosphaturic hormone produced in bones is a risk factor for cardiovascular diseases and thus mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25380933",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 68,
                    "offsetInEndSection": 179,
                    "text": "fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24466013",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 368,
                    "text": "fibroblast growth factor-23 (FGF23), a bone-derived phosphaturic hormone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24434184",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 264,
                    "text": " the phosphaturic hormone fibroblast growth factor 23 (FGF23) and soluble Klotho with all-cause mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 713,
                    "text": "In particular, diseases caused by changes in the expression and proteolytic control of the phosphaturic hormone fibroblast growth factor-23 (FGF23) have come to the forefront in terms of directing new models explaining mineral metabolism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 864,
                    "text": "serum levels of a phosphaturic hormone, fibroblast growth factor 23 (Fgf23), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007710",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is PTEN involved in follicular thyroid carcinoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11297621",
                "http://www.ncbi.nlm.nih.gov/pubmed/16487009",
                "http://www.ncbi.nlm.nih.gov/pubmed/9790504",
                "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
                "http://www.ncbi.nlm.nih.gov/pubmed/12203792",
                "http://www.ncbi.nlm.nih.gov/pubmed/21417916",
                "http://www.ncbi.nlm.nih.gov/pubmed/9832031"
            ],
            "ideal_answer": [
                "The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3962",
                "http://www.uniprot.org/uniprot/PTEN_XENLA"
            ],
            "type": "yesno",
            "id": "55031650e9bde69634000026",
            "snippets": [
                {
                    "offsetInBeginSection": 986,
                    "offsetInEndSection": 1221,
                    "text": "Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417916",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1422,
                    "text": "The frequency of germline pathogenic PTEN mutations in an unselected series of patients with DTC is relatively low, but it is enriched by considering follicular histology and macrocephaly",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21417916",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 594,
                    "text": "Similarly, there is increasing evidence demonstrating that mutations leading to activation of the phosphatidylinositol 3- kinase (PI3K)/AKT effectors -PTEN and PI3KCa- are essential for the pathogenesis of follicular thyroid carcinoma (FTC)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1351,
                    "offsetInEndSection": 1489,
                    "text": "A single male with follicular thyroid carcinoma from one of these 64 (2%) CS-like families harboured a germline point mutation, c.209T-->C",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9832031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 595,
                    "text": "Similarly, there is increasing evidence demonstrating that mutations leading to activation of the phosphatidylinositol 3- kinase (PI3K)/AKT effectors -PTEN and PI3KCa- are essential for the pathogenesis of follicular thyroid carcinoma (FTC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055323",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1123,
                    "offsetInEndSection": 1437,
                    "text": "The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12203792",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1656,
                    "text": "These results show a high frequency of PTEN promoter hypermethylation, especially in follicular tumors, suggesting its possible role in thyroid tumorigenesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16487009",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1093,
                    "offsetInEndSection": 1215,
                    "text": "Our findings suggest that the PTEN tumor suppressor gene is occasionally inactivated in sporadic follicular thyroid tumors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9790504",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 471,
                    "text": "Germline mutations in the tumor suppressor gene PTEN, which encodes a dual-specificity phosphatase, have been found in up to 80% of patients with Cowden syndrome suggesting a role of PTEN in the pathogenesis of follicular thyroid tumors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11297621",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 647,
                    "text": "The most common neoplasms in Cowden disease patients arise in the breast, skin, and thyroid (follicular subtype)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9790504",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1123,
                    "offsetInEndSection": 1436,
                    "text": "The transcriptional silencing of PTEN was significantly associated with the anaplastic subtype, suggesting that PTEN is involved in the carcinogenesis of highly malignant or late-stage thyroid cancers, whereas this particular mechanism appears to be of minor importance in differentiated follicular thyroid tumors",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12203792",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Tuberous Sclerosis a genetic disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20041940",
                "http://www.ncbi.nlm.nih.gov/pubmed/23622183",
                "http://www.ncbi.nlm.nih.gov/pubmed/19506736",
                "http://www.ncbi.nlm.nih.gov/pubmed/15456557",
                "http://www.ncbi.nlm.nih.gov/pubmed/9006662",
                "http://www.ncbi.nlm.nih.gov/pubmed/24226526",
                "http://www.ncbi.nlm.nih.gov/pubmed/16818174",
                "http://www.ncbi.nlm.nih.gov/pubmed/22021912",
                "http://www.ncbi.nlm.nih.gov/pubmed/24310804",
                "http://www.ncbi.nlm.nih.gov/pubmed/9770187",
                "http://www.ncbi.nlm.nih.gov/pubmed/18245941",
                "http://www.ncbi.nlm.nih.gov/pubmed/22068806",
                "http://www.ncbi.nlm.nih.gov/pubmed/23749404",
                "http://www.ncbi.nlm.nih.gov/pubmed/23966835",
                "http://www.ncbi.nlm.nih.gov/pubmed/20073603",
                "http://www.ncbi.nlm.nih.gov/pubmed/2600265",
                "http://www.ncbi.nlm.nih.gov/pubmed/22497684",
                "http://www.ncbi.nlm.nih.gov/pubmed/19744185",
                "http://www.ncbi.nlm.nih.gov/pubmed/21547713",
                "http://www.ncbi.nlm.nih.gov/pubmed/21907282",
                "http://www.ncbi.nlm.nih.gov/pubmed/20087180",
                "http://www.ncbi.nlm.nih.gov/pubmed/23359422",
                "http://www.ncbi.nlm.nih.gov/pubmed/12582162",
                "http://www.ncbi.nlm.nih.gov/pubmed/19624715",
                "http://www.ncbi.nlm.nih.gov/pubmed/24159711",
                "http://www.ncbi.nlm.nih.gov/pubmed/23661441",
                "http://www.ncbi.nlm.nih.gov/pubmed/22736301",
                "http://www.ncbi.nlm.nih.gov/pubmed/12364343",
                "http://www.ncbi.nlm.nih.gov/pubmed/19297407",
                "http://www.ncbi.nlm.nih.gov/pubmed/23438619",
                "http://www.ncbi.nlm.nih.gov/pubmed/15340059",
                "http://www.ncbi.nlm.nih.gov/pubmed/22544534",
                "http://www.ncbi.nlm.nih.gov/pubmed/18080139",
                "http://www.ncbi.nlm.nih.gov/pubmed/2706800",
                "http://www.ncbi.nlm.nih.gov/pubmed/1293183",
                "http://www.ncbi.nlm.nih.gov/pubmed/23035046",
                "http://www.ncbi.nlm.nih.gov/pubmed/12869586",
                "http://www.ncbi.nlm.nih.gov/pubmed/22025691",
                "http://www.ncbi.nlm.nih.gov/pubmed/16757313",
                "http://www.ncbi.nlm.nih.gov/pubmed/22125079",
                "http://www.ncbi.nlm.nih.gov/pubmed/11288117",
                "http://www.ncbi.nlm.nih.gov/pubmed/8129414",
                "http://www.ncbi.nlm.nih.gov/pubmed/21309039",
                "http://www.ncbi.nlm.nih.gov/pubmed/1479601",
                "http://www.ncbi.nlm.nih.gov/pubmed/21301339",
                "http://www.ncbi.nlm.nih.gov/pubmed/24092520",
                "http://www.ncbi.nlm.nih.gov/pubmed/8825048"
            ],
            "triples": [
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4098",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155",
                    "o": "http://www.dbpedia.org/resource/Tuberous_sclerosis"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155",
                    "o": "Tuberous_sclerosis"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4098",
                    "o": "Tuberous sclerosis-1, 191100"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4099",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1155"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4099",
                    "o": "Tuberous sclerosis-2, 191100"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/Q61037",
                    "o": "http://purl.uniprot.org/citations/10584558"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/10584558",
                    "o": "http://purl.uniprot.org/medline/20051947"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/10584558",
                    "o": "Genet. Res."
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_5136313033370014",
                    "o": "Tuberin"
                },
                {
                    "p": "http://purl.uniprot.org/core/alternativeName",
                    "s": "http://purl.uniprot.org/uniprot/Q61037",
                    "o": "http://linkedlifedata.com/resource/#_5136313033370015"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q61037",
                    "o": "http://linkedlifedata.com/resource/#_5136313033370014"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_5136313033370015",
                    "o": "Tuberous sclerosis 2 protein homolog"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/10584558",
                    "o": "http://purl.uniprot.org/pubmed/10584558"
                }
            ],
            "ideal_answer": [
                "Tuberous sclerosis is a genetic disorder with an autosomal dominant pattern of inheritance, variable expressivity, and incomplete penetrance. Two thirds of TSC cases result from sporadic genetic mutations, not inheritance, but their offspring may inherit it from them. Current genetic tests have difficulty locating the mutation in approximately 20% of individuals diagnosed with the disease. So far it has been mapped to two genetic loci, TSC1 and TSC2.\nTSC1 encodes for the protein hamartin, is located on chromosome 9 q34 and was discovered in 1997. TSC2 encodes for the protein Tuberin, is located on chromosome 16 p13.3 and was discovered in 1993. TSC2 is contiguous with PKD1, the gene involved in one form of polycystic kidney disease (PKD). Gross deletions affecting both genes may account for the 2% of individuals with TSC who also develop PKD in childhood. TSC2 has been associated with a more severe form of TSC. However, the difference is subtle and cannot be used to identify the mutation clinically. Estimates of the proportion of TSC caused by TSC2 range from 55% to 80-90%.",
                "Yes, Tuberous Sclerosis is a genetic disease, caused by mutations in the TSC1 or TSC2 gene."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/TSC2_RAT",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033596",
                "http://www.uniprot.org/uniprot/TSC1_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030342",
                "http://www.disease-ontology.org/api/metadata/DOID:13515",
                "http://www.disease-ontology.org/api/metadata/DOID:0050739",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014402",
                "http://www.uniprot.org/uniprot/TSC2_MOUSE",
                "http://www.disease-ontology.org/api/metadata/DOID:630",
                "http://www.uniprot.org/uniprot/TSC1_SCHPO",
                "http://www.uniprot.org/uniprot/TSC1_HUMAN",
                "http://www.uniprot.org/uniprot/TSC2_SCHPO",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005823",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012598",
                "http://www.biosemantics.org/jochem#4266396",
                "http://www.uniprot.org/uniprot/TSC1_MOUSE",
                "http://www.uniprot.org/uniprot/TSC2_HUMAN",
                "http://www.disease-ontology.org/api/metadata/DOID:0050325"
            ],
            "type": "yesno",
            "id": "52b06a68f828ad283c000005",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 65,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24310804",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 44,
                    "text": "Tuberous sclerosis is a rare genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24092520",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Tuberous sclerosis complex (TSC) is a multisystem genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23966835",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 464,
                    "text": "The disease is caused by mutational inactivation of the tumor suppressor gene tuberous sclerosis complex 1 (TSC1) or TSC2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23035046",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 428,
                    "text": "mTOR inhibitors have antiepileptogenic and antiseizure effects in animal models of the genetic disease, tuberous sclerosis complex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22544534",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "text": "Tuberous sclerosis (TSC) is an autosomal-dominant genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22497684",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 44,
                    "text": "Tuberous sclerosis is a rare genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22068806",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Tuberous Sclerosis Complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22125079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Tuberous sclerosis complex (TSC) is a multiorgan genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22025691",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22021912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Tuberous Sclerosis Complex (TSC) is a multiorgan genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21907282",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 311,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21301339",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 75,
                    "text": "Tuberous sclerosis complex (TSC) is a multiorgan genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20087180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 411,
                    "text": "In all these lesions, genetic alterations related to the tuberous sclerosis complex (TSC) have been demonstrated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20073603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 169,
                    "text": "Although epilepsy affects most patients with tuberous sclerosis complex (TSC), little is known about the natural history of epilepsy in this genetic disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20041940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "The tuberous sclerosis gene 2 product tuberin is an important regulator of the mammalian target of rapamycin (mTOR).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19744185",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19624715",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Tuberous Sclerosis Complex (TSC) is a multiorgan genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21547713",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "text": "Tuberous sclerosis complex (TSC) is a relatively rare autosomal dominant disorder",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19297407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Tuberous sclerosis is a genetic disease with autosomal dominant inheritance,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18245941",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 471,
                    "offsetInEndSection": 722,
                    "text": "PEComas are related to the genetic alterations of tuberous sclerosis complex (TSC), an autosomal dominant genetic disease due to losses of TSC1 (9q34) or TSC2 (16p13.3) genes which seem to have a role in the regulation of the Rheb/mTOR/p70S6K pathway.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18080139",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Tuberous sclerosis complex (TSC) is a multiorgan genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16818174",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16757313",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 44,
                    "text": "Tuberous sclerosis is a rare genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15456557",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15340059",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either TSC1 or TSC2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12869586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Tuberous sclerosis complex (TSC) is a genetic disease caused by mutations in either TSC1 or TSC2 tumor suppressor genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12582162",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "Mutation in either the TSC1 or TSC2 tumor suppressor gene is responsible for the inherited genetic disease of tuberous sclerosis complex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12364343",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Tuberous sclerosis (TSC) is a frequent autosomal-dominant condition (affecting 1 in 6000 individuals) caused by various mutations in either the hamartin (TSC1) or the tuberin gene (TSC2).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11288117",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 44,
                    "text": "Tuberous sclerosis is a rare genetic disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9770187",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 101,
                    "text": "Tuberous sclerosis (TS) is a genetic disease with prominent cutaneous and brain involvement ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8129414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 200,
                    "text": "TSC was recognized to be a genetic disease with autosomal dominant inheritance",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1293183",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 632,
                    "offsetInEndSection": 829,
                    "text": "On average TSC families are very small; in most cases there are fewer than two informative meioses. The size distribution of chromosome 9 linked families was similar to that of non-linked families.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1479601",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 507,
                    "text": "The effects of missense changes and small in-frame deletions and insertions on protein function are not easy to predict, and the identification of such variants in individuals at risk of a genetic disease can complicate genetic counselling. One option is to perform functional tests to assess whether the variants affect protein function. We have used this strategy to characterize variants identified in the TSC1 and TSC2 genes in individuals with, or suspected of having, Tuberous Sclerosis Complex (TSC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21309039",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 51,
                    "text": "Tuberous sclerosis is a dominant hereditary disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2600265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 181,
                    "offsetInEndSection": 283,
                    "text": "Many of these advances originated from studies of the genetic disease tuberous sclerosis complex (TSC)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24226526",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does gepotidacin activate bacterial topoisomerase?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26586303"
            ],
            "ideal_answer": [
                "No, gepotidacin is a bacterial topoisomerase inhibitor."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c0114ec133db5eb78000028",
            "snippets": [
                {
                    "offsetInBeginSection": 3,
                    "offsetInEndSection": 116,
                    "text": "GSK2140944 is a novel bacterial topoisomerase inhibitor in development for the treatment of bacterial infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586303",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is pazopanib an effective treatment of glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20200024",
                "http://www.ncbi.nlm.nih.gov/pubmed/23363814"
            ],
            "ideal_answer": [
                "No. Pazopanib does not improve survival of glioblastoma patients."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c72aaed7c78d6947100006f",
            "snippets": [
                {
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1141,
                    "text": "RESULTS: The six-month progression-free survival (PFS) rates in phase II (n = 41) were 0% and 15% in the PTEN/EGFRvIII-positive and PTEN/EGFRvIII-negative cohorts, respectively, leading to early termination. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23363814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1629,
                    "offsetInEndSection": 1780,
                    "text": "Single-agent pazopanib did not prolong PFS in this patient population but showed in situ biological activity as demonstrated by radiographic responses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200024",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does lucatumumab bind to CD140?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22475052"
            ],
            "ideal_answer": [
                "No, lucatumumab is a fully humanized anti-CD40 antibody that blocks interaction of CD40L with CD40 and also mediates antibody-dependent cell-mediated cytotoxicity (ADCC)."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c654c14e842deac67000025",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Lucatumumab is a fully humanized anti-CD40 antibody that blocks interaction of CD40L with CD40 and also mediates antibody-dependent cell-mediated cytotoxicity (ADCC). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475052",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475052",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 731,
                    "offsetInEndSection": 889,
                    "text": "Saturation of CD40 receptor on CLL cells was uniform at all doses post-treatment but also persisted at trough time points in the 3.0 mg/kg or greater cohorts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475052",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between serum interleukin-6 concentrations and outcomes of stroke patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17337911",
                "http://www.ncbi.nlm.nih.gov/pubmed/19901973",
                "http://www.ncbi.nlm.nih.gov/pubmed/18048088",
                "http://www.ncbi.nlm.nih.gov/pubmed/14730251",
                "http://www.ncbi.nlm.nih.gov/pubmed/18685925",
                "http://www.ncbi.nlm.nih.gov/pubmed/25295149"
            ],
            "ideal_answer": [
                "Yes. Greater serum interleukin-6 concentrations are associated with worse outcomes in ischemic and hemmorhagic stroke patients"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/IL6_PIG"
            ],
            "type": "yesno",
            "id": "54cf4bc3f693c3b16b00000d",
            "snippets": [
                {
                    "offsetInBeginSection": 1418,
                    "offsetInEndSection": 1496,
                    "text": " In addition, IL-6 concentrations affect clinical outcomes in ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25295149",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 968,
                    "offsetInEndSection": 1363,
                    "text": "After appropriate adjustment, the odds ratios for the association of markers and poor outcome (comparing the upper and the lower third) were interleukin-6, 3.1 (95% CI: 1.9-5.0); C-reactive protein, 1.9 (95% CI: 1.2-3.1); fibrinogen, 1.5 (95% CI: 1.0-2.36); white cell count, 2.1 (95% CI: 1.3-3.4); and glucose 1.3 (95% CI: 0.8-2.1). The results for interleukin-6 were similar to other studies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19901973",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1745,
                    "offsetInEndSection": 1992,
                    "text": "-6 and IL-10 levels were higher in patients with poor outcome. On logistic regression analysis, higher values of IL-6 were significantly associated with clinical outcome at 1 month (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02-1.54). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2116,
                    "offsetInEndSection": 2216,
                    "text": "In hemorrhagic stroke, high levels of IL-6 in the early phase indicated a poor neurological outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18685925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1551,
                    "text": "Initially elevated levels of hs-IL-6 at presentation further correlated with unfavorable clinical outcomes (by NIHSS and mRs) at both time points. Analysis of variance in the different quartiles identified an hs-IL-6 gradient-dependent correlation at both time points, such that the higher the initial hs-IL-6 concentration, the higher the elevation in inflammatory biomarkers and the poorer the neurological state at both time points (p<0.001 for NIHSS and p=0.001 for mRs, for trend across quartiles). CONCLUSIONS: This study demonstrates the potential of employing hs-IL-6 as an early stage biomarker for the prognosis of acute ischemic stroke. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18048088",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1325,
                    "text": "Another negative correlation was found between IL-6 and CNS scores (r = -0.451, p = 0.000).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17337911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1816,
                    "offsetInEndSection": 1950,
                    "text": "In addition, increased levels of IL-6 and reduced levels of protein C and protein S may play a role in acute ischemic stroke severity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17337911",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 490,
                    "text": "Variables that are predictors of adverse stroke outcome include erythrocyte sedimentation rate, and levels of C-reactive protein (CRP), interleukin-6, tumour necrosis factor-alpha and intercellular adhesion molecule-1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14730251",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are protamines ubiquitously expressed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29797354"
            ],
            "ideal_answer": [
                "No,\nProtamines are nuclear proteins which are specifically expressed in haploid male germ cells."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c9f1b0cecadf2e73f00003c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Protamines are nuclear proteins which are specifically expressed in haploid male germ cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29797354",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any association between suicide and autism in adolescents, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27956832",
                "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
                "http://www.ncbi.nlm.nih.gov/pubmed/28872268",
                "http://www.ncbi.nlm.nih.gov/pubmed/25200592",
                "http://www.ncbi.nlm.nih.gov/pubmed/29854129",
                "http://www.ncbi.nlm.nih.gov/pubmed/25084822",
                "http://www.ncbi.nlm.nih.gov/pubmed/17885828",
                "http://www.ncbi.nlm.nih.gov/pubmed/29706156",
                "http://www.ncbi.nlm.nih.gov/pubmed/23666287"
            ],
            "ideal_answer": [
                "Adults with autism spectrum disorder (ASD) are at increased risk of suicide compared to the general population."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c5217fd7e3cb0e231000005",
            "snippets": [
                {
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 957,
                    "text": ": In all subjects from our research on PubMed, 21.3% of subjects with autism spectrum disorder reported suicidal ideation, have attempted suicide or died by suicide (115 out of 539 subjects) and 7.7% of subjects supported for suicidal thoughts or attempted suicide exhibited an autism spectrum disorder (62 out of 806 subjects), all ages combined. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200592",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1057,
                    "offsetInEndSection": 1212,
                    "text": "Suicide attempts are accompanied by a willingness for death and can lead to suicide. They are more common in high-functioning autism and Asperger subjects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200592",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 1208,
                    "text": " A total sample of 10 adolescents and young adults diagnosed with AS was obtained. The high proportion of respondents with scores above the cutoff point on the overt victimization and relational victimization scales suggests that these adolescents and young adults experienced high levels of victimization. Of the sample, 20 percent met criteria for a diagnosis of Major Depressive Disorder, 30 percent met criteria for Generalized Anxiety Disorder and 50 percent had clinically significant level of suicidal ideation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17885828",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 177,
                    "text": "Previous studies reported a high prevalence of depression among patients with autism spectrum disorder (ASD) and suggested a relationship between ASD and suicidality",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872268",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1178,
                    "offsetInEndSection": 1270,
                    "text": "Patients with ASD had an increased risk of suicide attempts compared with those without ASD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872268",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 326,
                    "text": "The suicidal behaviors are frequently observed in the adolescents and adults with an ASD without intellectual deficience. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23666287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Suicide is a major problem in Western society. However we have very little understanding of suicidal behaviour among individuals with autism spectrum disorders. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 694,
                    "text": "The available research provides little empirical evidence for the processes underlying suicidal behaviour in adolescents and young adults with autism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24201088",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 226,
                    "offsetInEndSection": 395,
                    "text": " The present study aims to assess the rate of suicidality (suicidal ideation, behaviors and attempts) and associated risk factors for suicidality in high functioning ASD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27956832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 225,
                    "text": "here is a lack of clinical awareness on suicidal behaviors of children and adolescents with autism spectrum disorder (ASD)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27956832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 114,
                    "text": "suicidality in children and adolescents with diagnosis of high functioning autism spectrum disorder ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27956832",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1679,
                    "offsetInEndSection": 1771,
                    "text": "Consistent with the previous findings, rate of suicidality is higher in individuals with ASD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27956832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Detection of Suicidality in Adolescents with Autism Spectrum Disorders",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29854129",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Over 15% of young people with autism spectrum disorders (ASD) will contemplate or attempt suicide during adolescence. Yet,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29854129",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "Until recently, suicidality in autism spectrum disorder (ASD) was rarely discussed. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706156",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 27,
                    "offsetInEndSection": 67,
                    "text": "Suicidality in Autism Spectrum Disorder.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706156",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 172,
                    "offsetInEndSection": 376,
                    "text": "highlighted not only that suicidal thoughts and suicide attempts can occur in adolescents and young adults with ASD, but also that suicidality is likely more common in ASD than in the general population. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706156",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 757,
                    "text": "The emerging studies indicate that the increased risk of self-injurious behavior in younger and less cognitively able children with ASD3,4 is matched by an increased risk of suicidality in those at a more advanced developmental level.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29706156",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 959,
                    "text": "RESULTS\nIn all subjects from our research on PubMed, 21.3% of subjects with autism spectrum disorder reported suicidal ideation, have attempted suicide or died by suicide (115 out of 539 subjects) and 7.7% of subjects supported for suicidal thoughts or attempted suicide exhibited an autism spectrum disorder (62 out of 806 subjects), all ages combined.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25200592",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Risk of Suicide Attempts Among Adolescents and Young Adults With Autism Spectrum Disorder: A Nationwide Longitudinal Follow-Up Study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28872268",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "text": "Although the suicide risk of autism spectrum disorder (ASD) has been suggested to be higher than previously recognized, there are few case reports focusing on the process for preventing suicide reattempts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25084822",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do yeast LTR give rise to circular DNA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                "http://www.ncbi.nlm.nih.gov/pubmed/22977178",
                "http://www.ncbi.nlm.nih.gov/pubmed/28090380",
                "http://www.ncbi.nlm.nih.gov/pubmed/26979517"
            ],
            "ideal_answer": [
                "A recent study on circular DNAs in yeast found that transposable element sequence residing in circular structures mostly corresponded to full-length transposable elements. Circular retrotransposition products are generated by a LINE retrotransposon. Yeast LTR elements generate circular DNAs through recombination events between their flanking long terminal repeats (LTRs). Circular DNAs can be generated by recombination between LTRs residing at different genomic loci, in which case the circular DNA will contain the intervening sequence."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c34794fda8336e21a000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Circular retrotransposition products generated by a LINE retrotransposon",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977178",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Formation of Extrachromosomal Circular DNA from Long Terminal Repeats of Retrotransposons in Saccharomyces cerevisiae",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 304,
                    "text": "Ty eccDNA can arise from the circularization of extrachromosomal linear DNA during the transpositional life cycle of retrotransposons, or from circularization of genomic Ty DNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 478,
                    "text": "Circularization may happen through nonhomologous end-joining (NHEJ) of long terminal repeats (LTRs) flanking Ty elements, by Ty autointegration, or by LTR-LTR recombination",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 255,
                    "text": "We have recently shown that yeast LTR elements generate circular DNAs through recombination events between their flanking long terminal repeats (LTRs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 433,
                    "text": "Similarly, circular DNAs can be generated by recombination between LTRs residing at different genomic loci, in which case the circular DNA will contain the intervening sequence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 514,
                    "text": "A recent study on circular DNAs in yeast found that transposable element sequence residing in circular structures mostly corresponded to full-length transposable elements.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26979517",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is PTEN a tumour suppressor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29858604",
                "http://www.ncbi.nlm.nih.gov/pubmed/29460925"
            ],
            "ideal_answer": [
                "Yes"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e6df5b51af46fc130000025",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 34,
                    "text": "PTEN is a potent tumour suppressor",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29858604",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Genomic aberrations of the PTEN tumour suppressor gene are among the most common in prostate cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29460925",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the Wnt protein modified by notum?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18505598",
                "http://www.ncbi.nlm.nih.gov/pubmed/22669824",
                "http://www.ncbi.nlm.nih.gov/pubmed/22159580",
                "http://www.ncbi.nlm.nih.gov/pubmed/18429952",
                "http://www.ncbi.nlm.nih.gov/pubmed/24523458",
                "http://www.ncbi.nlm.nih.gov/pubmed/15647319",
                "http://www.ncbi.nlm.nih.gov/pubmed/25731175",
                "http://www.ncbi.nlm.nih.gov/pubmed/10049571",
                "http://www.ncbi.nlm.nih.gov/pubmed/24992682"
            ],
            "ideal_answer": [
                "Yes, \tNotum deacylates Wnt proteins to suppress signalling activity."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "57089865cf1c32585100000c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 62,
                    "text": "Notum deacylates Wnt proteins to suppress signalling activity.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25731175",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 860,
                    "offsetInEndSection": 1089,
                    "text": "Kinetic and mass spectrometric analyses of human proteins show that Notum is a carboxylesterase that removes an essential palmitoleate moiety from Wnt proteins and thus constitutes the first known extracellular protein deacylase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25731175",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 817,
                    "text": "the Wnt inhibitor notum",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992682",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 953,
                    "text": "the WNT-inhibitor notum.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523458",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "is pharmacological treatment of subclinical hypothyroidism effective in reducing cardiovascular events?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20807695",
                "http://www.ncbi.nlm.nih.gov/pubmed/16259335",
                "http://www.ncbi.nlm.nih.gov/pubmed/23559085",
                "http://www.ncbi.nlm.nih.gov/pubmed/16542047",
                "http://www.ncbi.nlm.nih.gov/pubmed/22529180",
                "http://www.ncbi.nlm.nih.gov/pubmed/16026106",
                "http://www.ncbi.nlm.nih.gov/pubmed/23369134",
                "http://www.ncbi.nlm.nih.gov/pubmed/17636722",
                "http://www.ncbi.nlm.nih.gov/pubmed/21823062",
                "http://www.ncbi.nlm.nih.gov/pubmed/19463607",
                "http://www.ncbi.nlm.nih.gov/pubmed/23252247",
                "http://www.ncbi.nlm.nih.gov/pubmed/19006851"
            ],
            "ideal_answer": [
                "whether SH confers a high risk for cardiovascular disease, and whether LT4 therapy has a long-term benefit that clearly outweighs the risks of overzealous treatment in these individuals, remain topics of controversy."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:114",
                "http://www.disease-ontology.org/api/metadata/DOID:1459",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016896",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002318",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007037"
            ],
            "type": "yesno",
            "id": "52d7b45e98d0239505000002",
            "snippets": [
                {
                    "offsetInBeginSection": 1802,
                    "offsetInEndSection": 2119,
                    "text": "The decision to treat elderly people is still an unresolved clinical challenge--first, due to a lack of appropriately powered randomized controlled trials of L-T4 in sHT patients, examining cardiovascular hard endpoints in various classes of age; and second, because of the negative effects of possible overtreatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23559085",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1562,
                    "offsetInEndSection": 1891,
                    "text": "The lack of specific randomized trials enrolling either old or very old subjects, aimed at evaluate the efficacy of hormonal replacement on overall survival and cardiovascular risk reduction along with the negative effects of possible over-treatment, makes the decision to treat older people a still unresolved clinical challenge",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23369134",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 924,
                    "offsetInEndSection": 1035,
                    "text": "In patients with type 2 DM, the presence of SH serves as an additional risk factor for endothelial dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23252247",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1535,
                    "offsetInEndSection": 1673,
                    "text": "Treatment of SCH with levothyroxine was associated with fewer IHD events in younger individuals, but this was not evident in older people.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22529180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1498,
                    "offsetInEndSection": 1695,
                    "text": "Subclinical hyperthyroidism seems to be a risk factor of developing major cardiovascular events, especially stroke in older adults from the general population with normal left ventricular function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21823062",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1709,
                    "text": "SCH appears to influence the postoperative outcome for patients by increasing the development of postoperative atrial fibrillation. However, it is still unproven whether preoperative thyroxine replacement therapy for patients with SCH might prevent postoperative atrial fibrillation after CABG.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19463607",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1197,
                    "offsetInEndSection": 1341,
                    "text": "In CHF patients TSH levels even slightly above normal range are independently associated with a greater likelihood of heart failure progression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19006851",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2028,
                    "offsetInEndSection": 2309,
                    "text": "In current RCTs, levothyroxine replacement therapy for subclinical hypothyroidism did not result in improved survival or decreased cardiovascular morbidity. Data on health-related quality of life and symptoms did not demonstrate significant differences between intervention groups.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17636722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2028,
                    "offsetInEndSection": 2423,
                    "text": "However, the actual effectiveness of thyroid hormone substitution in reducing the risk of cardiovascular events remains to be elucidated. In conclusion, the multiplicity and the possible reversibility of subclinical hypothyroidism-associated cardiovascular abnormalities suggest that the decision to treat a patient should depend on the presence of risk factors, rather than on a TSH threshold. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16542047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1408,
                    "offsetInEndSection": 1633,
                    "text": "However, whether SH confers a high risk for cardiovascular disease, and whether LT4 therapy has a long-term benefit that clearly outweighs the risks of overzealous treatment in these individuals, remain topics of controversy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16026106",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are cutaneous porphyrias inherited with a recessive pattern?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15868463",
                "http://www.ncbi.nlm.nih.gov/pubmed/11202049",
                "http://www.ncbi.nlm.nih.gov/pubmed/12859407"
            ],
            "ideal_answer": [
                "No, cutaneous porphyrias are inherited in a dominant (not recessive) pattern."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "58e11b9b6fddd3e83e00000b",
            "snippets": [
                {
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 728,
                    "text": "Five of the porphyrias are low-penetrance autosomal dominant conditions in which clinical expression results from additional factors that act by increasing demand for haem or by causing an additional decrease in enzyme activity or by a combination of these effects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "Molecular mechanisms of dominant expression in porphyria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "text": "Variegate porphyria (VP) is an autosomal-dominant disorder that is caused by inheritance of a partial deficiency of the enzyme protoporphyrinogen oxidase (EC 1.3.3.4). It is characterized by cutaneous photosensitivity and/or various neurological manifestations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12859407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "The acute porphyrias constitute a group of metabolic disorders engaging enzymes in the haem synthetic chain and generally following dominant inheritance patterns.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11202049",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there evidence to suggest that triiodothyronine has neuroprotective properties in traumatic brain injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9681483",
                "http://www.ncbi.nlm.nih.gov/pubmed/11719005",
                "http://www.ncbi.nlm.nih.gov/pubmed/12445968",
                "http://www.ncbi.nlm.nih.gov/pubmed/6798220",
                "http://www.ncbi.nlm.nih.gov/pubmed/23313345",
                "http://www.ncbi.nlm.nih.gov/pubmed/23601250",
                "http://www.ncbi.nlm.nih.gov/pubmed/839237",
                "http://www.ncbi.nlm.nih.gov/pubmed/7804793"
            ],
            "ideal_answer": [
                "Yes, it has been demonstrated that triiodothyronine exerts neuroprotective properties in traumatic brain injury setting."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "552010076b348bb82c000015",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Exogenous T3 administration provides neuroprotection in a murine model of traumatic brain injury.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 797,
                    "text": "Treatment with T3 (1.2\u03bcg/100g body weight, i.p.) 1h after TBI resulted in a significant improvement in motor and cognitive recovery after CCI, as well as in marked reduction of lesion volumes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 958,
                    "offsetInEndSection": 1433,
                    "text": "Western blot analysis revealed the ability of T3 to reduce brain trauma through modulation of cytoplasmic-nuclear shuttling of nuclear factor-\u03baB (NF-\u03baB). Twenty-four hours after brain trauma, T3-treated mice also showed significantly lower number of TUNEL(+) apoptotic neurons and curtailed induction of Bax, compared to vehicle control. In addition, T3 significantly enhanced the post-TBI expression of the neuroprotective neurotrophins (BDNF and GDNF) compared to vehicle. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1692,
                    "offsetInEndSection": 1798,
                    "text": "The stimulating effect of T3 on peripheral nerve regeneration may have considerable therapeutic potential.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12445968",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1651,
                    "offsetInEndSection": 1864,
                    "text": "The present study provides evidence that the peripheral nervous system has its own system responsible for the local production of 3,5,3'-triiodothyronine, which may play a key role during the regeneration process.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11719005",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 554,
                    "text": "Although it has been hypothesized that T3 may facilitate neuronal regeneration after CNS injury, the 5'-D2 response to brain injury is unknown.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9681483",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 907,
                    "offsetInEndSection": 1097,
                    "text": "The outcome after brain injury is closely correlated with the intensity of these changes, particularly with catecholamine plasma levels and the severity of the low triiodothyronine syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7804793",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "The thyroid hormones triiodothyronine (T3) and L-thyroxine appear to enhance regeneration in the peripheral and central nervous system (CNS). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6798220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 836,
                    "offsetInEndSection": 946,
                    "text": "T3 treatment influenced the general levels of incorporation of all treated groups over all days postoperation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6798220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1347,
                    "offsetInEndSection": 1459,
                    "text": "T3 effects appear to involve an increased sensitivity of the cells of the injured nervous system to the hormone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6798220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 791,
                    "text": "T3, when administered over an 8 week period, stimulated axonal regeneration in the dorsal cortex and corpus callosum and promoted healing of the wound in the corpus callosum. The results of this investigation suggest that the use of T3 in the clinical treatment of injury to the central nervous system may be of less value than the work of earlier authors had indicated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/839237",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1298,
                    "offsetInEndSection": 1433,
                    "text": "In addition, T3 significantly enhanced the post-TBI expression of the neuroprotective neurotrophins (BDNF and GDNF) compared to vehicle",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23313345",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are Notch mutations related to T-cell Acute Lymphoblastic Leukemia (T-ALL)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21302811",
                "http://www.ncbi.nlm.nih.gov/pubmed/24301524",
                "http://www.ncbi.nlm.nih.gov/pubmed/24252593",
                "http://www.ncbi.nlm.nih.gov/pubmed/18056171",
                "http://www.ncbi.nlm.nih.gov/pubmed/23033986",
                "http://www.ncbi.nlm.nih.gov/pubmed/23730497",
                "http://www.ncbi.nlm.nih.gov/pubmed/24401270",
                "http://www.ncbi.nlm.nih.gov/pubmed/24140475",
                "http://www.ncbi.nlm.nih.gov/pubmed/21463127",
                "http://www.ncbi.nlm.nih.gov/pubmed/20008221",
                "http://www.ncbi.nlm.nih.gov/pubmed/17575125",
                "http://www.ncbi.nlm.nih.gov/pubmed/20015880",
                "http://www.ncbi.nlm.nih.gov/pubmed/16707600",
                "http://www.ncbi.nlm.nih.gov/pubmed/24068942",
                "http://www.ncbi.nlm.nih.gov/pubmed/25493453",
                "http://www.ncbi.nlm.nih.gov/pubmed/18184405",
                "http://www.ncbi.nlm.nih.gov/pubmed/20967796",
                "http://www.ncbi.nlm.nih.gov/pubmed/21263446",
                "http://www.ncbi.nlm.nih.gov/pubmed/23022380"
            ],
            "ideal_answer": [
                "Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL). Activating mutations in NOTCH1, an essential regulator of T cell development, are frequently found in human T cell acute lymphoblastic leukemia (T-ALL). ",
                "Yes, Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL).T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is characterized by aberrant activation of NOTCH1 in over 60% of T-ALL cases."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:5603"
            ],
            "type": "yesno",
            "id": "5522fadb7b523f2123000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 467,
                    "text": "Notch receptors participate in a highly conserved signalling pathway that regulates normal development and tissue homeostasis in a context- and dose-dependent manner. Deregulated Notch signalling has been implicated in many diseases, but the clearest example of a pathogenic role is found in T-cell lymphoblastic leukaemia/lymphoma (T-LL), in which the majority of human and murine tumours have acquired mutations that lead to aberrant increases in Notch1 signalling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967796",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 351,
                    "text": "NOTCH proteins (NOTCH1, NOTCH2, NOTCH3 and NOTCH4) play crucial roles in embryonic development. Also, mounting evidence indicates that NOTCH contributes to the pathogenesis of hematopoietic and solid malignancies. Recent studies reported a high incidence of gain-of-function mutations of the NOTCH1 gene in T-cell acute lymphoblastic leukemias (ALL). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1126,
                    "offsetInEndSection": 1300,
                    "text": "Our data indicate that NOTCH1 is mutated in T-ALL, but not in other common human cancers, and that NOTCH2, NOTCH3 and NOTH4 genes are rarely mutated in common human cancers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18184405",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 602,
                    "text": "The Notch signaling pathway plays a critical role in maintaining the balance between cell proliferation, differentiation and apoptosis, and is a highly conserved signaling pathway that regulates normal development in a context- and dose-dependent manner. Dysregulation of Notch signaling has been suggested to be key events in a variety of hematological malignancies. Notch1 signaling appears to be the central oncogenic trigger in T cell acute lymphoblastic leukemia (T-ALL), in which the majority of human malignancies have acquired mutations that lead to constitutive activation of Notch1 signaling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24252593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 521,
                    "text": "T-cell acute lymphoblastic leukemia (T-ALL) is characterized as a high-risk stratified disease associated with frequent relapse, chemotherapy resistance, and a poorer prognostic outlook than B-precursor ALL. Many of the challenges in treating T-ALL reflect the lack of prognostic cytogenetic or molecular abnormalities on which to base therapy, including targeted therapy. Notch1 activating mutations were identified in more than 50% of T-ALL cases and can be therapeutically targeted with \u03b3-secretase inhibitors (GSIs). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140475",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 296,
                    "text": "Notch1 is a transmembrane receptor that is frequently mutated in human T-cell acute lymphoblastic leukemia (T-ALL). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068942",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 364,
                    "text": "T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is characterized by aberrant activation of NOTCH1 in over 60% of T-ALL cases. The high prevalence of activating NOTCH1 mutations highlights the critical role of NOTCH signaling in the pathogenesis of this disease and has prompted the development of therapeutic approaches targeting the NOTCH signaling pathway. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23730497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Activating mutations in NOTCH1, an essential regulator of T cell development, are frequently found in human T cell acute lymphoblastic leukemia (T-ALL). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23022380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "NOTCH signaling pathway is essential in T-cell development and NOTCH1 mutations are frequently present in T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16707600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 342,
                    "text": "Mutations in NOTCH1/FBXW7 activate NOTCH signaling and are of prognostic significance in patients with T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25493453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 79,
                    "offsetInEndSection": 207,
                    "text": "Gain-of-function mutations in Notch-1 have been reported in more than 50% of human T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Notch signaling is of crucial importance in normal T-cell development and Notch 1 is frequently mutated in T-cell acute lymphoblastic leukemias (T-ALL), leading to aberrantly high Notch signaling.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575125",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Activation of the Notch pathway occurs commonly in T acute lymphoblastic leukemia (T-ALL) because of mutations in Notch1 or Fbw7 and is involved in the regulation of cell proliferation and survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21263446",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "T-cell acute lymphoblastic leukemia (T-ALL) patients frequently display NOTCH1 activating mutations and Notch can transcriptionally down-regulate the tumor suppressor PTEN.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20015880",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "text": "The identification of activating mutations in NOTCH1 in over 50% of T-cell acute lymphoblastic leukemias (T-ALL) has generated major interest in the elucidation of the mechanisms of transformation downstream of oncogenic NOTCH and in the targeting of the NOTCH signaling pathway in this disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008221",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 263,
                    "text": "BACKGROUND: In T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), activating mutations of NOTCH1 are observed in more than 50% of cases, whereas the t(7;9)(q34;q34) involving NOTCH1 at 9q34 and TRB@ at 7q34 is an extremely rare but recurrent translocation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23033986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Activating mutations in NOTCH1 consitute the most prominent genetic abnormality in T-cell acute lymphoblastic leukemia (T-ALL).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21463127",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that is frequently associated with activating mutations in NOTCH1 and dysregulation of MYC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24401270",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "The Notch signaling pathway has been recognized as a key factor for the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), because of the high incidence of activating mutations of Notch1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24301524",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "Notch signaling is of crucial importance in normal T-cell development and Notch 1 is frequently mutated in T-cell acute lymphoblastic leukemias (T-ALL), leading to aberrantly high Notch signaling",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17575125",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "NOTCH signaling pathway is essential in T-cell development and NOTCH1 mutations are frequently present in T-cell acute lymphoblastic leukemia (T-ALL)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16707600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18056171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 207,
                    "text": "Gain-of-function mutations in Notch-1 have been reported in more than 50% of human T-cell acute lymphoblastic leukemia (T-ALL)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21302811",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does radiation for tinea capitis increases brain tumor risk?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1640715",
                "http://www.ncbi.nlm.nih.gov/pubmed/15799699",
                "http://www.ncbi.nlm.nih.gov/pubmed/8081035",
                "http://www.ncbi.nlm.nih.gov/pubmed/18447746",
                "http://www.ncbi.nlm.nih.gov/pubmed/11538033",
                "http://www.ncbi.nlm.nih.gov/pubmed/23227384",
                "http://www.ncbi.nlm.nih.gov/pubmed/8315464",
                "http://www.ncbi.nlm.nih.gov/pubmed/6930522",
                "http://www.ncbi.nlm.nih.gov/pubmed/15565500",
                "http://www.ncbi.nlm.nih.gov/pubmed/11949834",
                "http://www.ncbi.nlm.nih.gov/pubmed/213536",
                "http://www.ncbi.nlm.nih.gov/pubmed/2137438"
            ],
            "ideal_answer": [
                "Yes, radiation therapy for tinea capitis is associated with increased risk of meningiomas and gliomas."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e3238bcfbd6abf43b000056",
            "snippets": [
                {
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 763,
                    "text": "Emphasis is placed on meningiomas resulting from childhood treatment for primary brain tumor or tinea capitis, exposure to dental x-rays, and exposure to atomic explosions in Hiroshima and Nagasaki. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "It is well known that radiation can induce meningiomas. These tumors usually arise in patients with a history of low-dose radiation to the scalp for treatment of tinea capitis or high-dose radiation for a previous brain tumor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15565500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 675,
                    "text": "This paper describes six cases of radiation-associated intracranial meningiomas in patients previously treated with low-dose radiation to the scalp for tinea capitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15565500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 1008,
                    "text": "After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15799699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1078,
                    "offsetInEndSection": 1340,
                    "text": "The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas. The ERR for both types of tumor remains elevated at 30-plus years after exposure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15799699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "Although meningiomas are known to be induced by low doses of cranial irradiation, such as those given to treat tinea capitis, little experience has been reported on the induction of meningiomas by high-dose cranial irradiation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8315464",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 910,
                    "text": "The exposed rats had a greater incidence of pituitary chromophobe adenomas, epithelial and mesothelial cell tumors than the unexposed controls but the excessive occurrence of malignant gliomas that was observed in the monkeys was absent in the rats.  ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11538033",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 378,
                    "text": "We have analyzed 60 cases of intra-axial brain tumors associated with antecedent radiation therapy. These include four new cases. The patients had originally received radiation therapy for three reasons: (a) cranial irradiation for acute lymphoblastic leukemia (ALL), (b) definitive treatment of CNS neoplasia, and (c) treatment of benign disease (mostly cutaneous infections). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15799699",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Benign and malignant thyroid neoplasms after childhood irradiation for tinea capitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6930522",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 453,
                    "text": "There is evidence to show that moderate doses of ionising radiations given in childhood for tinea capitis are associated with a late risk of developing a meningioma",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/213536",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 676,
                    "text": "This paper describes six cases of radiation-associated intracranial meningiomas in patients previously treated with low-dose radiation to the scalp for tinea capitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15565500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 56,
                    "offsetInEndSection": 227,
                    "text": "These tumors usually arise in patients with a history of low-dose radiation to the scalp for treatment of tinea capitis or high-dose radiation for a previous brain tumor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15565500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 453,
                    "text": "There is evidence to show that moderate doses of ionising radiations given in childhood for tinea capitis are associated with a late risk of developing a meningioma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/213536",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 689,
                    "text": "In addition to high dose radiation-induced meningiomas, intracranial meningiomas were observed in patients who underwent low-dose radiation for tinea capitis in childhood, applied en mass to immigrants coming to Israel from the North Africa and the Middle East during the 1950.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11949834",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "A 39-year-old male developed primary brain lymphoma 33 years after receiving scalp irradiation for tinea capitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1640715",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "text": "Secondary glioblastoma multiforme (sGBM) can occur after a long latency period following radiation treatment of various diseases including brain tumors, leukemia, and more benign disorders like tinea capitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23227384",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 624,
                    "text": "The main data come from series of patients who underwent radiotherapy during childhood: a high incidence of tumors of the nervous system is found after irradiation of one to a few grays as treatment of a benign disease (especially tinea capitis), as well as after irradiation at higher doses of a few tens of grays for the treatment of cancer (in particular cerebral irradiation in acute lymphoblastic leukaemia).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8081035",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the petrous bone used in ancient DNA sampling?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28526291",
                "http://www.ncbi.nlm.nih.gov/pubmed/28625158",
                "http://www.ncbi.nlm.nih.gov/pubmed/28129388",
                "http://www.ncbi.nlm.nih.gov/pubmed/27355351",
                "http://www.ncbi.nlm.nih.gov/pubmed/26595274"
            ],
            "ideal_answer": [
                "Large-scale genomic analyses of ancient human populations have become feasible partly due to refined sampling methods. The inner part of petrous bones and the cementum layer in teeth roots are currently recognized as the best substrates for such research."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5abd3707fcf456587200002d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "text": "Large-scale genomic analyses of ancient human populations have become feasible partly due to refined sampling methods. The inner part of petrous bones and the cementum layer in teeth roots are currently recognized as the best substrates for such research.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129388",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 495,
                    "text": "Ancient DNA (aDNA) research involves invasive and destructive sampling procedures that are often incompatible with anthropological, anatomical, and bioarcheological analyses requiring intact skeletal remains. The osseous labyrinth inside the petrous bone has been shown to yield higher amounts of endogenous DNA than any other skeletal element; however, accessing this labyrinth in cases of a complete or reconstructed skull involves causing major structural damage to the cranial vault or base.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28625158",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 422,
                    "offsetInEndSection": 554,
                    "text": "first genome-wide ancient DNA from Anatolian Neolithic farmers, whose genetic material we obtained by extracting from petrous bones,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26595274",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is it possible to analyze exosomes with FACS?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29783743",
                "http://www.ncbi.nlm.nih.gov/pubmed/26154623",
                "http://www.ncbi.nlm.nih.gov/pubmed/30290833",
                "http://www.ncbi.nlm.nih.gov/pubmed/26598503"
            ],
            "ideal_answer": [
                "Yes,\na novel strategy for generating metabolically-labeled fluorescent exosomes that can be counted by flow cytometry assay (FACS) and characterized."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c9e6ab9ecadf2e73f000035",
            "snippets": [
                {
                    "offsetInBeginSection": 1458,
                    "offsetInEndSection": 1516,
                    "text": "whose presence was validated by a bead-exosome FACS assay.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26154623",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 467,
                    "text": "We analyzed exosomes from mouse (C57Bl/6) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including nanoparticle tracking analysis, biolayer interferometry, FACS, and electron microscopy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26598503",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 749,
                    "offsetInEndSection": 924,
                    "text": "we applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct FACS analysis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30290833",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 594,
                    "text": "we used a novel strategy for generating metabolically-labeled fluorescent exosomes that can be counted by flow cytometry assay (FACS) and characterized.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29783743",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is aganglionic megacolon a feature of Down syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23045564",
                "http://www.ncbi.nlm.nih.gov/pubmed/18075983",
                "http://www.ncbi.nlm.nih.gov/pubmed/2309705",
                "http://www.ncbi.nlm.nih.gov/pubmed/12028658"
            ],
            "ideal_answer": [
                "Down syndrome (DS) is recognized by characteristic facial features, intellectual disability, and an increased risk for cardiac malformations and duodenal atresia. Recently, Hirschsprung disease (HSCR), or congenital aganglionic megacolon, has been seen more often among patients with DS."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:14250"
            ],
            "type": "yesno",
            "id": "550311dae9bde69634000018",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 286,
                    "text": "Down syndrome (DS) is recognized by characteristic facial features, intellectual disability, and an increased risk for cardiac malformations and duodenal atresia. Recently, Hirschsprung disease (HSCR), or congenital aganglionic megacolon, has been seen more often among patients with DS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23045564",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 1078,
                    "text": "Of the 17 patients with HD who were studied, 10 were isolated (58.8%) and seven (41.1%) were associated to other structural abnormalities and psychomotor retardation. Three of the cases in this latter group were due to chromosome pathology (trisomy 21, Down syndrome)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18075983",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 408,
                    "text": "The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy. The patient condition improved after a colostomy performed in the setting of the treatment of Hirschprung disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 760,
                    "text": "Hirschsprung disease, or congenital aganglionic megacolon, is commonly assumed to be a sex-modified multifactorial trait. To test this hypothesis, complex segregation analysis was performed on data on 487 probands and their families. Demographic information on probands and the recurrence risk to relatives of probands are presented. An increased sex ratio (3.9 male:female) and an elevated risk to sibs (4%), as compared with the population incidence (0.02%), are observed, with the sex ratio decreasing and the recurrence risk to sibs increasing as the aganglionosis becomes more extensive. Down syndrome was found at an increased frequency among affected individuals but not among their unaffected sibs, and the increase was not associated with maternal age",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2309705",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Intestinal microvillous atrophy in a patient with Down syndrome and aganglionic megacolon.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 293,
                    "text": " The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 294,
                    "text": "The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 293,
                    "text": "The authors report the case of a female infant with Down syndrome, aganglionic megacolon, severe diarrhea, and jejunal biopsy with ultrastructural changes consistent with microvillous atrophy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12028658",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Could Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)\ncause sudden cardiac death?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24076290",
                "http://www.ncbi.nlm.nih.gov/pubmed/22050625",
                "http://www.ncbi.nlm.nih.gov/pubmed/18684293",
                "http://www.ncbi.nlm.nih.gov/pubmed/19601860",
                "http://www.ncbi.nlm.nih.gov/pubmed/19564966",
                "http://www.ncbi.nlm.nih.gov/pubmed/15890976",
                "http://www.ncbi.nlm.nih.gov/pubmed/18483626",
                "http://www.ncbi.nlm.nih.gov/pubmed/19575158",
                "http://www.ncbi.nlm.nih.gov/pubmed/19568611",
                "http://www.ncbi.nlm.nih.gov/pubmed/19631908",
                "http://www.ncbi.nlm.nih.gov/pubmed/20513597",
                "http://www.ncbi.nlm.nih.gov/pubmed/17959506",
                "http://www.ncbi.nlm.nih.gov/pubmed/24011300",
                "http://www.ncbi.nlm.nih.gov/pubmed/20361477",
                "http://www.ncbi.nlm.nih.gov/pubmed/22995932",
                "http://www.ncbi.nlm.nih.gov/pubmed/20143088",
                "http://www.ncbi.nlm.nih.gov/pubmed/19781797",
                "http://www.ncbi.nlm.nih.gov/pubmed/21616285",
                "http://www.ncbi.nlm.nih.gov/pubmed/22524859",
                "http://www.ncbi.nlm.nih.gov/pubmed/20091251",
                "http://www.ncbi.nlm.nih.gov/pubmed/22119737",
                "http://www.ncbi.nlm.nih.gov/pubmed/21893508",
                "http://www.ncbi.nlm.nih.gov/pubmed/22307399",
                "http://www.ncbi.nlm.nih.gov/pubmed/21872879",
                "http://www.ncbi.nlm.nih.gov/pubmed/19345240",
                "http://www.ncbi.nlm.nih.gov/pubmed/22749309",
                "http://www.ncbi.nlm.nih.gov/pubmed/23286974",
                "http://www.ncbi.nlm.nih.gov/pubmed/12837242",
                "http://www.ncbi.nlm.nih.gov/pubmed/23040497",
                "http://www.ncbi.nlm.nih.gov/pubmed/12574890",
                "http://www.ncbi.nlm.nih.gov/pubmed/22993115",
                "http://www.ncbi.nlm.nih.gov/pubmed/15749201",
                "http://www.ncbi.nlm.nih.gov/pubmed/17052226",
                "http://www.ncbi.nlm.nih.gov/pubmed/21135804",
                "http://www.ncbi.nlm.nih.gov/pubmed/21292648",
                "http://www.ncbi.nlm.nih.gov/pubmed/11807805",
                "http://www.ncbi.nlm.nih.gov/pubmed/23094885",
                "http://www.ncbi.nlm.nih.gov/pubmed/12386154"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11993336",
                    "o": "114251.0001"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1861943",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11993336"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1861943",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16614236"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1861943",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16614236"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11993336",
                    "o": "CASQ2, ASP307HIS"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16614236",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 2; CPVT2, ASP307HIS"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16614236",
                    "o": "114251.0001"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11975890",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16617838",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, ASN4104LYS"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867064",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16617838"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11975890",
                    "o": "RYR2, ASN4104LYS"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867064",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11975890"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16617838",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11932851",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11932851",
                    "o": "RYR2, ARG2474SER"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867063",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16617837"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867063",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11932851"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16617837",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, ARG2474SER"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16617837",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608313",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2674258",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16610181"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16610181",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, ALA4860GLY"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2674258",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16610181"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608313",
                    "o": "RYR2, ALA4860GLY"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2674258",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608313"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16610181",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11932853",
                    "o": "OMIM"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867068",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11932853"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867068",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16606467"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11932853",
                    "o": "RYR2, PRO2328SER"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16606467",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, PRO2328SER"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16606467",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11975891",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11975891",
                    "o": "RYR2, ARG4497CYS"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867065",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16617839"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16617839",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, ARG4497CYS"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867065",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11975891"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867065",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16617839"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16617839",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11961599",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867070",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11961599"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16610180",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, GLN4201ARG"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867070",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16610180"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867070",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16610180"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11961599",
                    "o": "RYR2, GLN4201ARG"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16610180",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11932850",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867062",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11932850"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867062",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16615879"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615879",
                    "o": "VENTRICULAR TACHYCARDIA, CATECHOLAMINERGIC POLYMORPHIC, 1; CPVT1, SER2246LEU"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1867062",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16615879"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11932850",
                    "o": "RYR2, SER2246LEU"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615879",
                    "o": "OMIM"
                }
            ],
            "ideal_answer": [
                "Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) can cause sudden cardiac death."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016757",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013610",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017180"
            ],
            "type": "yesno",
            "id": "52e8e96698d023950500001f",
            "snippets": [
                {
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 884,
                    "text": "Two siblings died suddenly at the ages of 9 and 10\u00a0years",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24076290",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 365,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a type of cardiac arrhythmia that occurs in people with a structurally normal heart. Stress or anxiety-induced release of endogenous catecholamines causes a dysfunction in the myocytic calcium-ion channel, leading to ventricular arrhythmias that can cause dizziness, syncope, or sudden cardiac death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011300",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1449,
                    "offsetInEndSection": 1607,
                    "text": "During a follow-up of 48\u00b194 months, arrhythmia events (sudden cardiac death and aborted cardiac arrest) associated with noncompliance occurred in 2 patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23286974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 500,
                    "text": "We report a family with repeat events of sudden cardiac death and recurrent ventricular fibrillation in a teenage girl, where autopsy data and clinical investigations were inconclusive. The diagnosis of catecholaminergic polymorphic ventricular tachycardia (CPVT) was established only following finding a gene mutation in the cardiac ryanodine receptor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23094885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 358,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a devastating inherited disorder characterized by episodic syncope and/or sudden cardiac arrest during exercise or acute emotion in individuals without structural cardiac abnormalities. Although rare, CPVT is suspected to cause a substantial part of sudden cardiac deaths in young individuals. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040497",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 593,
                    "text": "catecholaminergic polymorphic ventricular tachycardia (CPVT), and Brugada syndrome (BrS), leave no evidence to be found at autopsy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22993115",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 511,
                    "text": "a spectrum of sudden cardiac death (SCD)-predisposing heritable cardiac arrhythmia syndromes, including long QT syndrome (LQTS), short QT syndrome (SQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995932",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 344,
                    "text": "CPVT is a familial arrhythmogenic syndrome characterized by abnormal calcium (Ca(2+)) handling, ventricular arrhythmias, and sudden cardiac death",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22749309",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 714,
                    "offsetInEndSection": 832,
                    "text": "Mutations in RyR2 are linked to catecholaminergic polymorphic ventricular tachycardia (CPVT) and sudden cardiac death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22524859",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 537,
                    "text": "Patients with CPVT often present with exercise- or emotion induced syncope, the first presentation can also be sudden cardiac death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22119737",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 348,
                    "text": "Among the five major arrhythmogenic disorders occurring in the absence of a structural heart disease is catecholaminergic polymorphic ventricular tachycardia (CPVT), which is a highly lethal form of inherited arrhythmias. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22050625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 269,
                    "offsetInEndSection": 376,
                    "text": "Patients with CPVT are at high risk of developing life-threatening ventricular arrhythmias when untreated. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21893508",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by VT induced by adrenergic stress in the absence of structural heart disease and high incidence of sudden cardiac death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21872879",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 470,
                    "text": "CPVT is an inherited arrhythmia syndrome caused by gene mutations that destabilize cardiac ryanodine receptor Ca(2+) release channels. Sudden cardiac death is incompletely prevented by conventional drug therapy with \u03b2-blockers with or without Ca(2+) channel blockers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21616285",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease that can cause sudden cardiac death due to ventricular fibrillation (VF).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21292648",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 349,
                    "text": "Important potential causes of sudden cardiac deaths in the absence of heart disease are primary electrical diseases such as Brugada syndrome, long QT syndrome (LQTS), short QT syndrome and catecholaminergic polymorphic ventricular tachyarrhythmias. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21135804",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 425,
                    "text": "catecholaminergic polymorphic ventricular tachycardia (CPVT), and Brugada syndrome (BrS) are primary inherited arrhythmia syndromes that may cause syncope and sudden cardiac death in young individuals. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20513597",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 265,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a cardiac channelopathy characterized by altered intracellular calcium handling resulting in ventricular arrhythmias and high risk of cardiac sudden death in young cases with normal structural hearts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20361477",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disorder that causes syncopal episodes related with stress or emotion and even sudden cardiac deaths.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20143088",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 190,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia caused by mutations in the RyR2 gene manifests as severe arrhythmias, and may provide a candidate for sudden cardiac deaths.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19781797",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 306,
                    "text": "Patients diagnosed with an electrical cardiomyopathy have an increased risk of syncope and sudden cardiac death (SCD). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20091251",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1278,
                    "offsetInEndSection": 1399,
                    "text": "Patients with CPVT present with exercise-induced syncope and sudden cardiac death but normal resting electrocardiograms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19631908",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 820,
                    "text": "Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally normal heart and the majority of those patients are young. In this group of patients, changes in genes encoding cardiac ion channels produce modification of the function of the channel resulting in an electrophysiological substrate of VA and SCD. Collectively these disorders are referred to as Cardiac Ion Channelopathies. The 4 major syndromes in this group are: The Long QT Syndrome (LQTS), the Brugada Syndrome (BrS), the Short QT Syndrome (SQTS), and the Catecholaminergic Polymorphic VT (CPVT). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19601860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 101,
                    "offsetInEndSection": 365,
                    "text": "Important potential causes of sudden cardiac deaths in the absence of heart disease are primary electrical diseases such as Brugada syndrome, long QT syndrome (LQTS), short QT syndrome (SQTS), and catecholaminergic polymorphic ventricular tachyarrhythmias (CPVT). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19575158",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 266,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial cardiac arrhythmia that is related to RYR2 or CASQ2 gene mutation. It occurs in patients with structurally normal heart and causes exercise-emotion-triggered syncope and sudden cardiac death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19568611",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 722,
                    "offsetInEndSection": 879,
                    "text": "Potentially lethal ion channel disorders (channelopathies) such as the long QT syndromes (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19564966",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 513,
                    "text": "Aberrant spontaneous, diastolic Ca2+ leak from the SR due to dysfunctional RyR2 contributes to the formation of delayed after-depolarisations, which are thought to underlie the fatal arrhythmia that occurs in both heart failure (HF) and in catecholaminergic polymorphic ventricular tachycardia (CPVT). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19345240",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an uncommon heritable disease presenting with syncope or sudden cardiac death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18684293",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 287,
                    "text": "Mutations in RyR2 have been linked to exercise-induced sudden cardiac death (catecholaminergic polymorphic ventricular tachycardia [CPVT]).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18483626",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a heritable arrhythmia unmasked by exertion or stress, characterized by triggered activity and sudden cardiac death in affected patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17959506",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 692,
                    "text": "families that exhibit CPVT (catecholaminergic polymorphic ventricular tachycardia), a condition in which physical or emotional stress can trigger severe tachyarrhythmias that can lead to sudden cardiac death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17052226",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1432,
                    "text": "that often leads to sudden death in HF and in CPVT.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17052226",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by adrenergically mediated polymorphic ventricular tachycardia leading to syncope and sudden cardiac death.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15890976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an autosomal dominant inherited disorder characterized by adrenergic induced polymorphic ventricular tachycardias and associated with sudden cardiac death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15749201",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1001,
                    "offsetInEndSection": 1128,
                    "text": "These data suggest that \"leaky\" RyR2 channels can trigger fatal cardiac arrhythmias, providing a possible explanation for CPVT.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12837242",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrhythmogenic disorder characterized by syncopal events and sudden cardiac death at a young age during physical stress or emotion, in the absence of structural heart disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12386154",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 355,
                    "text": " catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12574890",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 284,
                    "text": "has recently been shown to be involved in at least two forms of sudden cardiac death (SCD): (1) Catecholaminergic polymorphic ventricular tachycardia (CPVT) ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807805",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Have mutations in the GARS gene been identified to cause Charcot-Marie-Tooth Disease Type 2D (CMT2D)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17035524",
                "http://www.ncbi.nlm.nih.gov/pubmed/23990368",
                "http://www.ncbi.nlm.nih.gov/pubmed/20301462",
                "http://www.ncbi.nlm.nih.gov/pubmed/16982418",
                "http://www.ncbi.nlm.nih.gov/pubmed/16014653",
                "http://www.ncbi.nlm.nih.gov/pubmed/20301420",
                "http://www.ncbi.nlm.nih.gov/pubmed/22462675",
                "http://www.ncbi.nlm.nih.gov/pubmed/17663003",
                "http://www.ncbi.nlm.nih.gov/pubmed/22144914",
                "http://www.ncbi.nlm.nih.gov/pubmed/16769947",
                "http://www.ncbi.nlm.nih.gov/pubmed/19412816"
            ],
            "triples": [
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1836",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CMT2D"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/CMT2D",
                    "o": "CMT2D"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1836",
                    "o": "Charcot-Marie-Tooth disease, type 2D, 601472"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458984",
                    "o": "C537993"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000277",
                    "o": "CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2D"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18468134",
                    "o": "Charcot-Marie-Tooth disease, axonal, Type 2D"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458984",
                    "o": "Charcot-Marie-Tooth disease, Type 2D"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12028806"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18458985"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11957249"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11957249",
                    "o": "CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2D"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18458984"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12000277"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000276",
                    "o": "CHARCOT-MARIE-TOOTH DISEASE, NEURONAL, TYPE 2D"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12028806",
                    "o": "CMT2D"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18468134"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458985",
                    "o": "Charcot-Marie-Tooth disease, neuronal, Type 2D"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1832274",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12000276"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458985",
                    "o": "C537993"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18468134",
                    "o": "C537993"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11957249",
                    "o": "601472"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000276",
                    "o": "601472"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000277",
                    "o": "601472"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12028806",
                    "o": "601472"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11957249",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000276",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12000277",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12028806",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458984",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458985",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18468134",
                    "o": "MeSH"
                }
            ],
            "ideal_answer": [
                "Charcot-Marie-Tooth disease type 2D (CMT2D) is caused by missense mutations in the glycyl-tRNA synthetase gene (GARS)."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/SYG_RAT",
                "http://www.uniprot.org/uniprot/SYG_HUMAN",
                "http://www.uniprot.org/uniprot/SYG_PONAB"
            ],
            "type": "yesno",
            "id": "52b2ecd34003448f55000003",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 165,
                    "text": "Charcot-Marie-Tooth disease type 2D is a hereditary axonal and glycyl-tRNA synthetase (GARS)-associated neuropathy that is caused by a mutation in GARS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990368",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 248,
                    "text": "Mutations in the GARS gene cause Charcot-Marie-Tooth 2D and distal spinal muscular atrophy type V - allelic disorders characterized by predominantly distal upper extremity weakness and atrophy, typically beginning during the second decade of life. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22462675",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Charcot-Marie-Tooth disease type 2D (CMT2D) is a dominantly inherited peripheral neuropathy caused by missense mutations in the glycyl-tRNA synthetase gene (GARS).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22144914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 854,
                    "text": "The 13 genes known to be associated with the CMT2 subtypes are KIF1B (CMT2A1), MFN2 (CMT2A2), RAB7A (formerly RAB7) (CMT2B), LMNA (CMT2B1), MED25 (CMT2B2), TRPV4 (CMTC), GARS (CMT2D), NEFL (CMT2E/1F), HSPB1 (CMT2F), MPZ (CMT2I/J), GDAP1 (CMT2H/K), HSPB8 (CMT2L), and AARS (CMT2N). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301462",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 976,
                    "offsetInEndSection": 1154,
                    "text": " The diagnosis of GARS-associated axonal neuropathy is based on clinical findings, electromyography (EMG), and molecular genetic testing of GARS, encoding glycyl-tRNA synthetase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20301420",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 400,
                    "text": "Sporadic juvenile muscular atrophy of the distal upper extremity or Hirayama's disease (HD) and autosomal dominant motor distal neuronopathy/axonopathy (CMT2D/dSMA-V), produced by glycyl-tRNA synthetase (GARS) gene mutations, share some clinical features including: young age of onset, predilection for the distal upper extremity, asymmetry, sparing of proximal muscles and unusual cold sensitivity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19412816",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 394,
                    "text": "Distal hereditary motor neuropathy type V (dHMN-V) and Charcot-Marie-Tooth syndrome (CMT) type 2 presenting with predominant hand involvement, also known as CMT2D and Silver syndrome (SS) are rare phenotypically overlapping diseases which can be caused by mutations in the Berardinelli-Seip Congenital Lipodystrophy 2 (BSCL2) and in the glycyl-tRNA synthetase encoding (GARS) genes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 313,
                    "text": "We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17035524",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Of the many inherited Charcot-Marie-Tooth peripheral neuropathies, type 2D (CMT2D) is caused by dominant point mutations in the gene GARS, encoding glycyl tRNA synthetase (GlyRS). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16982418",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 632,
                    "text": "Missense mutations in the glycyl-tRNA synthetase (GARS) gene have been recently reported in families with either dHMN-V, CMT2D, or both.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16769947",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 895,
                    "offsetInEndSection": 1359,
                    "text": "Based on the presence or absence of sensory changes, the disease phenotype was initially defined as distal spinal muscular atrophy type V (dSMA-V) in three families, Charcot-Marie-Tooth disease type 2D (CMT2D) in a single family, and as either dSMA-V or CMT2D in patients of another large family. Linkage to chromosome 7p15 and the presence of disease-associated heterozygous GARS mutations have been identified in patients from each of the five studied families. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16014653",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can mutations in Calmodulin cause ventricular fibrillation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24076290",
                "http://www.ncbi.nlm.nih.gov/pubmed/11807557"
            ],
            "ideal_answer": [
                "Yes, mutations in CALM underly IVF manifesting in childhood and adolescence."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/CALM_PARTE",
                "http://www.uniprot.org/uniprot/CALM_ANAPL",
                "http://www.uniprot.org/uniprot/CALM_PNECA",
                "http://www.uniprot.org/uniprot/CALM_BRYDI",
                "http://www.uniprot.org/uniprot/CALM_PFIPI",
                "http://www.uniprot.org/uniprot/CALM_SHEEP",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016277",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016278",
                "http://www.uniprot.org/uniprot/CALM_EMENI",
                "http://www.uniprot.org/uniprot/CALM_FAGSY",
                "http://www.uniprot.org/uniprot/CALM_PLEOS",
                "http://www.uniprot.org/uniprot/CALM_DANRE",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014693",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002147",
                "http://www.uniprot.org/uniprot/CALM_MAIZE",
                "http://www.uniprot.org/uniprot/CALM_WHEAT",
                "http://www.uniprot.org/uniprot/CALM_HALOK",
                "http://www.uniprot.org/uniprot/CALM_ASPOR",
                "http://www.uniprot.org/uniprot/CALM_HORVU",
                "http://www.uniprot.org/uniprot/CALM_CTEID",
                "http://www.uniprot.org/uniprot/CALM_SOLLC",
                "http://www.uniprot.org/uniprot/CALM_CIOIN",
                "http://www.uniprot.org/uniprot/CALM_METSE",
                "http://www.uniprot.org/uniprot/CALM_BOVIN",
                "http://www.uniprot.org/uniprot/CALM_STIJA",
                "http://www.uniprot.org/uniprot/CALM_OREMO",
                "http://www.uniprot.org/uniprot/CALM_LOCMI",
                "http://www.uniprot.org/uniprot/CALM_SCHPO",
                "http://www.uniprot.org/uniprot/CALM_TRYCR",
                "http://www.uniprot.org/uniprot/CALM_XENLA",
                "http://www.uniprot.org/uniprot/CALM_DROME",
                "http://www.uniprot.org/uniprot/CALM_CAPAN",
                "http://www.uniprot.org/uniprot/CALM_PHYPO",
                "http://www.uniprot.org/uniprot/CALM_CHLRE",
                "http://www.uniprot.org/uniprot/CALM_HUMAN",
                "http://www.uniprot.org/uniprot/CALM_SACJA",
                "http://www.uniprot.org/uniprot/CALM_PYTSP",
                "http://www.uniprot.org/uniprot/CALM_PAXIN",
                "http://www.uniprot.org/uniprot/CALM_TETPY",
                "http://www.uniprot.org/uniprot/CALM_ONCSP",
                "http://www.uniprot.org/uniprot/CALM_TRYBG",
                "http://www.uniprot.org/uniprot/CALM_TRYBB",
                "http://www.uniprot.org/uniprot/CALM_PATSP",
                "http://www.uniprot.org/uniprot/CALM_BLAEM",
                "http://www.uniprot.org/uniprot/CALM_TORCA",
                "http://www.uniprot.org/uniprot/CALM_EUPCH",
                "http://www.uniprot.org/uniprot/CALM_MALDO",
                "http://www.uniprot.org/uniprot/CALM_HELAN",
                "http://www.uniprot.org/uniprot/CALM_EPIAK",
                "http://www.uniprot.org/uniprot/CALM_PYUSP",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016276",
                "http://www.uniprot.org/uniprot/CALM_ALEFU",
                "http://www.uniprot.org/uniprot/CALM_MACPY",
                "http://www.uniprot.org/uniprot/CALM_SPIOL",
                "http://www.uniprot.org/uniprot/CALM_CAEEL",
                "http://www.uniprot.org/uniprot/CALM_HETTR",
                "http://www.uniprot.org/uniprot/CALM_APLCA",
                "http://www.uniprot.org/uniprot/CALM_PHYIN",
                "http://www.uniprot.org/uniprot/CALM_ELEEL",
                "http://www.uniprot.org/uniprot/CALM_STRPU",
                "http://www.uniprot.org/uniprot/CALM_MAGO7",
                "http://www.uniprot.org/uniprot/CALM_PLECO",
                "http://www.uniprot.org/uniprot/CALM_PERFV",
                "http://www.uniprot.org/uniprot/CALM_YEAST",
                "http://www.uniprot.org/uniprot/CALM_KLULA",
                "http://www.uniprot.org/uniprot/CALM_COLTR",
                "http://www.uniprot.org/uniprot/CALM_RABIT",
                "http://www.uniprot.org/uniprot/CALM_DICDI",
                "http://www.uniprot.org/uniprot/CALM_MYXGL",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018497",
                "http://www.uniprot.org/uniprot/CALM_EUGGR",
                "http://www.uniprot.org/uniprot/CALM_PONAB",
                "http://www.uniprot.org/uniprot/CALM_STYLE",
                "http://www.uniprot.org/uniprot/CALM_KARMI",
                "http://www.uniprot.org/uniprot/CALM_RAT",
                "http://www.uniprot.org/uniprot/CALM_PLAFA",
                "http://www.uniprot.org/uniprot/CALM_TETTH",
                "http://www.uniprot.org/uniprot/CALM_AGABI",
                "http://www.uniprot.org/uniprot/CALM_STRIE",
                "http://www.uniprot.org/uniprot/CALM_AJECG",
                "http://www.uniprot.org/uniprot/CALM_MOUSC",
                "http://www.uniprot.org/uniprot/CALM_GECJA",
                "http://www.uniprot.org/uniprot/CALM_SUBDO",
                "http://www.uniprot.org/uniprot/CALM_PROMN",
                "http://www.uniprot.org/uniprot/CALM_CANAX",
                "http://www.uniprot.org/uniprot/CALM_CHICK",
                "http://www.uniprot.org/uniprot/CALM_COLGL",
                "http://www.uniprot.org/uniprot/CALM_PLAF7",
                "http://www.uniprot.org/uniprot/CALM_LILLO",
                "http://www.uniprot.org/uniprot/CALM_NEUCR",
                "http://www.uniprot.org/uniprot/CALM_RENRE",
                "http://www.uniprot.org/uniprot/CALM_MOUSE",
                "http://www.uniprot.org/uniprot/CALM_ACHKL",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018487",
                "http://www.uniprot.org/uniprot/CALM_LYTPI",
                "http://www.uniprot.org/uniprot/CALM_MEDSA",
                "http://www.uniprot.org/uniprot/CALM_LUMRU"
            ],
            "type": "yesno",
            "id": "52b2f0864003448f55000007",
            "snippets": [
                {
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 1613,
                    "text": "We characterized a family presenting with a history of ventricular fibrillation (VF) and sudden death without ECG or echocardiographic abnormalities at rest. Two siblings died suddenly at the ages of 9 and 10 years, and another two were resuscitated from out-of-hospital cardiac arrest with documented VF at age 10 and 16, respectively. Exome sequencing identified a missense mutation affecting a highly conserved residue (p.Phe90Leu) in the CALM1 gene encoding calmodulin. This mutation was also carried by one of the sibs who died suddenly, for whom DNA was available. The mutation was present in the mother and in an sibling, both asymptomatic but displaying a marginally prolonged QT-interval during exercise. CONCLUSIONS: We identified a mutation in CALM1 underlying IVF manifesting in childhood and adolescence. The causality of the mutation is supported by previous studies demonstrating that Phe90 mediates the direct interaction of CaM with target peptides",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24076290",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 917,
                    "text": "Here we show that calmodulin (CaM), a ubiquitous Ca2+-sensing protein, binds to the carboxy-terminal 'IQ' domain of the human cardiac Na channel (hH1) in a Ca2+-dependent manner. This binding interaction significantly enhances slow inactivation-a channel-gating process linked to life-threatening idiopathic ventricular arrhythmias. Mutations targeted to the IQ domain disrupted CaM binding and eliminated Ca2+/CaM-dependent slow inactivation, whereas the gating effects of Ca2+/CaM were restored by intracellular application of a peptide modelled after the IQ domain. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11807557",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is lithium effective for treatment of amyotrophic lateral sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                "http://www.ncbi.nlm.nih.gov/pubmed/26892289",
                "http://www.ncbi.nlm.nih.gov/pubmed/22091594",
                "http://www.ncbi.nlm.nih.gov/pubmed/21936930",
                "http://www.ncbi.nlm.nih.gov/pubmed/29399045",
                "http://www.ncbi.nlm.nih.gov/pubmed/22378918",
                "http://www.ncbi.nlm.nih.gov/pubmed/29400298",
                "http://www.ncbi.nlm.nih.gov/pubmed/18367867",
                "http://www.ncbi.nlm.nih.gov/pubmed/18250315",
                "http://www.ncbi.nlm.nih.gov/pubmed/20702794",
                "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                "http://www.ncbi.nlm.nih.gov/pubmed/28978660",
                "http://www.ncbi.nlm.nih.gov/pubmed/20363190"
            ],
            "ideal_answer": [
                "No, lithium is not effective for treatment of amyotrophic lateral sclerosis."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c662c507c78d6947100000d",
            "snippets": [
                {
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 331,
                    "text": "In terms of disease-modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29399045",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1343,
                    "text": "Despite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29400298",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 949,
                    "offsetInEndSection": 1211,
                    "text": "The effect of lithium was different for UNC13A carriers (p = 0.027), but not for C9orf72 carriers (p = 0.22). The 12-month survival probability for UNC13A carriers treated with lithium carbonate improved from 40.1% (95% CI 23.2-69.1) to 69.7% (95% CI 50.4-96.3).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978660",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1174,
                    "text": "Studies in ALS showed consistently negative results and presented evidence against the use of lithium for the treatment of this disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26892289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "BACKGROUND\nLithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "In a pilot clinical study that we recently published we found that lithium administration slows the progression of Amyotrophic Lateral Sclerosis (ALS) in human patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18367867",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "BACKGROUND Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "BACKGROUND A neuroprotective effect of lithium in amyotrophic lateral sclerosis (ALS) has been recently reported.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Lithium delays progression of amyotrophic lateral sclerosis.ALS is a devastating neurodegenerative disorder with no effective treatment. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250315",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 395,
                    "text": "Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.<AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 310,
                    "text": "<b>INTRODUCTION</b>: Lithium was proposed in 2008 as an effective candidate in the treatment of ALS after a report claimed that it was able to delay functional deterioration by 40% and that none of the 16 patients treated with a combination of lithium plus riluzole had died during a 15-month follow-up period.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 1643,
                    "text": "A recently published study also ruled out any possible modest effect.<br><b>CONCLUSIONS</b>: There is evidence to suggest that lithium has no short-term benefits in ALS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1644,
                    "offsetInEndSection": 1898,
                    "text": "A comparison of the group of patients treated with lithium+riluzole and the control group treated with riluzole alone showed no statistically significant differences in rates of functional decline, deterioration of respiratory function, or survival time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 519,
                    "text": "None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250315",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is davunetide being considered for the treatment of progressive supranuclear palsy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22347799"
            ],
            "ideal_answer": [
                "Yes, Davunetide's efficacy and tolerability are being tested in a placebo-controlled study in PSP patients."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a7d5033faa1ab7d2e000015",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1366,
                    "text": "Davunetide's efficacy and tolerability are being tested in a placebo-controlled study in PSP patients, making it the most advanced drug candidate in this indication. This review examines the disease characteristics of PSP, the rationale for treating PSP with davunetide and assesses some of the challenges of clinical trials in this patient population.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22347799",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has proteomics been used in the study of Pick's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11880199",
                "http://www.ncbi.nlm.nih.gov/pubmed/16987245",
                "http://www.ncbi.nlm.nih.gov/pubmed/16555340",
                "http://www.ncbi.nlm.nih.gov/pubmed/12650976"
            ],
            "ideal_answer": [
                "Yes, proteomics has been used in the study of Pick's disease."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020543",
                "http://www.disease-ontology.org/api/metadata/DOID:4",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D040901",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057180",
                "http://www.disease-ontology.org/api/metadata/DOID:11870",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020774"
            ],
            "type": "yesno",
            "id": "532f05bdd6d3ac6a34000026",
            "snippets": [
                {
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 993,
                    "text": "In Pick's disease, increased AGE, CML, CEL, HNE and MDAL bands of about 50 kDa were observed in the frontal cortex (but not in the occipital cortex) in association with increased density of glial acidic protein bands.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16987245",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 529,
                    "text": "Thus, brain and cerebrospinal fluid (CSF) samples from patients with Alzheimer's disease, Down syndrome, Pick's disease, Parkinson's disease, schizophrenia, and other disorders as well as brain and CSF from animals serving as models of neurological disorders have been analyzed by proteomics. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16555340",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 493,
                    "offsetInEndSection": 771,
                    "text": "The present study is designed to investigate expression of peroxiredoxins (Prxs), the newly characterized family of highly conserved antioxidant enzymes, and other antioxidant enzymes in frontal cortex and cerebellum of DS, AD and PD patients using the technique of proteomics. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12650976",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 486,
                    "text": "HMT levels were measured in the frontal cortex and cerebellum of brains of patients with AD, DS, and PiD, and normal aged subjects using proteomics techniques. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11880199",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the 3D structure of  the genome remain stable during cell differentiation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25693564",
                "http://www.ncbi.nlm.nih.gov/pubmed/26340639",
                "http://www.ncbi.nlm.nih.gov/pubmed/24346698",
                "http://www.ncbi.nlm.nih.gov/pubmed/25218583",
                "http://www.ncbi.nlm.nih.gov/pubmed/22495300",
                "http://www.ncbi.nlm.nih.gov/pubmed/23199754",
                "http://www.ncbi.nlm.nih.gov/pubmed/24905166",
                "http://www.ncbi.nlm.nih.gov/pubmed/25479748",
                "http://www.ncbi.nlm.nih.gov/pubmed/24305663"
            ],
            "ideal_answer": [
                "Many studies have suggested a link between the spatial organization of genomes and fundamental biological processes such as genome reprogramming, gene expression, and differentiation. The open chromatin of embryonic stem cells (ESCs) condenses into repressive heterochromatin as cells exit the pluripotent state. The relation between alterations in chromatin structure and changes in gene expression during cell differentiation has served as a paradigm to understand the link between genome organization and function. Insulators are involved in 3D genome organization at multiple spatial scales and are important for dynamic reorganization of chromatin structure during reprogramming and differentiation. Architectural proteins orchestrate higher-order chromatin organization through the establishment of interactions between regulatory elements across multiple spatial scales. The regulation of these proteins, their interaction with DNA, and their co-occurrence in the genome, may be responsible for the plasticity of 3D chromatin architecture that dictates cell and time-specific blueprints of gene expression.",
                "Chromatin insulators have emerged as one of the central components of the genome organization tool-kit across species. We identify large, megabase-sized local chromatin interaction domains, which we term 'topological domains', as a pervasive structural feature of the genome organization. Many studies have suggested a link between the spatial organization of genomes and fundamental biological processes such as genome reprogramming, gene expression, and differentiation. Thus, p63 and its direct target Brg1 play an essential role in remodelling the higher-order chromatin structure of the EDC and in the specific positioning of this locus within the landscape of the 3D nuclear space, as required for the efficient expression of EDC genes in epidermal progenitor cells during skin development."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0030154",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002454"
            ],
            "type": "yesno",
            "id": "56ebfac12ac5ed1459000001",
            "snippets": [
                {
                    "offsetInBeginSection": 940,
                    "offsetInEndSection": 1109,
                    "text": "We identify large, megabase-sized local chromatin interaction domains, which we term 'topological domains', as a pervasive structural feature of the genome organization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495300",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1376,
                    "text": "The domains are stable across different cell types and highly conserved across species, indicating that topological domains are an inherent property of mammalian genomes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495300",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 733,
                    "text": "Insulators are involved in 3D genome organization at multiple spatial scales and are important for dynamic reorganization of chromatin structure during reprogramming and differentiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26340639",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "The relation between alterations in chromatin structure and changes in gene expression during cell differentiation has served as a paradigm to understand the link between genome organization and function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218583",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 521,
                    "offsetInEndSection": 929,
                    "text": "Architectural proteins orchestrate higher-order chromatin organization through the establishment of interactions between regulatory elements across multiple spatial scales. The regulation of these proteins, their interaction with DNA, and their co-occurrence in the genome, may be responsible for the plasticity of 3D chromatin architecture that dictates cell and time-specific blueprints of gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25218583",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 430,
                    "text": "The role of 3D genome organisation in the control and execution of lineage-specific transcription programmes during the development and differentiation of multipotent stem cells into specialised cell types remains poorly understood.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346698",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Chromatin structural states and their remodelling, including higher-order chromatin folding and three-dimensional (3D) genome organisation, play an important role in the control of gene expression",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346698",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 431,
                    "offsetInEndSection": 666,
                    "text": "Here, we show that substantial remodelling of the higher-order chromatin structure of the epidermal differentiation complex (EDC), a keratinocyte lineage-specific gene locus on mouse chromosome 3, occurs during epidermal morphogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24346698",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Many studies have suggested a link between the spatial organization of genomes and fundamental biological processes such as genome reprogramming, gene expression, and differentiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24305663",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 908,
                    "text": "Moreover, we reveal that formation of such highly condensed, transcriptionally repressed heterochromatin promotes transcriptional activation of differentiation genes and loss of pluripotency.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479748",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "The open chromatin of embryonic stem cells (ESCs) condenses into repressive heterochromatin as cells exit the pluripotent state.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479748",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 715,
                    "text": "we find that localized heterochromatin condensation of ribosomal RNA genes initiates establishment of highly condensed chromatin structures outside of the nucleolus",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25479748",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 676,
                    "text": "We focus on the emerging relationship between genome organization and lineage-specific transcriptional regulation, which we argue are inextricably linked.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905166",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 408,
                    "text": "Cells face the challenge of storing two meters of DNA in the three-dimensional (3D) space of the nucleus that spans only a few microns. The nuclear organization that is required to overcome this challenge must allow for the accessibility of the gene regulatory machinery to the DNA and, in the case of embryonic stem cells (ESCs), for the transcriptional and epigenetic changes that accompany differentiation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199754",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 715,
                    "offsetInEndSection": 1076,
                    "text": "In this review we summarize some of the recent findings illuminating the 3D structure of the eukaryotic genome, as well as the relationship between genome topology and function from the level of whole chromosomes to enhancer-promoter loops with a focus on features affecting genome organization in ESCs and changes in nuclear organization during differentiation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23199754",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 742,
                    "text": "We observe that although self-associating chromatin domains are stable during differentiation, chromatin interactions both within and between domains change in a striking manner, altering 36% of active and inactive chromosomal compartments throughout the genome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25693564",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is human lysyl oxidase-like 2 a glycoprotein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21954900",
                "http://www.ncbi.nlm.nih.gov/pubmed/23319596"
            ],
            "ideal_answer": [
                "Yes, human lysyl oxidase-like 2 is a glycoprotein."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ad240f70340b9f058000015",
            "snippets": [
                {
                    "offsetInBeginSection": 1382,
                    "offsetInEndSection": 1580,
                    "text": "This method was successfully applied to a novel recombinant protein, human lysyl oxidase-like 2. Furthermore, the glycosylation PTMs were readily detected at two glycosylation sites in the protein. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21954900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 232,
                    "text": "application to the characterization of human lysyl oxidase-like 2 glycosylation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21954900",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1404,
                    "offsetInEndSection": 1531,
                    "text": "These results suggest that the N-glycan at Asn-644 of hLOXL2 enhances the solubility and stability of the LOX catalytic domain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23319596",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can a given genotype exhibit opposite fitness effects (beneficial and detrimental) within the same environment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23169561",
                "http://www.ncbi.nlm.nih.gov/pubmed/15454545",
                "http://www.ncbi.nlm.nih.gov/pubmed/19226414"
            ],
            "ideal_answer": [
                "A given genotype can be either beneficial or detrimental, even deleterious, depending on the environment in which an organism lives. This is known as antagonistic pleiotropy. Antagonistic pleiotropy can operate even within the same environment. For example, in Escherichia coli, certain mutations can exhibit beneficial, deleterious or neutral fitness effects at different growth rates. Also, antagonistic pleiotropy is involved in the evolution of ageing, since a certain genotype may affect late- and early-life fitness in opposite directions."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5549f7a1f35db7552600000d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 311,
                    "text": "Mutations beneficial in one environment may cause costs in different environments, resulting in antagonistic pleiotropy. Here, we describe a novel form of antagonistic pleiotropy that operates even within the same environment, where benefits and deleterious effects exhibit themselves at different growth rates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169561",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 951,
                    "text": "The hfq mutations were beneficial, deleterious or neutral at an intermediate growth rate (0.5\u2009h(-1)) and one changed from beneficial to deleterious within a 36\u2009min difference in doubling time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169561",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "Two genetic models exist to explain the evolution of ageing - mutation accumulation (MA) and antagonistic pleiotropy (AP).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19226414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 345,
                    "text": "Under AP, late-acting deleterious mutations accumulate because they confer beneficial effects early in life.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19226414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 1135,
                    "text": "Many marker loci responded in opposite directions to selection for late- and early-life fitness, indicating negative genetic correlations or trade-offs between those traits. Indirect evidence suggested that some negative genetic correlations were due to antagonistic pleiotropy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15454545",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 311,
                    "text": "Here, we describe a novel form of antagonistic pleiotropy that operates even within the same environment, where benefits and deleterious effects exhibit themselves at different growth rates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169561",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "The basis of antagonistic pleiotropy in hfq mutations that have opposite effects on fitness at slow and fast growth rates.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169561",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 310,
                    "text": "Here, we describe a novel form of antagonistic pleiotropy that operates even within the same environment, where benefits and deleterious effects exhibit themselves at different growth rates",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169561",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are defects in recombination repair involved in carcinogenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22276468",
                "http://www.ncbi.nlm.nih.gov/pubmed/11178982",
                "http://www.ncbi.nlm.nih.gov/pubmed/23541693",
                "http://www.ncbi.nlm.nih.gov/pubmed/21404276",
                "http://www.ncbi.nlm.nih.gov/pubmed/24051048",
                "http://www.ncbi.nlm.nih.gov/pubmed/23721719",
                "http://www.ncbi.nlm.nih.gov/pubmed/19083132",
                "http://www.ncbi.nlm.nih.gov/pubmed/17397816",
                "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
                "http://www.ncbi.nlm.nih.gov/pubmed/12016139",
                "http://www.ncbi.nlm.nih.gov/pubmed/12592385",
                "http://www.ncbi.nlm.nih.gov/pubmed/17636314",
                "http://www.ncbi.nlm.nih.gov/pubmed/12427531",
                "http://www.ncbi.nlm.nih.gov/pubmed/12488587",
                "http://www.ncbi.nlm.nih.gov/pubmed/22798379",
                "http://www.ncbi.nlm.nih.gov/pubmed/21267443",
                "http://www.ncbi.nlm.nih.gov/pubmed/17363343",
                "http://www.ncbi.nlm.nih.gov/pubmed/22665067",
                "http://www.ncbi.nlm.nih.gov/pubmed/23675572",
                "http://www.ncbi.nlm.nih.gov/pubmed/12191483",
                "http://www.ncbi.nlm.nih.gov/pubmed/20298636",
                "http://www.ncbi.nlm.nih.gov/pubmed/10753787",
                "http://www.ncbi.nlm.nih.gov/pubmed/16258176",
                "http://www.ncbi.nlm.nih.gov/pubmed/24104500",
                "http://www.ncbi.nlm.nih.gov/pubmed/11395777",
                "http://www.ncbi.nlm.nih.gov/pubmed/23628323",
                "http://www.ncbi.nlm.nih.gov/pubmed/23620081",
                "http://www.ncbi.nlm.nih.gov/pubmed/16555998",
                "http://www.ncbi.nlm.nih.gov/pubmed/23125219",
                "http://www.ncbi.nlm.nih.gov/pubmed/15660524",
                "http://www.ncbi.nlm.nih.gov/pubmed/21427292"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/title",
                    "s": "http://purl.uniprot.org/pubmed/9111189",
                    "o": "Which DNA polymerases are used for DNA-repair in eukaryotes?"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/9111189",
                    "o": "Carcinogenesis"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/9111189",
                    "o": "http://purl.uniprot.org/pubmed/9111189"
                },
                {
                    "p": "http://purl.uniprot.org/core/title",
                    "s": "http://purl.uniprot.org/pubmed/11062157",
                    "o": "Identification of single nucleotide polymorphisms in human DNA repair genes."
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/11062157",
                    "o": "Carcinogenesis"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/11062157",
                    "o": "http://purl.uniprot.org/pubmed/11062157"
                },
                {
                    "p": "http://purl.uniprot.org/core/title",
                    "s": "http://purl.uniprot.org/pubmed/12419828",
                    "o": "Diet, cancer and aging in DNA mismatch repair deficient mice."
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/12419828",
                    "o": "http://purl.uniprot.org/pubmed/12419828"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/12419828",
                    "o": "Carcinogenesis"
                },
                {
                    "p": "http://purl.uniprot.org/core/citation",
                    "s": "http://purl.uniprot.org/uniprot/P18887",
                    "o": "http://purl.uniprot.org/citations/10783319"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/10783319",
                    "o": "Carcinogenesis"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/10783319",
                    "o": "http://purl.uniprot.org/medline/20247096"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/10783319",
                    "o": "http://purl.uniprot.org/pubmed/10783319"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_5031383838370036",
                    "o": "X-ray repair cross-complementing protein 1"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_5031383838370035",
                    "o": "DNA repair protein XRCC1"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/citations/10783319",
                    "o": "http://purl.uniprot.org/pubmed/10783319"
                },
                {
                    "p": "http://purl.uniprot.org/core/title",
                    "s": "http://purl.uniprot.org/pubmed/10590213",
                    "o": "Involvement of p53 in X-ray induced intrachromosomal recombination in mice."
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/pubmed/10590213",
                    "o": "http://purl.uniprot.org/pubmed/10590213"
                },
                {
                    "p": "http://purl.uniprot.org/core/name",
                    "s": "http://purl.uniprot.org/pubmed/10590213",
                    "o": "Carcinogenesis"
                }
            ],
            "ideal_answer": [
                "Yes. The breast cancer-associated BRCA1 and BRCA2 proteins are strongly implicated in recombination repair.",
                "Carcinogenesis or oncogenesis or tumorigenesis is literally the creation of cancer. It is a process by which normal cells are transformed into cancer cells. It is characterized by a progression of changes at the cellular, genetic and epigenetic level that ultimately reprogram a cell to undergo uncontrolled cell division, thus forming a malignant mass.\nCarcinogenesis is caused by mutation and epimutation of the genetic material of normal cells, which upsets the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. The uncontrolled and often rapid proliferation of cells can lead to benign tumors; some types of these may turn into malignant tumors (cancer). Based on studies, carcinogenesis also related with the defects in recombination repair."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004260",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005785",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000724",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059767",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D059765",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006310",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0036298",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063646",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011995",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006281",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000725",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051721"
            ],
            "type": "yesno",
            "id": "52f77f752059c6d71c00002b",
            "snippets": [
                {
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 518,
                    "text": "Inherited mutations in genes involved in HR are associated with gene rearrangement and may be a prerequisite for tumor development in some cancer-prone hereditary diseases like Bloom, Werner and Rothmund-Thomson syndromes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22276468",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 312,
                    "text": "Variants in the XRCC3 gene might result in altered protein structure or function which may influence DSBR efficiency and lead to cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24104500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 349,
                    "text": "Although alcohol consumption is related to increased cancer risk, its molecular mechanism remains unclear. Here, we demonstrate that an intake of 10% alcohol for 4 weeks in rats is genotoxic due to induction of micronuclei. Acetaldehyde (AA), the first product of ethanol metabolism, is believed to be responsible for DNA damage induced by alcohol. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23125219",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 447,
                    "text": "Although efficiency of these repair processes substantially decrease the efficacy of cancer chemotherapies that target DNA, compromised DNA repair contributes to mutagenesis and genomic instability leading to carcinogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16555998",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 82,
                    "text": "damage response and repair pathways are important barriers to carcinogenesis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23620081",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 111,
                    "offsetInEndSection": 542,
                    "text": "olymorphisms in DNA repair genes and differences in repair capacity between individuals have been widely documented. For colorectal cancer, the loss of mismatch repair gene activity is a key genetic determinant. Nucleotide excision repair (NER), recombination repair (RR) and base excision repair (BER) pathways have critical roles in protection against other cancers, and we wished to investigate their role in colorectal cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12865926",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can enasidenib be used for the treatment of acute myeloid leukemia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29770715"
            ],
            "ideal_answer": [
                "Yes, enasidenib has been approved for the treatment of adults with relapsed and refracctory acture myelogenous leukemia with an IDH2 mutation."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c6587d77c78d69471000005",
            "snippets": [
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 222,
                    "text": "In August 2017, the United States Federal Drug Administration (FDA) approved enasidenib (Idhifa, Celgene/Agios) for adults with relapsed and refractory acute myelogenous leukemia (AML) with an IDH2 mutation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29770715",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Protoporphyrinogen oxidase localized to the mitochondrium?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12556518",
                "http://www.ncbi.nlm.nih.gov/pubmed/20603160",
                "http://www.ncbi.nlm.nih.gov/pubmed/16621625"
            ],
            "ideal_answer": [
                "Yes,\nMitochondrial targeting of human protoporphyrinogen oxidase."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e8220e6835f4e4777000032",
            "snippets": [
                {
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 525,
                    "text": "We showed that 28 amino acids in the amino terminus of PPOX contain an independently functioning signal for mitochondrial targeting.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12556518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 978,
                    "offsetInEndSection": 1084,
                    "text": "Based on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16621625",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "text": "Mitochondrial targeting of human protoporphyrinogen oxidase.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16621625",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 681,
                    "text": "In the present study, PfPPO has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20603160",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Drk essential for anesthesia-resistant memory (ARM) in Drosophila?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28973902"
            ],
            "ideal_answer": [
                "Yes. Drk, the Drosophila ortholog of the adaptor protein Grb2, is essential for ARM within adult mushroom body neurons in Drosophila."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D004331",
                "https://meshb.nlm.nih.gov/record/ui?ui=D004330",
                "http://amigo.geneontology.org/amigo/term/GO:0007615"
            ],
            "type": "yesno",
            "id": "5a7607f683b0d9ea66000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 519,
                    "text": "Anesthesia-resistant memory (ARM) was described decades ago, but the mechanisms that underlie this protein synthesis-independent form of consolidated memory inDrosophilaremain poorly understood. Whether the several signaling molecules, receptors, and synaptic proteins currently implicated in ARM operate in one or more pathways and how they function in the process remain unclear. We present evidence that Drk, theDrosophilaortholog of the adaptor protein Grb2, is essential for ARM within adult mushroom body neurons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973902",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 523,
                    "text": "We present evidence that Drk, the Drosophila ortholog of the adaptor protein Grb2, is essential for ARM within adult mushroom body neurons.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973902",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is  farnesoid X receptor (FXR) a nuclear receptor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23784309",
                "http://www.ncbi.nlm.nih.gov/pubmed/23688559",
                "http://www.ncbi.nlm.nih.gov/pubmed/24068255",
                "http://www.ncbi.nlm.nih.gov/pubmed/23772048",
                "http://www.ncbi.nlm.nih.gov/pubmed/24037988",
                "http://www.ncbi.nlm.nih.gov/pubmed/23651738",
                "http://www.ncbi.nlm.nih.gov/pubmed/23982684",
                "http://www.ncbi.nlm.nih.gov/pubmed/24177031",
                "http://www.ncbi.nlm.nih.gov/pubmed/24004079",
                "http://www.ncbi.nlm.nih.gov/pubmed/24261510",
                "http://www.ncbi.nlm.nih.gov/pubmed/23720266",
                "http://www.ncbi.nlm.nih.gov/pubmed/24291500",
                "http://www.ncbi.nlm.nih.gov/pubmed/24091600",
                "http://www.ncbi.nlm.nih.gov/pubmed/23609136",
                "http://www.ncbi.nlm.nih.gov/pubmed/24064762",
                "http://www.ncbi.nlm.nih.gov/pubmed/23811326",
                "http://www.ncbi.nlm.nih.gov/pubmed/23861371",
                "http://www.ncbi.nlm.nih.gov/pubmed/23824184",
                "http://www.ncbi.nlm.nih.gov/pubmed/24089008",
                "http://www.ncbi.nlm.nih.gov/pubmed/23680185",
                "http://www.ncbi.nlm.nih.gov/pubmed/24041925",
                "http://www.ncbi.nlm.nih.gov/pubmed/24211198"
            ],
            "ideal_answer": [
                "Yes, farnesoid X receptor (FXR) is a nuclear receptor."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/NR1H4_HUMAN",
                "http://www.uniprot.org/uniprot/NR1H4_MOUSE",
                "http://www.uniprot.org/uniprot/NR1H4_BOVIN",
                "http://www.biosemantics.org/jochem#4250490",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0004879",
                "http://www.uniprot.org/uniprot/NR1H4_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018160"
            ],
            "type": "yesno",
            "id": "55263a1898daae017c000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "Farnesoid X receptor (FXR) belongs to the ligand-activated nuclear receptor superfamily, and functions as a transcription factor regulating the transcription of numerous genes involved in bile acid homeostasis, lipoprotein and glucose metabolism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24291500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 210,
                    "text": " Farnesoid X receptor (FXR) is an ascending target for metabolic and inflammatory diseases. As a nuclear receptor, FXR exhibits many physiological effects in transcription control of several genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24261510",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 269,
                    "text": " FXR is a member of the nuclear receptor superfamily which is also highly expressed in the liver. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24211198",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Farnesoid X receptor (FXR) is a bile acid nuclear receptor described through mouse knockout studies as a tumor suppressor for the development of colon adenocarcinomas",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24177031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Farnesoid X receptor (FXR, Nr1h4) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24091600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1403,
                    "offsetInEndSection": 1445,
                    "text": "the nuclear receptor farnesoid X receptor ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24089008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 704,
                    "offsetInEndSection": 784,
                    "text": " farnesoid X receptor (FXR), a nuclear receptor activated by bile acid ligands. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 339,
                    "text": "T-\u03b2-MCA is an farnesoid X receptor (FXR) nuclear receptor antagonist,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064762",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 356,
                    "text": " Farnesoid X receptor (FXR), a nuclear receptor (NR) and originally considered as a bile acid-activated transcriptional factor, ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24041925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 234,
                    "text": " The nuclear receptor farnesoid X receptor (FXR) plays a major role in the enterohepatic cycling of bile acids",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24037988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Liver X receptors, LXRs, are ligand-activated transcription factors that belong to the group H nuclear receptor (NR) superfamily. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24004079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "The intracellular nuclear receptor farnesoid X receptor and the transmembrane G protein-coupled receptor TGR5 respond to bile acids by activating transcriptional networks and/or signalling cascades.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23982684",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 243,
                    "text": "ncluding those of nuclear receptors, primarily farnesoid X receptor (FXR), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23824184",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1333,
                    "offsetInEndSection": 1383,
                    "text": "ile acids and their cognate nuclear receptor, FXR,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23861371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Farnesoid X receptor (FXR, Nr1h4) and small heterodimer partner (SHP, Nr0b2) are nuclear receptors that are critical to liver homeostasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23811326",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 347,
                    "offsetInEndSection": 412,
                    "text": "he activation of the nuclear receptor farnesoid X receptor (FXR\u03b1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23784309",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 322,
                    "text": "bile acid-activated nuclear receptor farnesoid X receptor (FXR)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23772048",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1587,
                    "text": " nuclear receptor signaling, notably by the farnesoid X receptor (FXR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23720266",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "FXR (farnesoid X receptor, NRIH4), a nuclear receptor, plays a major role in the control of cholesterol metabolism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23688559",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 214,
                    "text": "The role of the nuclear receptor FXR is unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680185",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 18,
                    "offsetInEndSection": 39,
                    "text": "nuclear receptor FXR ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680185",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 27,
                    "offsetInEndSection": 114,
                    "text": "a member of the nuclear receptor superfamily of ligand-activated transcription factors,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23651738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Farnesoid X receptor (FXR) is a nuclear receptor that functions as a bile acid sensor controlling bile acid homeostasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23609136",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can FOXOs modulate longevity?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20874444",
                "http://www.ncbi.nlm.nih.gov/pubmed/22438832",
                "http://www.ncbi.nlm.nih.gov/pubmed/18208360",
                "http://www.ncbi.nlm.nih.gov/pubmed/21076489",
                "http://www.ncbi.nlm.nih.gov/pubmed/15942449",
                "http://www.ncbi.nlm.nih.gov/pubmed/20592766",
                "http://www.ncbi.nlm.nih.gov/pubmed/19408108",
                "http://www.ncbi.nlm.nih.gov/pubmed/21431325",
                "http://www.ncbi.nlm.nih.gov/pubmed/15126506",
                "http://www.ncbi.nlm.nih.gov/pubmed/19861158",
                "http://www.ncbi.nlm.nih.gov/pubmed/18371346",
                "http://www.ncbi.nlm.nih.gov/pubmed/21114762",
                "http://www.ncbi.nlm.nih.gov/pubmed/22187289",
                "http://www.ncbi.nlm.nih.gov/pubmed/19066462",
                "http://www.ncbi.nlm.nih.gov/pubmed/18193389"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4MB78",
                    "o": "http://linkedlifedata.com/resource/#_42344D42373800B"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42344D42373800B",
                    "o": "GJ14344"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42344D42373800A",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42344D42373800B",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4PTD3",
                    "o": "http://linkedlifedata.com/resource/#_42345054443300D"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42345054443300C",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42345054443300D",
                    "o": "GE24216"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42345054443300D",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4HF64",
                    "o": "http://linkedlifedata.com/resource/#_42344846363400D"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42344846363400D",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42344846363400D",
                    "o": "GM24148"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42344846363400C",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B3P0K6",
                    "o": "http://linkedlifedata.com/resource/#_423350304B3600D"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_423350304B3600C",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_423350304B3600D",
                    "o": "GG16833"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_423350304B3600D",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4KBF6",
                    "o": "http://linkedlifedata.com/resource/#_42344B42463600B"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42344B42463600B",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42344B42463600B",
                    "o": "GI21984"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42344B42463600A",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q298W7",
                    "o": "http://linkedlifedata.com/resource/#_51323938573700B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51323938573700A",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51323938573700B",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_51323938573700B",
                    "o": "GA16248"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4JSC2",
                    "o": "http://linkedlifedata.com/resource/#_42344A53433200B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42344A53433200A",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42344A53433200B",
                    "o": "GH22274"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42344A53433200B",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4G4S8",
                    "o": "http://linkedlifedata.com/resource/#_42344734533800E"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42344734533800E",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42344734533800E",
                    "o": "GL24235"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42344734533800D",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3832745",
                    "o": "C477334"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1311653",
                    "o": "http://linkedlifedata.com/resource/umls/label/A3832745"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3832745",
                    "o": "FOXO protein, Drosophila"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1311653",
                    "o": "http://linkedlifedata.com/resource/umls/label/A3832745"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3832745",
                    "o": "MeSH"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B3LYS5",
                    "o": "http://linkedlifedata.com/resource/#_42334C59533500D"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42334C59533500C",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42334C59533500D",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42334C59533500D",
                    "o": "GF16233"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/B4NFR1",
                    "o": "http://linkedlifedata.com/resource/#_42344E46523100B"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_42344E46523100B",
                    "o": "foxo"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_42344E46523100A",
                    "o": "Forkhead box protein O"
                },
                {
                    "p": "http://purl.uniprot.org/core/orfName",
                    "s": "http://linkedlifedata.com/resource/#_42344E46523100B",
                    "o": "GK22687"
                }
            ],
            "ideal_answer": [
                "FOXOs are reliable markers of longevity."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/FOXO_DROME",
                "http://www.uniprot.org/uniprot/FOXO_DROSE",
                "http://www.uniprot.org/uniprot/FOXO_DROPE",
                "http://www.uniprot.org/uniprot/FOXO_DROMO",
                "http://www.uniprot.org/uniprot/FOXO_CAEEL",
                "http://www.uniprot.org/uniprot/FOXO_DROPS",
                "http://www.uniprot.org/uniprot/FOXO_DROGR",
                "http://www.uniprot.org/uniprot/FOXO_DROYA",
                "http://www.uniprot.org/uniprot/FOXO_DROWI",
                "http://www.uniprot.org/uniprot/FOXO_DROER",
                "http://www.uniprot.org/uniprot/FOXO_DROVI",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008136",
                "http://www.uniprot.org/uniprot/FOXO_DROAN"
            ],
            "type": "yesno",
            "id": "52b2ec944003448f55000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Forkhead box O (FOXO) transcription factors have a conserved function in regulating metazoan lifespan.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22438832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1475,
                    "offsetInEndSection": 1641,
                    "text": "In contrast to FoxO1, FoxO3a and FoxO6 were specifically diminished in the CNS of HFD animals possibly contributing to the reduced lifespan observed in these animals.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22187289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1048,
                    "offsetInEndSection": 1291,
                    "text": "Interestingly, many target proteins of AMPK are so-called longevity factors, e.g., SIRT1, p53, and FoxOs, which not only can increase the stress resistance and extend the lifespan of many organisms but also inhibit the inflammatory responses. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21431325",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 437,
                    "text": "Components of anti-ageing and autophagy include SirTs and FoxOs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21114762",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1659,
                    "offsetInEndSection": 1959,
                    "text": "Since Sirts and FoxOs are reliable markers of longevity, the results appear to suggest that Longevinex induces longevity after prolonged feeding via induction of autophagy, while it converts death signals into survival signals and provides cardioprotection within a relatively shorter period of time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21076489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Forkhead box O (FOXO) transcription factors are involved in various cellular processes, including cell proliferation, stress resistance, metabolism, and longevity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20874444",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 217,
                    "offsetInEndSection": 595,
                    "text": "In this respect, members of the mammalian forkhead transcription factors of the O class (FoxOs) that include FoxO1, FoxO3, FoxO4 and FoxO6 are increasingly being recognized as exciting prospects for multiple disorders. These transcription factors govern development, proliferation, survival and longevity during multiple cellular environments that can involve oxidative stress. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20592766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 897,
                    "offsetInEndSection": 1160,
                    "text": "Here we discuss the fascinating but complex role of FoxOs during cellular injury and oxidative stress, progenitor cell development, fertility, angiogenesis, cardiovascular function, cellular metabolism and diabetes, cell longevity, immune surveillance and cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20592766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 813,
                    "offsetInEndSection": 896,
                    "text": "Many longevity genes, e.g. FoxOs and SIRT1, are inhibitors of NF-kappaB signaling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19861158",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 954,
                    "offsetInEndSection": 1126,
                    "text": "Interestingly, several longevity genes such as SIRT1, SIRT6, and FoxOs can clearly suppress NF-kappaB signaling and in this way delay the aging process and extend lifespan.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19408108",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 548,
                    "offsetInEndSection": 772,
                    "text": "Yet, FoxOs also can significantly affect normal cell survival and longevity, requiring new treatments for neoplastic growth to modulate novel pathways that integrate cell proliferation, metabolism, inflammation and survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19066462",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 897,
                    "text": "These observations link FoxO function in mammalian systems with the evolutionarily conserved role of FoxO in promotion of stress resistance and longevity in lower phylogenetic systems. Furthermore, these findings have implications for aging in higher organisms and in malignant stem cell biology, and suggest that FoxOs may play an important role in the maintenance and integrity of stem cell compartments in a broad spectrum of tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18371346",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 343,
                    "text": "Forkhead box O (FoxO) transcription factors are important downstream targets of the PI3K/Akt signaling pathway and crucial regulators of cell fate. This function of FoxOs relies on their ability to control diverse cellular functions, including proliferation, differentiation, apoptosis, DNA repair, defense against oxidative stress and ageing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18208360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 619,
                    "offsetInEndSection": 872,
                    "text": "This brief review focuses on the molecular mechanisms, cellular effects and resulting organismal phenotypes generated by differentially regulated FoxO proteins and discusses our current understanding of the role of FoxOs in disease and ageing processes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18208360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 957,
                    "text": "In this review, we focus on the several interactions of aging-associated signaling cascades regulated either by Sirtuins and FoxOs or NF-kappaB signaling pathways. We provide evidence that signaling via the longevity factors of FoxOs and SIRT1 can inhibit NF-kappaB signaling and simultaneously protect against inflamm-aging process.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18193389",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 846,
                    "text": "In diverse species transcription factors belonging to the forkhead/winged helix box gene, group O (FOXO) subfamily have been found to be crucial in downstream suppression of the life-shortening effects of insulin/insulin-like growth factor-I receptor signalling pathways that, when upregulated, accelerate ageing by suppression of FOXO. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15942449",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1293,
                    "text": "In humans, FOXO3a, as well as FOXO1 and -4, and their downstream effectors, could hold the key to counteracting ageing and common diseases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15942449",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "FOXO transcription factors have important roles in metabolism, cellular proliferation, stress tolerance, and aging. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15126506",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Semagacestat effective for treatment of Alzheimer's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
                "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
                "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                "http://www.ncbi.nlm.nih.gov/pubmed/23196551",
                "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
                "http://www.ncbi.nlm.nih.gov/pubmed/25292430",
                "http://www.ncbi.nlm.nih.gov/pubmed/21149978",
                "http://www.ncbi.nlm.nih.gov/pubmed/28978478"
            ],
            "ideal_answer": [
                "No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c73acf27c78d6947100008a",
            "snippets": [
                {
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 402,
                    "text": "However, a large phase 3 trial of semagacestat, a potential non-transition state analog (non-TSA) GSI, in patients with Alzheimer's disease (AD) was terminated due to unexpected aggravation of cognitive deficits and side effects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978478",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "BACKGROUND: In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 398,
                    "text": "A clinical trial with the wide-spectrum \u03b3-secretase inhibitor semagacestat has, however, demonstrated that global inhibition of all \u03b3-secretases causes serious toxicity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25292430",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "OBJECTIVE: Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2360,
                    "offsetInEndSection": 2626,
                    "text": "CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "text": "BACKGROUND\nIn a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2539,
                    "offsetInEndSection": 2631,
                    "text": "Semagacestat was associated with more adverse events, including skin cancers and infections.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2366,
                    "offsetInEndSection": 2538,
                    "text": "CONCLUSIONS\nAs compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "OBJECTIVE\nSemagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 640,
                    "text": "Recently disclosed Phase III findings on semagacestat indicated that Alzheimer's disease (AD) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "The recent failure of semagacestat in two large Phase III studies questions the value of \u03b3-secretase inhibitors in treating Alzheimer's disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "A phase 3 trial of semagacestat for treatment of Alzheimer's disease.As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 983,
                    "text": "Preliminary results from Phase III studies showed that semagacestat failed to slow disease progression, and it was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196551",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 287,
                    "text": "Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of\u00a0Alzheimer's Disease.In participants with mild to moderate AD, high dose semagacestat treatment was associated with greater severity and faster worsening of NPS in a pattern resembling an agitated depression. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1950,
                    "offsetInEndSection": 2164,
                    "text": "Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "text": "<b>OBJECTIVE</b>: Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 898,
                    "offsetInEndSection": 1099,
                    "text": "Other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin-related TEAEs, renal and hepatic changes, increased QT interval, and weight loss.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1896,
                    "offsetInEndSection": 2113,
                    "text": "Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P&lt;0.001 for all comparisons with placebo).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can siRNA affect response to afatinib treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23266614",
                "http://www.ncbi.nlm.nih.gov/pubmed/22436374",
                "http://www.ncbi.nlm.nih.gov/pubmed/23555954"
            ],
            "ideal_answer": [
                "When afatinib was combined with an EGFR-specific siRNA there was a strong biological effect on growth inhibition and induction of apoptosis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0030422",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D034741",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0090065"
            ],
            "type": "yesno",
            "id": "54297ed2289fd6cb07000001",
            "snippets": [
                {
                    "offsetInBeginSection": 619,
                    "offsetInEndSection": 812,
                    "text": "On the other hand, miR-146a enhanced the inhibition of cell proliferation by drugs targeting EGFR, including both TKIs (gefitinib, erlotinib, and afatinib) and a monoclonal antibody (cetuximab)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23555954",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 814,
                    "offsetInEndSection": 1002,
                    "text": "These effects were independent of the EGFR mutation status (wild type, sensitizing mutation or resistance mutation), but were less potent compared to the effects of siRNA targeting of EGFR",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23555954",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1147,
                    "offsetInEndSection": 1280,
                    "text": "Among the anti-EGFR agents tested, the strongest biological effect was observed when afatinib was combined with T790M-specific-siRNAs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23266614",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1752,
                    "text": "The combination of a potent, irreversible kinase inhibitor such as afatinib, with T790M-specific-siRNAs should be further investigated as a new strategy in the treatment of lung cancer containing the resistant T790M mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23266614",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2418,
                    "offsetInEndSection": 2517,
                    "text": "The strongest biological effect was observed when afatinib was combined with an EGFR-specific siRNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22436374",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2175,
                    "offsetInEndSection": 2417,
                    "text": "The addition of EGFR siRNA to either TKIs or cetuximab additively enhanced growth inhibition and induction of apoptosis in all five cell lines, independent of the EGFR mutation status (wild-type or sensitizing mutation or resistant mutation).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22436374",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2934,
                    "offsetInEndSection": 3205,
                    "text": "The combination of a potent, irreversible kinase inhibitor such as afatinib, with EGFR-specific siRNAs should be further investigated as a new strategy in the treatment of lung cancer and other EGFR dependent cancers, including those with downstream resistance mutations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22436374",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any role for Pds5b in cohesion establishment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24141881"
            ],
            "ideal_answer": [
                "Yes. Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/PD5AA_XENLA",
                "http://www.uniprot.org/uniprot/PD5BA_XENLA",
                "http://www.uniprot.org/uniprot/PDS5A_RAT",
                "http://amigo.geneontology.org/amigo/term/GO:0034085",
                "http://www.uniprot.org/uniprot/PDS5B_RAT",
                "http://amigo.geneontology.org/amigo/term/GO:0034087",
                "http://www.uniprot.org/uniprot/PDS5B_MOUSE",
                "http://amigo.geneontology.org/amigo/term/GO:0034089"
            ],
            "type": "yesno",
            "id": "5889e2c83b87a8a73800000a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Pds5B is required for cohesion establishment and Aurora B accumulation at centromeres.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 1070,
                    "text": "Here, we demonstrate that Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin. While both proteins contribute to telomere and arm cohesion, Pds5B is specifically required for centromeric cohesion. Furthermore, reduced accumulation of Aurora B at the inner centromere region in cells lacking Pds5B impairs its error correction function, promoting chromosome mis-segregation and aneuploidy. Our work supports a model in which the composition and function of cohesin complexes differs between different chromosomal regions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Pds5B is required for cohesion establishment and Aurora B accumulation at centromeres.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 628,
                    "text": "Here, we demonstrate that Pds5 proteins are essential for cohesion establishment by allowing Smc3 acetylation by the cohesin acetyl transferases (CoATs) Esco1/2 and binding of Sororin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24141881",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can clonidine be used to reduce agitation in children.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/14977793",
                "http://www.ncbi.nlm.nih.gov/pubmed/17416907",
                "http://www.ncbi.nlm.nih.gov/pubmed/20514964",
                "http://www.ncbi.nlm.nih.gov/pubmed/21150631",
                "http://www.ncbi.nlm.nih.gov/pubmed/16677266",
                "http://www.ncbi.nlm.nih.gov/pubmed/18095969",
                "http://www.ncbi.nlm.nih.gov/pubmed/17019218",
                "http://www.ncbi.nlm.nih.gov/pubmed/17986032",
                "http://www.ncbi.nlm.nih.gov/pubmed/12173195",
                "http://www.ncbi.nlm.nih.gov/pubmed/16632814",
                "http://www.ncbi.nlm.nih.gov/pubmed/16301230",
                "http://www.ncbi.nlm.nih.gov/pubmed/23394604",
                "http://www.ncbi.nlm.nih.gov/pubmed/11473855"
            ],
            "ideal_answer": [
                "Yes, clonidine is effective in prevention of post-anesthesia agitation in children."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011595",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002648",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003000"
            ],
            "type": "yesno",
            "id": "515df89e298dcd4e5100002f",
            "snippets": [
                {
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 1089,
                    "text": "Children receiving clonidine immediately after anesthesia induction had statistically significant improvement in postoperative agitation at the 15-minute mark (P = .096) and last score obtained (P = .095) using the Watcha scale.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394604",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 330,
                    "text": "Clonidine has proven to be effective in reducing the incidence of post-operative agitation at a higher dose (3 and 2 \u03bcg kg\u207b\u00b9).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150631",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1200,
                    "offsetInEndSection": 1396,
                    "text": "Post-anaesthetic agitation was observed in two patients (6.6%) in group 1, eight patients (26.6%) in group 2 as compared to 12 patients (40%) in group 3 after 15 min of post-operative observation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150631",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1397,
                    "offsetInEndSection": 1503,
                    "text": "The mean scores in group 1 at 15 and 30 min were significantly lower than those in group 3 (P value <0.05)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150631",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1630,
                    "offsetInEndSection": 1860,
                    "text": "Caudal clonidine at a lower dose (1 \u03bcg kg\u207b\u00b9) could be effective in reducing the incidence of sevoflurane-induced emergence agitation in children undergoing urogenital and lower limb surgery without any significant adverse effects.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150631",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 770,
                    "offsetInEndSection": 878,
                    "text": "Only the 4 microg kg-1 dose of clonidine was associated with a significant reduction in emergence agitation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17416907",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 879,
                    "offsetInEndSection": 1001,
                    "text": "Fewer children in the clonidine 4 microg kg-1 group displayed agitation (25%) than in the midazolam group (60%) (P=0.025).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17416907",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1128,
                    "offsetInEndSection": 1276,
                    "text": "In comparison with midazolam, clonidine 4 microg kg-1 reduced sevoflurane-induced emergence agitation without increasing postoperative side-effects.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17416907",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1336,
                    "offsetInEndSection": 1450,
                    "text": "Prophylactic use of clonidine against sevoflurane-induced agitation may represent a new and promising application.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17019218",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 888,
                    "offsetInEndSection": 1125,
                    "text": "One hundred and twenty children were included in this study: 59 of whom received clonidine, and 61 placebo; 41% of those in the placebo group exhibited moderate-severe EA compared with only 22% of those in the clonidine group (P < 0.03).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16677266",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1495,
                    "offsetInEndSection": 1690,
                    "text": "Findings demonstrate that i.v. clonidine administered after induction of anesthesia significantly reduces the incidence of EA in young children, but is associated with sleepiness postoperatively.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16677266",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 921,
                    "offsetInEndSection": 981,
                    "text": "Clonidine could not prevent agitation (incidence 54%, 13/24)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16632814",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1245,
                    "offsetInEndSection": 1337,
                    "text": "Clonidine 1.5 microg/kg did not differ from placebo with respect to postoperative agitation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16632814",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Clonidine is effective in treating sevoflurane-induced postanesthesia agitation in children.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16301230",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 866,
                    "text": "Pain and discomfort scores were significantly decreased in the clonidine group; the incidence of agitation was reduced by 57% (P = 0.029) and the incidence of severe agitation by 67% (P = 0.064). Relative risks for developing agitation and severe agitation were 0.43 (95% confidence interval, 0.24-0.78) and 0.32 (0.09-1.17), respectively.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16301230",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 963,
                    "text": "Clonidine produces a substantial reduction in the risk of postsevoflurane agitation in children.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16301230",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1011,
                    "offsetInEndSection": 1103,
                    "text": "Agitation was observed in 12 midazolam-treated and five clonidine-treated patients (P=0.05).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14977793",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1649,
                    "offsetInEndSection": 1745,
                    "text": "Compared with midazolam, clonidine premedication reduced agitation during sevoflurane induction.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14977793",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1351,
                    "offsetInEndSection": 1590,
                    "text": "Clonidine 3 micrograms kg-1 prevented agitation after sevoflurane anaesthesia, independently of the route of administration. The effect of clonidine appears to be dose-dependent, as an epidural dose of 1 microgram kg-1 failed to reduce it.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12173195",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 61,
                    "text": "Clonidine prevents sevoflurane-induced agitation in children.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473855",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 563,
                    "text": "In 16 placebo and 2 clonidine-treated patients agitation was observed (P < 0.001)",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473855",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 565,
                    "offsetInEndSection": 723,
                    "text": "In 6 patients of the Placebo group, agitation was graded as severe, whereas none of the patients in the Clonidine group developed severe agitation (P = 0.02).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473855",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 944,
                    "text": "We conclude that clonidine effectively prevents agitation after sevoflurane anesthesia.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473855",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1239,
                    "text": "Clonidine 2 microg/kg IV after anesthetic induction effectively reduces the incidence of agitation without resulting in clinically relevant bradycardia and hypotension.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11473855",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1496,
                    "offsetInEndSection": 1730,
                    "text": "Children receiving clonidine prior to undergoing strabismus surgery have a small but noticeable reduction in postoperative agitation, stay slightly longer in the post-anesthesia care unit, and have higher rates of parent satisfaction.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394604",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 599,
                    "text": "We report three cases of preoperative use of intranasal clonidine in pediatric patients, all for different indications. One patient was treated for preoperative agitation and hallucinations associated with oral midazolam. One patient was given clonidine as a premedicant. The third patient was treated for preoperative agitation and hypertension. All three patients had subjective resolution of indicated symptoms and none experienced adverse outcomes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18095969",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 389,
                    "offsetInEndSection": 532,
                    "text": "Oral or intravenous clonidine has been successfully used for the prevention of sevoflurane-induced agitation during emergence from anaesthesia.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17019218",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is pregabalin effective for treatment of patients with restless leg syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23859128",
                "http://www.ncbi.nlm.nih.gov/pubmed/22851801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18656214",
                "http://www.ncbi.nlm.nih.gov/pubmed/24521108",
                "http://www.ncbi.nlm.nih.gov/pubmed/17489946",
                "http://www.ncbi.nlm.nih.gov/pubmed/23746768",
                "http://www.ncbi.nlm.nih.gov/pubmed/24363103",
                "http://www.ncbi.nlm.nih.gov/pubmed/23385700",
                "http://www.ncbi.nlm.nih.gov/pubmed/22937989",
                "http://www.ncbi.nlm.nih.gov/pubmed/24119681",
                "http://www.ncbi.nlm.nih.gov/pubmed/23304742",
                "http://www.ncbi.nlm.nih.gov/pubmed/20466589",
                "http://www.ncbi.nlm.nih.gov/pubmed/24899755",
                "http://www.ncbi.nlm.nih.gov/pubmed/22570552",
                "http://www.ncbi.nlm.nih.gov/pubmed/20427750",
                "http://www.ncbi.nlm.nih.gov/pubmed/23771546",
                "http://www.ncbi.nlm.nih.gov/pubmed/23703310",
                "http://www.ncbi.nlm.nih.gov/pubmed/23524988"
            ],
            "ideal_answer": [
                "Yes, numerous evidence from clinical trials indicate that pregabalic is effective for treatment of patients diagnosed with restless leg syndrome."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4236113"
            ],
            "type": "yesno",
            "id": "54cf4a0ef693c3b16b00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 1504,
                    "offsetInEndSection": 1784,
                    "text": "CONCLUSIONS: This study demonstrated improvements in objective and subjective measures of sleep maintenance and sleep architecture with pregabalin compared with placebo and pramipexole. Effects of pregabalin on periodic limb movement arousal index were comparable to pramipexole. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24899755",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2175,
                    "offsetInEndSection": 2372,
                    "text": "CONCLUSIONS: Pregabalin provided significantly improved treatment outcomes as compared with placebo, and augmentation rates were significantly lower with pregabalin than with 0.5 mg of pramipexole.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24521108",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1095,
                    "offsetInEndSection": 1318,
                    "text": "The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24363103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 905,
                    "text": "Pregabalin has been established as effective for up to 1 year in treating RLS/WED (Level A evidence). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859128",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2827,
                    "offsetInEndSection": 2982,
                    "text": "In the group of anticonvulsants, only the trials performed with \u03b1\u2082\u03b4 ligands such as gabapentin, gabapentin enacarbil, and pregabalin showed good efficacy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23746768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1395,
                    "offsetInEndSection": 1619,
                    "text": "Alternative or additional pharmacologic treatment with a lower level of overall quality of evidence includes opioids (codeine, tramadol, and oxycodone) and anticonvulsants (gabapentin, gabapentin enacarbil, and pregabalin). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23703310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 1116,
                    "text": "There is sufficient evidence to conclude that dopamine agonists such as rotigotine transdermal patch, pramipexole, ropinirole, gabapentin enacarbil, pregabalin and gabapentin are effective in the short-term treatment of RLS and rotigotine, followed by gabapentin enacarbil, ropinirole, pramipexole and gabapentin for long-term treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23524988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 818,
                    "text": "Calcium channel alpha-2-delta ligands (gabapentin, gabapentin enacarbil, and pregabalin) provide alternative therapies for RLS especially in patients with augmentation, impulse control disorders, or hypersomnia induced by dopamine agonists. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2129,
                    "offsetInEndSection": 2381,
                    "text": "Alpha-2-delta ligands (gabapentin enacarbil, gabapentin, and pregabalin) increased the number of IRLS responders (RR=1.66; [95% CI: 1.33 to 2.09], k=3, high strength of evidence) and mean change in IRLS symptom scores (k=3, high strength of evidence). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23304742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1193,
                    "offsetInEndSection": 1408,
                    "text": "RECOMMENDATIONS: Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 810,
                    "text": "Therapies with an OPTION level of recommendation include carbamazepine, gabapentin, pregabalin, clonidine, and for patients with low ferritin levels, iron supplementation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22851801",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1565,
                    "text": "CONCLUSIONS: In this 6-week phase 2b study, pregabalin reduced RLS symptoms in patients with moderate-to-severe idiopathic RLS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20466589",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1974,
                    "offsetInEndSection": 2206,
                    "text": "CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that pregabalin is effective for the treatment of restless legs syndrome and improves sleep architecture and periodic limb movements in placebo-unresponsive patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427750",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2493,
                    "offsetInEndSection": 2634,
                    "text": "In severe, refractory or neuropathy-associated RLS, antiepileptic (gabapentin, pregabalin) or opioid (oxycodone, tramadol) drugs can be used.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18656214",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1094,
                    "offsetInEndSection": 1315,
                    "text": "The alpha-2-delta ligands, including gabapentin, gabapentin enacarbil, and pregabalin, are effective for RLS without known occurrence of augmentation or impulse control disorders, although sedation and dizziness can occur",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24363103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1935,
                    "offsetInEndSection": 2139,
                    "text": "This study provides Class II evidence that pregabalin is effective for the treatment of restless legs syndrome and improves sleep architecture and periodic limb movements in placebo-unresponsive patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427750",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1163,
                    "offsetInEndSection": 1360,
                    "text": "Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937989",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25874001"
            ],
            "ideal_answer": [
                "Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a772e9dfaa1ab7d2e000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "text": "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 801,
                    "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1192,
                    "text": "The study was a 4-week Phase Ib multiple ascending dose, randomized, double-blind, placebo-controlled trial of AZD0530 in AD patients with Mini-Mental State Examination (MMSE) scores ranging from 16 to 26. A total of 24 subjects were recruited in three sequential groups, with each randomized to receive oral AZD0530 at doses of 50\u00a0mg, 100\u00a0mg, 125\u00a0mg, or placebo daily for 4\u00a0weeks. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2307,
                    "offsetInEndSection": 2657,
                    "text": "AZD0530 is reasonably safe and well tolerated in patients with mild-to-moderate AD, achieving substantial central nervous system penetration with oral dosing at 100-125\u00a0mg. Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Bobble head doll syndrome associated with hydrocephalus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25878736",
                "http://www.ncbi.nlm.nih.gov/pubmed/29593205",
                "http://www.ncbi.nlm.nih.gov/pubmed/22886034",
                "http://www.ncbi.nlm.nih.gov/pubmed/24075844",
                "http://www.ncbi.nlm.nih.gov/pubmed/25506155",
                "http://www.ncbi.nlm.nih.gov/pubmed/29303456",
                "http://www.ncbi.nlm.nih.gov/pubmed/7674025"
            ],
            "ideal_answer": [
                "Yes, Bobble head doll syndrome is associated with obstructive hydrocephalus."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c55d75807647bbc4b000008",
            "snippets": [
                {
                    "offsetInBeginSection": 647,
                    "offsetInEndSection": 788,
                    "text": "The first is a 14-year-old boy with BHDS associated with aqueductal obstruction and triventricular hydrocephalus secondary to a tectal tumor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29303456",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 288,
                    "text": "Brain magnetic resonance imaging showed a large suprasellar arachnoid cyst extending into the third ventricle, with obstructive hydrocephalus, characteristic of bobble-head doll syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29593205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 501,
                    "offsetInEndSection": 619,
                    "text": "MRI Scan showed a large contrast-enhanced lesion in the region of the third ventricle along with gross hydrocephalus. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506155",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 479,
                    "text": "Bobble-head doll syndrome is usually associated with dilation of the third ventricle, but is rarely associated with posterior fossa disease.PATIENT: We describe an infant with fetal hydrocephalus and an arachnoid cyst of the posterior fossa.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24075844",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 326,
                    "offsetInEndSection": 416,
                    "text": "All the patients presented a psychomotor retardation due to an obstructive hydrocephalus. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22886034",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "Suprasellar arachnoid cysts can have varied presentations with signs and symptoms of obstructive hydrocephalus, visual impairment, endocrinal dysfunction, gait ataxia and rarely bobble-head doll movement.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25878736",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 592,
                    "text": "We present three cases with bobble-head doll syndrome associated with a large suprasellar arachnoid cyst and obstructive hydrocephalus, which were treated with endoscopic cystoventriculocisternostomy and marsupialization of the cyst.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25878736",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do orphan and gene related CpG islands follow power-law-like distributions?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25242375"
            ],
            "ideal_answer": [
                "Yes. Orphan and gene related CpG Islands follow power-law-like distributions in several genomes. The observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018899"
            ],
            "type": "yesno",
            "id": "56bb154aac7ad10019000003",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Orphan and gene related CpG Islands follow power-law-like distributions in several genomes: evidence of function-related and taxonomy-related modes of distribution.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 778,
                    "text": "Here, an investigation of their distributional characteristics in a variety of genomes is undertaken for both whole CGI populations as well as for CGI subsets that lie away from known genes (gene-unrelated or \"orphan\" CGIs). In both cases power-law-like linearity in double logarithmic scale is found.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1703,
                    "text": " Our results on power-law-like linearity found in orphan CGI populations suggest that the observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow. The power-law-like patterns in the genomic distributions of CGIs described herein are found to be compatible with several other features of the composition, abundance or functional role of CGIs reported in the current literature across several genomes, on the basis of the proposed evolutionary model.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1394,
                    "offsetInEndSection": 1608,
                    "text": "Our results on power-law-like linearity found in orphan CGI populations suggest that the observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1695,
                    "offsetInEndSection": 1996,
                    "text": "The power-law-like patterns in the genomic distributions of CGIs described herein are found to be compatible with several other features of the composition, abundance or functional role of CGIs reported in the current literature across several genomes, on the basis of the proposed evolutionary model.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1402,
                    "text": "Our results on power-law-like linearity found in orphan CGI populations suggest that the observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1703,
                    "text": "Our results on power-law-like linearity found in orphan CGI populations suggest that the observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow. The power-law-like patterns in the genomic distributions of CGIs described herein are found to be compatible with several other features of the composition, abundance or functional role of CGIs reported in the current literature across several genomes, on the basis of the proposed evolutionary model.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 779,
                    "text": "Initially, they were assigned the role of transcriptional regulation of protein-coding genes, especially the house-keeping ones, while more recently there is found evidence that they are involved in several other functions as well, which might include regulation of the expression of RNA genes, DNA replication etc. Here, an investigation of their distributional characteristics in a variety of genomes is undertaken for both whole CGI populations as well as for CGI subsets that lie away from known genes (gene-unrelated or \"orphan\" CGIs). In both cases power-law-like linearity in double logarithmic scale is found. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1401,
                    "text": "Our results on power-law-like linearity found in orphan CGI populations suggest that the observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1402,
                    "offsetInEndSection": 1703,
                    "text": "The power-law-like patterns in the genomic distributions of CGIs described herein are found to be compatible with several other features of the composition, abundance or functional role of CGIs reported in the current literature across several genomes, on the basis of the proposed evolutionary model.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1198,
                    "offsetInEndSection": 1412,
                    "text": "Our results on power-law-like linearity found in orphan CGI populations suggest that the observed distributional pattern is independent of the analogous pattern that protein coding segments were reported to follow.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25242375",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21306953",
                "http://www.ncbi.nlm.nih.gov/pubmed/24328549",
                "http://www.ncbi.nlm.nih.gov/pubmed/25647781"
            ],
            "ideal_answer": [
                "No. The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c73ad347c78d69471000098",
            "snippets": [
                {
                    "offsetInBeginSection": 1673,
                    "offsetInEndSection": 1853,
                    "text": "CONCLUSIONS: Axitinib/gemcitabine, while tolerated, did not provide survival benefit over gemcitabine alone in patients with advanced pancreatic cancer from Japan or other regions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 644,
                    "offsetInEndSection": 1257,
                    "text": "RESULTS: Among Japanese patients, median overall survival was not estimable (95% confidence interval, 7.4 months-not estimable) with axitinib/gemcitabine (n = 58) and 9.9 months (95% confidence interval, 7.4-10.5) with placebo/gemcitabine (n = 56) (hazard ratio 1.093 [95% confidence interval, 0.525-2.274]). Median survival follow-up (range) was 5.1 months (0.02-12.3) with axitinib/gemcitabine vs. 5.4 months (1.8-10.5) with placebo/gemcitabine. Similarly, no difference was detected in overall survival between axitinib/gemcitabine and placebo/gemcitabine in patients from North America or the European Union. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1757,
                    "offsetInEndSection": 2144,
                    "text": "At an interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed. Median overall survival was 8\u00b75 months (95% CI 6\u00b79-9\u00b75) for gemcitabine plus axitinib (n=314, data missing for two patients) and 8\u00b73 months (6\u00b79-10\u00b73) for gemcitabine plus placebo (n=316; hazard ratio 1\u00b7014, 95% CI 0\u00b7786-1\u00b7309; one-sided p=0\u00b75436). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306953",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2417,
                    "offsetInEndSection": 2538,
                    "text": "INTERPRETATION: The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306953",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2423,
                    "offsetInEndSection": 2542,
                    "text": "INTERPRETATION\nThe addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306953",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1453,
                    "text": "However, as with other tyrosine kinase inhibitors of the same class, axitinib does not prolong overall survival; therefore, selection of second-line tyrosine kinase inhibitor therapy, including axitinib, must be carefully considered to maximize outcomes for each patient.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24328549",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1679,
                    "offsetInEndSection": 1858,
                    "text": "CONCLUSIONS\nAxitinib/gemcitabine, while tolerated, did not provide survival benefit over gemcitabine alone in patients with advanced pancreatic cancer from Japan or other regions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1285,
                    "text": "Similarly, no difference was detected in overall survival between axitinib/gemcitabine and placebo/gemcitabine in patients from North America or the European Union.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1645,
                    "offsetInEndSection": 1812,
                    "text": "Axitinib/gemcitabine, while tolerated, did not provide survival benefit over gemcitabine alone in patients with advanced pancreatic cancer from Japan or other regions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25647781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2373,
                    "offsetInEndSection": 2477,
                    "text": "The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21306953",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are whole-genome duplications more divergent than small-scale duplications in yeast?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19625390",
                "http://www.ncbi.nlm.nih.gov/pubmed/21079672",
                "http://www.ncbi.nlm.nih.gov/pubmed/17916239",
                "http://www.ncbi.nlm.nih.gov/pubmed/27799339",
                "http://www.ncbi.nlm.nih.gov/pubmed/23300483",
                "http://www.ncbi.nlm.nih.gov/pubmed/20525287"
            ],
            "ideal_answer": [
                "Whole-genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small-scale duplicate counterparts."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c2f8127133db5eb78000032",
            "snippets": [
                {
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 999,
                    "text": " Also, we observe that transporter and glycolytic genes have a higher probability to be retained in duplicate after WGD and subsequent gene loss, both in the model as in S. cerevisiae, which leads to an increase in glycolytic flux after WGD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625390",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 603,
                    "offsetInEndSection": 758,
                    "text": "We show that the retention of genes in duplicate in the model, corresponds nicely with those retained in duplicate after the ancestral WGD in S. cerevisiae",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625390",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1455,
                    "text": "Thus, our model confirms the hypothesis that WGD has been important in the adaptation of yeast to the new, glucose-rich environment that arose after the appearance of angiosperms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19625390",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 489,
                    "offsetInEndSection": 708,
                    "text": "Whole-genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small-scale duplicate counterparts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17916239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 709,
                    "text": "The results uncover the WGD as a major source for the evolution of a complex interconnected block of transcriptional pathways.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20525287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1862,
                    "offsetInEndSection": 2062,
                    "text": "These selected pairs, both WGD and SSD, tend to have decelerated functional evolution, have higher propensities of co-clustering into the same protein complexes, and share common interacting partners.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21079672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1214,
                    "offsetInEndSection": 1467,
                    "text": "Moreover, we find additional transcriptional profiles that are suggestive of neo- and subfunctionalization of duplicate gene copies. These patterns are strongly correlated with the functional dependencies and sequence divergence profiles of gene copies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799339",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 235,
                    "text": "Functional and transcriptional divergence between the copies after gene duplication has been considered the main driver of innovations .",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799339",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 726,
                    "text": "Whole-genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small-scale duplicate counterparts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17916239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 163,
                    "offsetInEndSection": 382,
                    "text": "Empirical data shows that whole-genome duplications (WGDs) are more likely to be retained than small-scale duplications (SSDs), though their relative contribution to the functional fate of duplicates remains unexplored.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300483",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28904741",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450506",
                "http://www.ncbi.nlm.nih.gov/pubmed/21677849",
                "http://www.ncbi.nlm.nih.gov/pubmed/28315371",
                "http://www.ncbi.nlm.nih.gov/pubmed/23039946",
                "http://www.ncbi.nlm.nih.gov/pubmed/28642378",
                "http://www.ncbi.nlm.nih.gov/pubmed/28138355"
            ],
            "ideal_answer": [
                "Yes, the complete genome sequence of Arthrobacter (two strains) is deposited in GenBank."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001173",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016678"
            ],
            "type": "yesno",
            "id": "51593dc8d24251bc05000099",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Complete genome sequence of Arthrobacter phenanthrenivorans type strain (Sphe3).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21677849",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Complete genome sequence and metabolic potential of the quinaldine-degrading bacterium Arthrobacter sp. Rue61a.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23039946",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 387,
                    "text": "Here, we described the high quality draft genome sequence, annotations and the features ofArthrobactersp. B6.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28138355",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Complete genome sequence of Arthrobacter sp. ZXY-2 associated with effective atrazine degradation and salt adaptation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28315371",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "We announce here the draft genome sequence ofArthrobactersp. strain EpSL27, isolated from the stem and leaves of the medicinal plantEchinacea purpureaand able to inhibit human-pathogenic bacterial strains. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28642378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "We report here the 4.6-Mb genome sequence of a nylon oligomer-degrading bacterium,Arthrobactersp. strain KI72.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450506",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 287,
                    "text": "Arthrobacter alpinusR3.8 is a psychrotolerant bacterial strain isolated from a soil sample obtained at Rothera Point, Adelaide Island, close to the Antarctic Peninsula. Strain R3.8 was sequenced in order to help discover potential cold active enzymes with biotechnological applications. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28904741",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is nucleosome eviction ATP-dependent?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
                "http://www.ncbi.nlm.nih.gov/pubmed/20513433",
                "http://www.ncbi.nlm.nih.gov/pubmed/17235287",
                "http://www.ncbi.nlm.nih.gov/pubmed/22177115",
                "http://www.ncbi.nlm.nih.gov/pubmed/19470761",
                "http://www.ncbi.nlm.nih.gov/pubmed/19029894",
                "http://www.ncbi.nlm.nih.gov/pubmed/23460895",
                "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
                "http://www.ncbi.nlm.nih.gov/pubmed/24008565"
            ],
            "ideal_answer": [
                "Yes, nucleosome eviction and chromatin remodelling depends on ATP"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000786",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006337",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009707",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000255"
            ],
            "type": "yesno",
            "id": "532ff558d6d3ac6a34000037",
            "snippets": [
                {
                    "offsetInBeginSection": 33,
                    "offsetInEndSection": 166,
                    "text": "ATP-dependent chromatin remodeling and nucleosome-depleted 'barriers' co-operate to determine the kinetics of nucleosome organization",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068556",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 275,
                    "text": "ATP-dependent nucleosome-remodeling factors endow chromatin with structural flexibility by promoting assembly or disruption of nucleosomes and the exchange of histone variants.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24008565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 948,
                    "offsetInEndSection": 1164,
                    "text": "remodeling takes place in an ATP-independent manner. Binding of distamycin to the linker and nucleosomal DNA culminates in eviction of the linker histone and the formation of a population of off-centered nucleosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23460895",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 735,
                    "text": "which promotes histone deposition onto DNA, and a novel activity, which prevents nucleosome eviction but not remodeling mediated by the ATP-dependent RSC complex",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22177115",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 134,
                    "text": "ATP-dependent chromatin remodeling complex SWI/SNF regulates transcription and has been implicated in promoter nucleosome eviction",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20513433",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 122,
                    "text": "ATP-dependent nucleosome-remodeling enzyme involved in transcription, replication, and the DNA damage response",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1361,
                    "offsetInEndSection": 1430,
                    "text": "Iec1-Ino80 complex promotes transcription through nucleosome eviction",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 323,
                    "text": "Ino80 complex from fission yeast mediates ATP-dependent nucleosome remodeling in vitro",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19933844",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 969,
                    "offsetInEndSection": 1153,
                    "text": "reconstitution of nucleosome disassembly using the ATP-dependent chromatin remodeler Rsc and Vps75 revealed that these proteins can cooperate to remove H2A/H2B dimers from nucleosomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19470761",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 106,
                    "text": "TP-dependent chromatin-remodeling complexes, such as RSC, can reposition, evict or restructure nucleosome",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19029894",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 87,
                    "text": "TP-dependent chromatin remodeling complexes play a critical role in chromatin dynamics",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17235287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 418,
                    "text": " activity of SWI/SNF to histone eviction in trans from gene promoters.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17235287",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is SATB1 necessary for T-cell maturation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17652321",
                "http://www.ncbi.nlm.nih.gov/pubmed/16371359",
                "http://www.ncbi.nlm.nih.gov/pubmed/15618465"
            ],
            "ideal_answer": [
                "Special AT-rich sequence binding protein 1 (SATB1) regulates gene expression essential in immune T-cell maturation and switching of fetal globin species, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin remodeling.",
                "Yes. SATB1 is an essential factor for the regulation of T-cell maturation.",
                "Special AT-rich binding protein 1 (SATB1) nuclear protein, expressed predominantly in T cells, regulates genes through targeting chromatin remodeling during T-cell maturation. SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell.",
                "Special AT-rich binding protein 1 (SATB1) nuclear protein, expressed predominantly in T cells, regulates genes through targeting chromatin remodeling during T-cell maturation. the transcription factor SATB1 that regulates the T-cell maturation SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell.",
                "Yes, SATB1 is necessary for T-cell maturation.",
                "Yes. SATB1 is an essential regulator of T-cell maturation.",
                "Yes, SATB1 is required for T-cell maturation.",
                "SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell. Special AT-rich sequence binding protein 1 (SATB1) regulates gene expression essential in immune T-cell maturation and switching of fetal globin species, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin remodeling.",
                "Yes. SATB1 is associated with the late-M-to-early-G1 phase of T-cell maturation and its activation correlates with histone H3 hyperacetylation, DNA methylation, and chromatin reorganization at the transcriptional level, while it is involved in the early stages of T cell differentiation into the erythroid lineage.",
                "yes, SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell. ",
                "Special AT-rich binding protein 1 (SATB1) nuclear protein, expressed predominantly in T cells, regulates genes through targeting chromatin remodeling during T-cell maturation.",
                "Special AT-rich binding protein 1 (SATB1) nuclear protein, expressed predominantly in T cells, regulates genes through targeting chromatin remodeling during T-cell maturation. the transcription factor SATB1 that regulates the T-cell maturation",
                "the transcription factor SATB1 that regulates the T-cell maturation. SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell.",
                "Special AT-rich binding protein 1 (SATB1) nuclear protein, expressed predominantly in T cells, regulates genes through targeting chromatin remodeling during T-cell maturation. Special AT-rich sequence binding protein 1 (SATB1) regulates gene expression essential in immune T-cell maturation and switching of fetal globin species, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin remodeling.",
                "the transcription factor SATB1 that regulates the T-cell maturation Special AT-rich sequence binding protein 1 (SATB1) regulates gene expression essential in immune T-cell maturation and switching of fetal globin species, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin remodeling."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d36b4817bc3fee31f000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Special AT-rich binding protein 1 (SATB1) nuclear protein, expressed predominantly in T cells, regulates genes through targeting chromatin remodeling during T-cell maturation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15618465",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 157,
                    "text": "the transcription factor SATB1 that regulates the T-cell maturation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16371359",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16371359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "text": "Special AT-rich sequence binding protein 1 (SATB1) regulates gene expression essential in immune T-cell maturation and switching of fetal globin species, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin remodeling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652321",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29398602",
                "http://www.ncbi.nlm.nih.gov/pubmed/30217516"
            ],
            "ideal_answer": [
                "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium and causes anaplasmosis",
                "The genus Anaplasma belonging to the Anaplasmataceae family (order Rickettsiales) comprises obligate intracellular Gram-negative bacteria of veterinary and public health importance. nov."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c98ac7fecadf2e73f00002b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 441,
                    "text": "The genus Anaplasma belonging to the Anaplasmataceae family (order Rickettsiales) comprises obligate intracellular Gram-negative bacteria of veterinary and public health importance. Six species and five types of strains genetically related are currently assigned to the genus Anaplasma including Anaplasma marginale, A. centrale, A. bovis, A. phagocytophilum, A. ovis and A. platys as classified species, and \"A. capra\", A. odocolei sp. nov.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29398602",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Human granulocytic anaplasmosis (HGA), an increasingly recognized febrile tick-borne illness, is caused by a gram-negative obligate intracellular bacterium Anaplasma phagocytophilum",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30217516",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can the iPS cell technology be used in Fanconi anemia therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20224565",
                "http://www.ncbi.nlm.nih.gov/pubmed/19483674"
            ],
            "ideal_answer": [
                "iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications in Fanconi anemia."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057026",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064987",
                "http://www.disease-ontology.org/api/metadata/DOID:13636"
            ],
            "type": "yesno",
            "id": "54edef0594afd6150400000d",
            "snippets": [
                {
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 507,
                    "text": "We explain a protocol for the reproducible generation of genetically corrected iPSCs starting from the skin biopsies of Fanconi anemia patients using retroviral transduction with OCT4, SOX2 and KLF4",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20224565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 645,
                    "text": "Before reprogramming, the fibroblasts and/or keratinocytes of the patients are genetically corrected with lentiviruses expressing FANCA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20224565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 610,
                    "text": "Here we show that, on correction of the genetic defect, somatic cells from Fanconi anaemia patients can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 823,
                    "text": "Most importantly, we show that corrected Fanconi-anaemia-specific iPS cells can give rise to haematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, that is, disease-free",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is cardiac magnetic resonance imaging indicated in the pre-participation screening of athletes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22375189",
                "http://www.ncbi.nlm.nih.gov/pubmed/21567995",
                "http://www.ncbi.nlm.nih.gov/pubmed/22375228",
                "http://www.ncbi.nlm.nih.gov/pubmed/22653640",
                "http://www.ncbi.nlm.nih.gov/pubmed/19734502",
                "http://www.ncbi.nlm.nih.gov/pubmed/20599016",
                "http://www.ncbi.nlm.nih.gov/pubmed/16831826",
                "http://www.ncbi.nlm.nih.gov/pubmed/20048491",
                "http://www.ncbi.nlm.nih.gov/pubmed/10663764",
                "http://www.ncbi.nlm.nih.gov/pubmed/19055989",
                "http://www.ncbi.nlm.nih.gov/pubmed/24029371",
                "http://www.ncbi.nlm.nih.gov/pubmed/21118665",
                "http://www.ncbi.nlm.nih.gov/pubmed/20705486",
                "http://www.ncbi.nlm.nih.gov/pubmed/15689345",
                "http://www.ncbi.nlm.nih.gov/pubmed/21791458",
                "http://www.ncbi.nlm.nih.gov/pubmed/22983606",
                "http://www.ncbi.nlm.nih.gov/pubmed/22853772",
                "http://www.ncbi.nlm.nih.gov/pubmed/16004915",
                "http://www.ncbi.nlm.nih.gov/pubmed/15166900",
                "http://www.ncbi.nlm.nih.gov/pubmed/12446071",
                "http://www.ncbi.nlm.nih.gov/pubmed/18325444",
                "http://www.ncbi.nlm.nih.gov/pubmed/23897528",
                "http://www.ncbi.nlm.nih.gov/pubmed/21278396",
                "http://www.ncbi.nlm.nih.gov/pubmed/20833588",
                "http://www.ncbi.nlm.nih.gov/pubmed/16914373",
                "http://www.ncbi.nlm.nih.gov/pubmed/18208827",
                "http://www.ncbi.nlm.nih.gov/pubmed/21782775",
                "http://www.ncbi.nlm.nih.gov/pubmed/23097483",
                "http://www.ncbi.nlm.nih.gov/pubmed/21486912",
                "http://www.ncbi.nlm.nih.gov/pubmed/22457200"
            ],
            "ideal_answer": [
                "Currently cardiac magnetic resonance imaging is not indicated in the pre-participation screening of athletes. However the potential of this imaging technique to provide new information on cardiac function morphology and myocardial composition, in particular with regard to myocardial fibrosis, gets it potentially suitable to be applied in the pre-participation screening of athletes"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019028",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054874",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008279",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013177",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056352"
            ],
            "type": "yesno",
            "id": "531d3dc0267d7dd053000005",
            "snippets": [
                {
                    "offsetInBeginSection": 1858,
                    "offsetInEndSection": 2112,
                    "text": "As modern imaging further enhances our understanding of the spectrum of athlete's heart, its role may expand from the assessment of athletes with suspected disease to being part of comprehensive pre-participation screening in apparently healthy athletes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 801,
                    "offsetInEndSection": 872,
                    "text": "Finally we will address the role of CMR in pre-participation screening.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23097483",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "The TRPM2 gene is associated with development of spontaneous thromboembolism?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28199210",
                "http://www.ncbi.nlm.nih.gov/pubmed/15708008",
                "http://www.ncbi.nlm.nih.gov/pubmed/18957938",
                "http://www.ncbi.nlm.nih.gov/pubmed/22487454",
                "http://www.ncbi.nlm.nih.gov/pubmed/27616276",
                "http://www.ncbi.nlm.nih.gov/pubmed/12765697",
                "http://www.ncbi.nlm.nih.gov/pubmed/26558786",
                "http://www.ncbi.nlm.nih.gov/pubmed/25236871",
                "http://www.ncbi.nlm.nih.gov/pubmed/28082421",
                "http://www.ncbi.nlm.nih.gov/pubmed/28970008",
                "http://www.ncbi.nlm.nih.gov/pubmed/16252251",
                "http://www.ncbi.nlm.nih.gov/pubmed/21140288",
                "http://www.ncbi.nlm.nih.gov/pubmed/23129587",
                "http://www.ncbi.nlm.nih.gov/pubmed/22475739",
                "http://www.ncbi.nlm.nih.gov/pubmed/20515676",
                "http://www.ncbi.nlm.nih.gov/pubmed/23371039"
            ],
            "ideal_answer": [
                "TheTransientReceptorPotentialMelastatin 2 (TRPM2) is a member of G protein coupled receptor superfamily and a novel dual-function protein that possesses both ion channel andAdenosine 5'-DiphosPhataseRibose (ADPR) hydrolase function. TRPM2 is involved in Ca2+signaling in various cells as an endogenous redox sensor for oxidative stress and reactive oxygen species, and contributes to cytokine production, insulin release, motility, Ca2+entry and Ca2+-dependent cellular reactions such as endothelial hyper-permeability and apoptosis and may regulate the bacteriocidal activity of Macrophages"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5ab144fefcf4565872000012",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 533,
                    "text": "TheTransientReceptorPotentialMelastatin 2 (TRPM2) is a member of G protein coupled receptor superfamily and a novel dual-function protein that possesses both ion channel andAdenosine 5'-DiphosPhataseRibose (ADPR) hydrolase function. TRPM2 is involved in Ca2+signaling in various cells as an endogenous redox sensor for oxidative stress and reactive oxygen species, and contributes to cytokine production, insulin release, motility, Ca2+entry and Ca2+-dependent cellular reactions such as endothelial hyper-permeability and apoptosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28199210",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 313,
                    "text": "We show here that the redox-sensitive transient receptor potential (TRP) cation channel TRPM2 is expressed in the phagosomal membrane and regulates macrophage bactericidal activity through the activation of phagosomal acidification",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28082421",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 400,
                    "text": "The transient receptor potential melastatin-2 (TRPM2) is an oxidative stress sensing channel that is expressed in a number of inflammatory cells and therefore it has been suggested that inhibition of TRPM2 could lead to a beneficial effect in COPD patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22475739",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 246,
                    "text": "TRPM2 is a recently identified TRPM family cation channel which is unique among known ion channels in that it contains a C-terminal domain which is homologous to the NUDT9 ADP-ribose hydrolase and possesses intrinsic ADP-ribose hydrolase activity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12765697",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1419,
                    "offsetInEndSection": 1859,
                    "text": "These results suggest that TRPM2 may participate in antigen-induced extracellular Ca(2+) influx and subsequent degranulation. In addition, TRPM2 inhibitors were shown to improve food allergic reactions in a mouse model. Together, these results suggest that TRPM2 inhibitors suppress MMC degranulation via regulation of the increase in [Ca(2+)]cyt. Thus, TRPM2 may play a key role in degranulation by modulating intracellular Ca(2+) in MMCs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371039",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 287,
                    "text": "he Na+ and Ca(2+)-permeable melastatin related transient receptor potential 2 (TRPM2) channels can be gated either by ADP-ribose (ADPR) in concert with Ca(2+) or by hydrogen peroxide (H(2)O(2)), an experimental model for oxidative stress, binding to the channel's enzymatic Nudix domain",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21140288",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 242,
                    "offsetInEndSection": 471,
                    "text": "hese alterations of the extracellular milieu change the activity of transient receptor potential melastatin subfamily member 2 (TRPM2), a nonselective cation channel expressed in the central nervous system and the immune system. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25236871",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 730,
                    "offsetInEndSection": 868,
                    "text": "TRPM2 (Transient Receptor Potential Melastatin 2) is a Ca2+-permeable ion channel that is activated under conditions of oxidative stress. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28970008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 325,
                    "text": "Transient receptor potential melastatin 2 (TRPM2) is a thermosensitive, Ca2+-permeable cation channel. TRPM2 contributes to the pathogenesis of inflammatory bowel disease, and inflammatory and neuropathic pain. We hypothesized that TRPM2 is important for visceral nociception and the development of visceral hypersensitivity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27616276",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 507,
                    "text": "Here, we describe the computational identification of a melanoma-enriched antisense transcript, TRPM2-AS, mapped within the locus of TRPM2, an ion channel capable of mediating susceptibility to cell death",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18957938",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 576,
                    "text": "The transient receptor potential melastatin 2 (TRPM2) channel, a Ca(2+)-permeable nonselective cation channel activated by oxidative stress, has been implicated in neurodegenerative diseases, and more recently in amyloid-induced toxicity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26558786",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Transient receptor potential melastatin 2 (TRPM2) is a calcium-permeable cation channel activated by ADP-ribose or reactive oxygen species.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15708008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 627,
                    "text": " Transient receptor potential melastatin type 2 (TRPM2) is a Ca2+ permeable non-selective cation channel expressed in several cell types including hippocampal pyramidal neurons. Moreover, activation of TRPM2 during oxidative stress has been linked to cell death. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22487454",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) been reported to be a plasminogen receptor in pathogenic bacteria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28011643",
                "http://www.ncbi.nlm.nih.gov/pubmed/15039372",
                "http://www.ncbi.nlm.nih.gov/pubmed/17449317",
                "http://www.ncbi.nlm.nih.gov/pubmed/25666684"
            ],
            "ideal_answer": [
                "Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) has been reported to be a plasminogen receptor in many pathogenic bacteria."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c57031107647bbc4b000014",
            "snippets": [
                {
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 508,
                    "text": " binding of plasminogen (Plg) to bacterial surfaces, as it has been shown that this interaction contributes to bacterial adhesion to host cells, invasion of host tissues, and evasion of the immune system. Several bacterial proteins are known to serve as receptors for Plg including glyceraldehyde-3-phosphate dehydrogenase (GAPDH),",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28011643",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 556,
                    "text": "Moreover, several isoforms of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and galectin (GAL) were identified in both antigenic extracts as plasminogen-binding proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666684",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1230,
                    "offsetInEndSection": 1339,
                    "text": "Purified GAPDH was found to bind human plasminogen and fibrinogen in Far-Western blot and ELISA-based assays.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17449317",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 446,
                    "text": "GAPDH exhibits a high affinity for plasmin and a significantly lower affinity for plasminogen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15039372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 715,
                    "text": "Moreover, several isoforms of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and galectin (GAL) were identified in both antigenic extracts as plasminogen-binding proteins. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25666684",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the gene CDKN2A nevogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15304099",
                "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                "http://www.ncbi.nlm.nih.gov/pubmed/475444",
                "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                "http://www.ncbi.nlm.nih.gov/pubmed/10620111"
            ],
            "ideal_answer": [
                "Yes, CDKN2A is nevogenic"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a9d79ca1d1251d03b00001d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Phenotypic characteristics of members of a melanoma prone kindred with a V126D CDKN2A gene mutation were monitored over approximately 15 y.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15304099",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 559,
                    "text": " Rare germline mutations in CDKN2A predispose to melanoma and appear to be nevogenic, although the correlation between nevus phenotype and mutation status is poor. It is plausible that more common CDKN2A variants may influence both melanoma susceptibility and nevus susceptibility. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 651,
                    "text": "supporting the view that CDKN2A is nevogenic.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the interaction of MOV10 and RNASEH2 promote L1 retrotransposition?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29315404"
            ],
            "ideal_answer": [
                "MOV10 interacts with RNASEH2, and their interplay is crucial for restricting L1 retrotransposition."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c93e6a1ecadf2e73f00001b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Interplay between RNASEH2 and MOV10 controls LINE-1 retrotransposition.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29315404",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 774,
                    "text": "We show that MOV10 interacts with RNASEH2, and their interplay is crucial for restricting L1 retrotransposition. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29315404",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1104,
                    "offsetInEndSection": 1423,
                    "text": "Furthermore, we show that RNASEH2-MOV10-mediated L1 restriction downregulates expression of the rheumatoid arthritis-associated inflammatory cytokines and matrix-degrading proteinases in synovial cells, implicating a potential causal relationship between them and disease development in terms of disease predisposition.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29315404",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is pembrolizumab effective against Ewing's sarcoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28988646"
            ],
            "ideal_answer": [
                "None of the 13 patients with Ewing's sarcoma receiving pembrolizumab had an objective response."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5be49287133db5eb7800001e",
            "snippets": [
                {
                    "offsetInBeginSection": 2286,
                    "offsetInEndSection": 2358,
                    "text": "None of the 13 patients with Ewing's sarcoma had an objective response. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988646",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1540,
                    "offsetInEndSection": 1741,
                    "text": "Between March 13, 2015, and Feb 18, 2016, we enrolled 86 patients, 84 of whom received pembrolizumab (42 in each disease cohort) and 80 of whom were evaluable for response (40 in each disease cohort). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988646",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can life style changes reduce oxidative stress",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21150342",
                "http://www.ncbi.nlm.nih.gov/pubmed/23185200",
                "http://www.ncbi.nlm.nih.gov/pubmed/19031760",
                "http://www.ncbi.nlm.nih.gov/pubmed/23105513"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18450882",
                    "o": "D008019"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18450882",
                    "o": "Life Style Induced Illness"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2936742",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18450882"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18450882",
                    "o": "MeSH"
                }
            ],
            "ideal_answer": [
                "Our results suggested that life style changes which related to migration might reduce DNA damage in Hasake nationalities."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008019",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018384"
            ],
            "type": "yesno",
            "id": "52f88a972059c6d71c000033",
            "snippets": [
                {
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1435,
                    "text": "The CFS group had an unfavorable lipid profile and signs of oxidative stress induced damage to lipids and proteins. These results might be indicative of early proatherogenic processes in this group of patients who are otherwise at low risk for atherosclerosis. Antioxidant treatment and life style changes are indicated for women with CFS, as well as closer observation in order to assess the degree of atherosclerosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23185200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1792,
                    "offsetInEndSection": 1981,
                    "text": "Once detected, these patients may be offered more aggressive treatment strategies such as early pharmacotherapy in addition to life style changes targeted to maintaining pericyte integrity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21150342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 976,
                    "text": "Our results suggested that life style changes which related to migration might reduce DNA damage in Hasake nationalities.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19031760",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 943,
                    "offsetInEndSection": 1268,
                    "text": "Low levels of antioxidants and increased oxidative stress with insulin resistance in metabolic syndrome suggests that besides therapeutic life style changes (TLC) as suggested in ATP III guidelines inclusion of antioxidant vitamins, fruits and vegetable could be beneficial to ward off the consequences of metabolic syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23105513",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Pim-1 a protein phosphatase?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29399171",
                "http://www.ncbi.nlm.nih.gov/pubmed/29355758"
            ],
            "ideal_answer": [
                "No,\nPim-1 is a kinase and not a phosphatase."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5cb37f76ecadf2e73f00005c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "Pim-1 proto-oncogene, serine/threonine kinase (PIM-1) phosphorylates a series of substrates to exert its oncogenic function in numerous malignancies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29399171",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "text": "The Pim1 serine/threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29355758",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has the gorilla genome been determined?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11592477",
                "http://www.ncbi.nlm.nih.gov/pubmed/27034376",
                "http://www.ncbi.nlm.nih.gov/pubmed/22398555",
                "http://www.ncbi.nlm.nih.gov/pubmed/27435933"
            ],
            "ideal_answer": [
                "Yes, the gorilla genome has been sequenced."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "58dfec676fddd3e83e000006",
            "snippets": [
                {
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 638,
                    "text": "Starting with human, chimpanzee, gorilla, and orangutan genomes, our software generated an exhaustive data set of 292 ALs (\u223c1 kb each) in \u223c3 h. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27435933",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 101,
                    "offsetInEndSection": 258,
                    "text": "We generated a high-quality assembly of the gorilla genome using single-molecule, real-time sequence technology and a string graph de novo assembly algorithm",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 301,
                    "text": "Here we present the assembly and analysis of a genome sequence for the western lowland gorilla, and compare the whole genomes of all extant great ape genera.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22398555",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "DNA sequencing reveals that the genomes of the human, gorilla and chimpanzee share more than 98% homology.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592477",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is hypersensitivity to DNA crosslinking agents a hallmark of Fanconi anemia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16904272",
                "http://www.ncbi.nlm.nih.gov/pubmed/8058745",
                "http://www.ncbi.nlm.nih.gov/pubmed/19275569",
                "http://www.ncbi.nlm.nih.gov/pubmed/15277238",
                "http://www.ncbi.nlm.nih.gov/pubmed/18047734",
                "http://www.ncbi.nlm.nih.gov/pubmed/22690333",
                "http://www.ncbi.nlm.nih.gov/pubmed/10526221",
                "http://www.ncbi.nlm.nih.gov/pubmed/19101576",
                "http://www.ncbi.nlm.nih.gov/pubmed/21240275",
                "http://www.ncbi.nlm.nih.gov/pubmed/22053284",
                "http://www.ncbi.nlm.nih.gov/pubmed/21478198",
                "http://www.ncbi.nlm.nih.gov/pubmed/22532920",
                "http://www.ncbi.nlm.nih.gov/pubmed/21568838",
                "http://www.ncbi.nlm.nih.gov/pubmed/20034732",
                "http://www.ncbi.nlm.nih.gov/pubmed/21109493",
                "http://www.ncbi.nlm.nih.gov/pubmed/25002988",
                "http://www.ncbi.nlm.nih.gov/pubmed/17396147",
                "http://www.ncbi.nlm.nih.gov/pubmed/19748364",
                "http://www.ncbi.nlm.nih.gov/pubmed/16493006",
                "http://www.ncbi.nlm.nih.gov/pubmed/23444773",
                "http://www.ncbi.nlm.nih.gov/pubmed/1809228",
                "http://www.ncbi.nlm.nih.gov/pubmed/19738377",
                "http://www.ncbi.nlm.nih.gov/pubmed/23318445",
                "http://www.ncbi.nlm.nih.gov/pubmed/20120016",
                "http://www.ncbi.nlm.nih.gov/pubmed/11751423",
                "http://www.ncbi.nlm.nih.gov/pubmed/21939290"
            ],
            "ideal_answer": [
                "Yes, hypersensitivity to DNA crosslinking agents is one of the hallmarks of Fanconi anemia, the others being defective FANCD2 monoubiquitination, and genomic instability."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199",
                "http://www.disease-ontology.org/api/metadata/DOID:1062",
                "http://www.disease-ontology.org/api/metadata/DOID:13636"
            ],
            "type": "yesno",
            "id": "54ecb66d445c3b5a5f000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "The Fanconi anemia (FA) core complex plays a central role in the DNA damage response network",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17396147",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 958,
                    "text": "FAAP100-deficient cells display hallmark features of FA cells, including defective FANCD2 monoubiquitination, hypersensitivity to DNA crosslinking agents, and genomic instability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17396147",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Fanconi anemia (FA) is a rare genetic disorder characterized by aplastic anemia, cancer/leukemia susceptibility and cellular hypersensitivity to DNA crosslinking agents, such as cisplatin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18047734",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "text": "Fanconi anemia (FA) is an inherited chromosomal recessive syndrome characterized by cellular hypersensitivity to DNA crosslinking agents and bone marrow failure, which cause aplastic anemia, and an increased incidence of malignancy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275569",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Features of chromosomal aberrations, hypersensitivity to DNA crosslinking agents, and predisposition to malignancy have suggested a fundamental anomaly of DNA repair in Fanconi anemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8058745",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "text": "Fanconi anemia (FA) is one of several genetic diseases with characteristic cellular hypersensitivity to DNA crosslinking agents which suggest that FA proteins may function as part of DNA repair processes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10526221",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "text": "Fanconi anemia (FA) is characterized by cellular hypersensitivity to DNA crosslinking agents, but how the Fanconi pathway protects cells from DNA crosslinks and whether FA proteins act directly on crosslinks remain unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19748364",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Fanconi Anemia (FA) is a rare genetic disorder associated with a bone-marrow failure, cancer predisposition and hypersensitivity to DNA crosslinking agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23318445",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Fanconi anemia (FA) is a heterogeneous disease associated with a bone marrow failure, cancer predisposition and hypersensitivity to DNA crosslinking agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25002988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Fanconi anemia (FA) is an inherited disorder characterized by defective DNA repair and cellular sensitivity to DNA crosslinking agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21939290",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "Fanconi anemia (FA) is an inherited disease characterized by bone marrow failure, increased cancer risk and hypersensitivity to DNA cross-linking agents, implying a role for this pathway in the maintenance of genomic stability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109493",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 267,
                    "text": "Genetic or epigenetic inactivation of the pathway formed by the Fanconi Anemia (FA) proteins occurs in several cancer types, including head and neck squamous cell carcinomas (HNSCC), rendering the affected tumors potentially hypersensitive to DNA crosslinking agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20034732",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "text": "Fanconi Anemia (FA) is a rare autosomic recessive and X-linked disease with chromosomal instability after exposure to crosslinking agents as the hallmark.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22053284",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "Fanconi Anemia (FA) is an autosomal recessive disease characterized by chromosome instability, cellular hypersensitivity to DNA cross-linking agents, and increased predisposition to malignancies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22532920",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "text": "The Bloom protein (BLM) and Topoisomerase IIIalpha are found in association with proteins of the Fanconi anemia (FA) pathway, a disorder manifesting increased cellular sensitivity to DNA crosslinking agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19738377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 714,
                    "offsetInEndSection": 958,
                    "text": "Using siRNA depletion and gene knockout techniques, we show that FAAP100-deficient cells display hallmark features of FA cells, including defective FANCD2 monoubiquitination, hypersensitivity to DNA crosslinking agents, and genomic instability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17396147",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "Fanconi anemia (FA) is a recessive human cancer prone syndrome featuring bone marrow failure, developmental abnormalities and hypersensitivity to DNA crosslinking agents exposure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16904272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 381,
                    "text": "FA is a chromosome instability syndrome characterized by childhood-onset aplastic anemia, cancer or leukemia susceptibility, and cellular hypersensitivity to DNA crosslinking agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16493006",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 336,
                    "text": "Functional defects in the Fanconi pathway can result in a marked hypersensitivity to interstrand crosslinking agents, such as mitomycin C.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15277238",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 204,
                    "offsetInEndSection": 316,
                    "text": "At the cellular level, hypersensitivity to DNA interstrand crosslinks is the defining feature in Fanconi anemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21240275",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 644,
                    "text": "DNA crosslinking agents may led to DNA cross-linking lesion, and Fanconi anemia pathway plays a key role in repairing its cross-linking.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23444773",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 346,
                    "text": "Fanconi anemia (FA), an autosomal recessive disorder of children, is characterized by congenital or childhood aplastic anemia, multiple developmental anomalies, increased incidence of myeloid leukemia, increased spontaneous chromosome breakage, and cellular and chromosomal hypersensitivity to DNA bifunctional crosslinking and alkylating agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1809228",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3,
                    "offsetInEndSection": 167,
                    "text": "elegans provides an excellent model system for the study of the Fanconi Anemia (FA), one of the hallmarks of which is sensitivity to interstrand crosslinking agents",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22690333",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 714,
                    "offsetInEndSection": 957,
                    "text": "Using siRNA depletion and gene knockout techniques, we show that FAAP100-deficient cells display hallmark features of FA cells, including defective FANCD2 monoubiquitination, hypersensitivity to DNA crosslinking agents, and genomic instability",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17396147",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 316,
                    "text": "One of the hallmark phenotypes of FA is cellular hypersensitivity to agents that induce DNA interstrand crosslinks (ICLs), such as mitomycin C (MMC)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21478198",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 788,
                    "offsetInEndSection": 983,
                    "text": "Furthermore, the cytological hallmark of FA, the DNA crosslink-induced radial chromosome formation, exemplifies an innate impairment in the repair of these particularly cytotoxic DNA lesions [A.D",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101576",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "text": "Fanconi anemia (FA) is characterized by cellular hypersensitivity to DNA crosslinking agents, but how the Fanconi pathway protects cells from DNA crosslinks and whether FA proteins act directly on crosslinks remain unclear",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19748364",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Features of chromosomal aberrations, hypersensitivity to DNA crosslinking agents, and predisposition to malignancy have suggested a fundamental anomaly of DNA repair in Fanconi anemia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8058745",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 231,
                    "text": "Fanconi anemia (FA) is an inherited chromosomal recessive syndrome characterized by cellular hypersensitivity to DNA crosslinking agents and bone marrow failure, which cause aplastic anemia, and an increased incidence of malignancy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19275569",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 266,
                    "text": "Genetic or epigenetic inactivation of the pathway formed by the Fanconi Anemia (FA) proteins occurs in several cancer types, including head and neck squamous cell carcinomas (HNSCC), rendering the affected tumors potentially hypersensitive to DNA crosslinking agents",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20034732",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Fanconi anemia (FA) is a human autosomal disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinking agents such as mitomycin C and diepoxybutane",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11751423",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 101,
                    "text": "The Fanconi anemia pathway promotes DNA glycosylase-dependent excision of interstrand DNA crosslinks.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20120016",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 643,
                    "text": "DNA crosslinking agents may led to DNA cross-linking lesion, and Fanconi anemia pathway plays a key role in repairing its cross-linking",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23444773",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 380,
                    "text": "FA is a chromosome instability syndrome characterized by childhood-onset aplastic anemia, cancer or leukemia susceptibility, and cellular hypersensitivity to DNA crosslinking agents",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16493006",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 331,
                    "text": "The disease is manifested by defects in DNA repair, hypersensitivity to DNA crosslinking agents, and a high degree of chromosomal aberrations",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21568838",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is hydroxyurea usually used to treated infectious disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21196716",
                "http://www.ncbi.nlm.nih.gov/pubmed/26275071",
                "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
                "http://www.ncbi.nlm.nih.gov/pubmed/15307105",
                "http://www.ncbi.nlm.nih.gov/pubmed/20008183"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0020402",
                    "o": "hydroxyurea"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0020402",
                    "o": "http://linkedlifedata.com/resource/umls/label/A0481276"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0481276",
                    "o": "hydroxyurea"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0020402",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7996376"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7996376",
                    "o": "hydroxyurea"
                }
            ],
            "ideal_answer": [
                "Hydroxyurea represents the only available disease-modifying therapy for Sickle Cell Anemia (SCA)."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:10923",
                "http://www.biosemantics.org/jochem#4275774",
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4275774",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006450",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000755",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006918"
            ],
            "type": "yesno",
            "id": "58dbbdac8acda3452900001e",
            "snippets": [
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 294,
                    "text": "Hydroxyurea represents the only available disease-modifying therapy for SCA, and has proven safety and efficacy in high-resource countries",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1579,
                    "offsetInEndSection": 1777,
                    "text": "In conclusion, the data here presented suggests that hydroxyurea may prevent priapism attacks in sickle cell disease, probably at higher doses than usually prescribed for painful crisis prevention..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21196716",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 546,
                    "text": "t may also attenuate optimal response to hydroxyurea therapy, the only effective and practical treatment option for SCD in sub-Saharan Africa",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677923",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Hydroxyurea is one of the most successfully used therapies for sickle cell disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15307105",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 252,
                    "text": "Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20008183",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Apremilast effective for Behcet\u2019s syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24882690",
                "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                "http://www.ncbi.nlm.nih.gov/pubmed/26487500",
                "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
                "http://www.ncbi.nlm.nih.gov/pubmed/27163156",
                "http://www.ncbi.nlm.nih.gov/pubmed/25875256"
            ],
            "ideal_answer": [
                "Yes. Apremilast was proven to be effective for treatment of Behcet\u2019s syndrome."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D016896",
                "http://www.disease-ontology.org/api/metadata/DOID:13241",
                "https://meshb.nlm.nih.gov/record/ui?ui=D001528"
            ],
            "type": "yesno",
            "id": "5a7340962dc08e987e000017",
            "snippets": [
                {
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 843,
                    "text": "Apremilast is an immunomodulatory agent that works through phosphodiesterase 4 inhibition. A randomized controlled trial has shown that it is effective for the management of oral and genital ulcers and is generally well tolerated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 386,
                    "offsetInEndSection": 686,
                    "text": "AREAS COVERED: This review provides a digest of all current experience and evidence about pharmacological agents recently described as having a role in the treatment of BS, including interleukin (IL)-1 inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon-alpha-2a, and apremilast.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27163156",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1719,
                    "offsetInEndSection": 1840,
                    "text": "CONCLUSIONS: Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1823,
                    "offsetInEndSection": 1940,
                    "text": " Apremilast, an inhibitor of phosphodiesterase-4, was effective in a phase 2, double blind, placebo-controlled study.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26487500",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1677,
                    "offsetInEndSection": 1880,
                    "text": "There were two serious adverse events in patients receiving apremilast.<br><b>CONCLUSIONS</b>: Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 300,
                    "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1732,
                    "offsetInEndSection": 1853,
                    "text": "CONCLUSIONS Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Beh\u00e7et's syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882690",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1998,
                    "text": "oral ulcers the hallmark of beh\u00e7et s syndrome can be resistant to conventional treatment therefore alternative agents are needed apremilast is an oral phosphodiesterase 4 inhibitor that modulates several inflammatory pathways we conducted a phase 2 multicenter placebo controlled study in which 111 patients with beh\u00e7et s syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks this regimen was followed by a 12 week extension phase in which the placebo group was switched to apremilast and a 28 day post treatment observational follow up phase the patients and clinicians were unaware of the study assignments throughout the trial the primary end point was the number of oral ulcers at week 12 secondary outcomes included pain from these ulcers measured on a 100 mm visual analogue scale with higher scores indicating worse pain the number of genital ulcers overall disease activity and quality of life the mean sd number of oral ulcers per patient at week 12 was significantly lower in the apremilast group than in the placebo group 0 5 1 0 vs 2 1 2 6 p 0 001 the mean decline in pain from oral ulcers from baseline to week 12 was greater with apremilast than with placebo 44 7 24 3 mm vs 16 0 32 5 mm p 0 001 nausea vomiting and diarrhea were more common in the apremilast group with 22 9 and 12 incidents respectively among 55 patients than in the placebo group with 10 1 and 2 incidents respectively among 56 patients findings that were similar to those in previous studies of apremilast there were two serious adverse events in patients receiving apremilast apremilast was effective in treating oral ulcers which are the cardinal manifestation of beh\u00e7et s syndrome this preliminary study was neither large enough nor long enough to assess long term efficacy the effect on other manifestations of beh\u00e7et s syndrome or the risk of uncommon serious adverse events funded by celgene clinicaltrials gov number nct00866359.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1057,
                    "text": "current trends in the management of beh\u00e7et s syndrome will be reviewed in this article biologic agents have gained increasing importance over the years in the management of beh\u00e7et s syndrome long term results of observational studies have shown that anti tumor necrosis factor agents may be effective in beh\u00e7et s syndrome patients with refractory eye involvement case series reporting about use of anti tumor necrosis factor agents in vascular and gastrointestinal involvement have also shown good results caution is required for infectious complications with these agents apremilast is an immunomodulatory agent that works through phosphodiesterase 4 inhibition a randomized controlled trial has shown that it is effective for the management of oral and genital ulcers and is generally well tolerated the outcome of beh\u00e7et s syndrome with major organ involvement has improved with more effective management strategies especially with the use of biologic agents in severe cases controlled trials are needed to guide physicians in making treatment decisions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is celecoxib effective for treatment of amyotrophic lateral sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16802291"
            ],
            "ideal_answer": [
                "No. In clinical trial celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe. A biological effect of celecoxib was not demonstrated in the cerebrospinal fluid. Further studies of celecoxib at a dosage of 800 mg/day in ALS were not recommended."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c6638717c78d69471000012",
            "snippets": [
                {
                    "offsetInBeginSection": 1197,
                    "offsetInEndSection": 1488,
                    "text": "NTERPRETATION: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe. A biological effect of celecoxib was not demonstrated in the cerebrospinal fluid. Further studies of celecoxib at a dosage of 800 mg/day in ALS are not warranted.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1365,
                    "text": "Prostaglandin E(2) levels in cerebrospinal fluid were not elevated at baseline and did not decline with treatment.<br><b>INTERPRETATION</b>: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16802291",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is DNA methylation an epigenetic modification of chromatin related to gene expression?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25512710",
                "http://www.ncbi.nlm.nih.gov/pubmed/23604474",
                "http://www.ncbi.nlm.nih.gov/pubmed/25534027",
                "http://www.ncbi.nlm.nih.gov/pubmed/22359296",
                "http://www.ncbi.nlm.nih.gov/pubmed/22078060",
                "http://www.ncbi.nlm.nih.gov/pubmed/25437055",
                "http://www.ncbi.nlm.nih.gov/pubmed/25531272",
                "http://www.ncbi.nlm.nih.gov/pubmed/22922032",
                "http://www.ncbi.nlm.nih.gov/pubmed/25514241",
                "http://www.ncbi.nlm.nih.gov/pubmed/22992936"
            ],
            "ideal_answer": [
                "Epigenetic changes such as DNA methylation alter gene expression at the level of transcription by upregulating, downregulating, or silencing genes completely."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0010467",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006306",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0000785"
            ],
            "type": "yesno",
            "id": "54d9f7894b1fd0d33c00000a",
            "snippets": [
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 164,
                    "text": "DNA methylation is a chemical modification of DNA involved in the regulation of gene expression by controlling the access to the DNA sequence. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25531272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 163,
                    "text": "Epigenetic marks such as DNA methylation play important biological roles in gene expression regulation and cellular differentiation during development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25534027",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "DNA methylation patterns are characterized by highly conserved developmental programs, but allow for divergent gene expression resulting from stochastic epigenetic drift or divergent environments.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25437055",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "DNA methylation plays a critical role in the regulation of gene expression. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25514241",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Epigenetic changes such as DNA methylation and histone methylation and acetylation alter gene expression at the level of transcription by upregulating, downregulating, or silencing genes completely.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25512710",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 358,
                    "text": "Dysregulation of epigenetic events can be pathological, leading to cardiovascular disease, neurological disorders, metabolic disorders, and cancer development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25512710",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "DNA methylation is a pervasive epigenetic DNA modification that strongly affects chromatin regulation and gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Epigenetic control, which includes DNA methylation and histone modifications, leads to chromatin remodeling and regulated gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23604474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "text": "Epigenetic modifications on the DNA sequence (DNA methylation) or on chromatin-associated proteins (i.e., histones) comprise the \"cellular epigenome\"; together these modifications play an important role in the regulation of gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22992936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 426,
                    "text": "Epigenetics is a process involved in gene regulation, mediated via DNA methylation, histone modification, chromatin remodeling, and functional noncoding RNAs, which influences the accessibility of the underlying DNA to transcriptional regulatory factors that activate or repress expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22359296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 101,
                    "offsetInEndSection": 322,
                    "text": "Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22078060",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is poly (ADP- ribosylation) involved in transcriptional control?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1828533",
                "http://www.ncbi.nlm.nih.gov/pubmed/9790974",
                "http://www.ncbi.nlm.nih.gov/pubmed/18396434",
                "http://www.ncbi.nlm.nih.gov/pubmed/17158748",
                "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
                "http://www.ncbi.nlm.nih.gov/pubmed/18851700"
            ],
            "ideal_answer": [
                "Yes, poly (ADP- ribosylation) plays a role in the maintenance of transcriptional fidelity."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020727",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006351",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070212"
            ],
            "type": "yesno",
            "id": "53380000d6d3ac6a34000059",
            "snippets": [
                {
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 547,
                    "text": "Histone phosphorylation, ubiquitylation, SUMOylation and poly-ADP-ribosylation, as well as ATP-dependent nucleosome remodeling complexes, play equally pivotal roles in the maintenance of transcriptional fidelity",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18851700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 188,
                    "text": "oly(ADP-ribose) polymerase-1 (PARP-1; EC 2.4.2.30) is an abundant nuclear protein that is involved in DNA repair, cell cycle control, programmed cell death and transcriptional regulation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18396434",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 213,
                    "text": "Many lines of evidence suggest that poly(ADP-ribose) polymerase-1 (Parp-1) is involved in transcriptional regulation of various genes as a coactivator or a corepressor by modulating chromatin structure",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1631,
                    "offsetInEndSection": 1765,
                    "text": "These results suggest that Parp-1 is required to maintain transcriptional regulation of a wide variety of genes on a genome-wide scale",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17286852",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 480,
                    "offsetInEndSection": 602,
                    "text": "PARP-1 was identified as a part of the mH2A1.1 nucleosome complex and was found to be associated with the Hsp70.1 promoter",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17158748",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1020,
                    "offsetInEndSection": 1174,
                    "text": "Upon heat shock, the Hsp70.1 promoter-bound PARP-1 is released to activate transcription through ADP-ribosylation of other Hsp70.1 promoter-bound proteins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17158748",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1028,
                    "offsetInEndSection": 1409,
                    "text": "Cycloheximide-induced cells were treated with two chemical inhibitors of poly(ADP-ribose) polymerase. 3-Aminobenzamide inhibited 75% of PAP gene induction and 4-hydroxyquinazolone, the highly specific inhibitor of the enzyme, blocked almost completely PAP expression, suggesting that ADP-ribosylation was indeed required for the upregulation of PAP gene expression by cycloheximide",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9790974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 471,
                    "offsetInEndSection": 589,
                    "text": " inhibitors of poly(ADP-ribose) polymerase suppressed UV-induced HIV-1 gene expression but not tat-mediated expression",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1828533",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 110,
                    "text": "oly(ADP-ribose) polymerase inhibitors suppress UV-induced human immunodeficiency virus type 1 gene expression",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1828533",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is cadasil syndrome a hereditary disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23799017",
                "http://www.ncbi.nlm.nih.gov/pubmed/23355563",
                "http://www.ncbi.nlm.nih.gov/pubmed/23587639",
                "http://www.ncbi.nlm.nih.gov/pubmed/21772710",
                "http://www.ncbi.nlm.nih.gov/pubmed/23221354",
                "http://www.ncbi.nlm.nih.gov/pubmed/23597439",
                "http://www.ncbi.nlm.nih.gov/pubmed/21197470",
                "http://www.ncbi.nlm.nih.gov/pubmed/24274803",
                "http://www.ncbi.nlm.nih.gov/pubmed/23465844",
                "http://www.ncbi.nlm.nih.gov/pubmed/23868154",
                "http://www.ncbi.nlm.nih.gov/pubmed/23394849",
                "http://www.ncbi.nlm.nih.gov/pubmed/23412372",
                "http://www.ncbi.nlm.nih.gov/pubmed/23799141",
                "http://www.ncbi.nlm.nih.gov/pubmed/23649698",
                "http://www.ncbi.nlm.nih.gov/pubmed/23308019",
                "http://www.ncbi.nlm.nih.gov/pubmed/23602593",
                "http://www.ncbi.nlm.nih.gov/pubmed/23460375",
                "http://www.ncbi.nlm.nih.gov/pubmed/23705041",
                "http://www.ncbi.nlm.nih.gov/pubmed/23832984",
                "http://www.ncbi.nlm.nih.gov/pubmed/23639391",
                "http://www.ncbi.nlm.nih.gov/pubmed/23584202"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
                    "o": "UMLS_CUI:C0751587"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
                    "o": "cadasil"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400718",
                    "o": "C499374"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1452875",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8407072"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400738",
                    "o": "Notch homolog 3 (Drosophila) protein, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400718",
                    "o": "NOTCH3 protein, human"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1452875",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400718"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1452875",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8407072"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1452875",
                    "o": "http://linkedlifedata.com/resource/umls/label/A8400738"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8407072",
                    "o": "CADASIL protein, human"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400738",
                    "o": "C499374"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8407072",
                    "o": "C499374"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/diseaseontology/id/DOID:13945",
                    "o": "MSH2010_2010_02_22:D046589"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400718",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8400738",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A8407072",
                    "o": "MeSH"
                }
            ],
            "ideal_answer": [
                "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebral small vessel disease, clinically characterized by migraine, recurrent transient ischemic attacks or strokes, psychiatric disorders and cognitive decline. Strokes are typically ischemic, while hemorrhagic events have been only sporadically described. CADASIL is the most common form of hereditary cerebral angiopathy."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D046589",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020271",
                "http://www.disease-ontology.org/api/metadata/DOID:225",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D030342",
                "http://www.disease-ontology.org/api/metadata/DOID:4",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=diseases_category",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004194",
                "http://www.disease-ontology.org/api/metadata/DOID:13945"
            ],
            "type": "yesno",
            "id": "532361fd9b2d7acc7e000013",
            "snippets": [
                {
                    "offsetInBeginSection": 23,
                    "offsetInEndSection": 487,
                    "text": " CADASIL is the most frequent hereditary small-vessel disease of the brain. The clinical impact of various MR imaging markers has been repeatedly studied in this disorder, but alterations of contrast between gray matter and normal-appearing white matter remain unknown. The aim of this study was to evaluate the contrast alterations between gray matter and normal-appearing white matter on T1-weighted images in patients with CADASIL compared with healthy subjects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23868154",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 158,
                    "text": " (CADASIL) is the most common form of hereditary cerebral angiopathy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23705041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 386,
                    "text": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebral small vessel disease, clinically characterized by migraine, recurrent transient ischemic attacks or strokes, psychiatric disorders and cognitive decline. Strokes are typically ischemic, while hemorrhagic events have been only sporadically described",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23639391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 233,
                    "text": "Mutations in the TREX1 and NOTCH3 genes cause retinal vasculopathy with cerebral leukodystrophy (RVCL) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), respectively",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23602593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 225,
                    "offsetInEndSection": 569,
                    "text": "We used immunohistochemistry and immunogold electron microscopy (EM) to examine the distribution of GOM and NOTCH3 ectodomain (N3ECD) protein in microvasculature of brain gray matter and white matter in patients with CADASIL, non-CADASIL hereditary small-vessel disease and sporadic age-related degenerative disease, and comparable-age controls",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23584202",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is LPS a microbial product?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25957290",
                "http://www.ncbi.nlm.nih.gov/pubmed/18406367",
                "http://www.ncbi.nlm.nih.gov/pubmed/26029695",
                "http://www.ncbi.nlm.nih.gov/pubmed/25259707"
            ],
            "ideal_answer": [
                "Yes, the lipopolysaccharide (LPS) is a component of the bacterial cell wall."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56e6f419a12c1fc13b000002",
            "snippets": [
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 321,
                    "text": "and microbial translocation [lipopolysaccaride (LPS), microbial 16S rDNA and sCD14] ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25259707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18406367",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 827,
                    "text": "bacterial lipopolysaccharide (LPS)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029695",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 327,
                    "text": "sterile bacterial wall lipopolysaccharide (LPS) to investigate the changes in innate lung microbiota",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957290",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does neuroglobin has neuroprotective properties in the setting of traumatic brain injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23658829",
                "http://www.ncbi.nlm.nih.gov/pubmed/24491879",
                "http://www.ncbi.nlm.nih.gov/pubmed/20345238",
                "http://www.ncbi.nlm.nih.gov/pubmed/20476562",
                "http://www.ncbi.nlm.nih.gov/pubmed/20544857",
                "http://www.ncbi.nlm.nih.gov/pubmed/25624825",
                "http://www.ncbi.nlm.nih.gov/pubmed/21915648",
                "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                "http://www.ncbi.nlm.nih.gov/pubmed/24642455"
            ],
            "ideal_answer": [
                "Yes, neuroglobin has neuroprotective properties in the setting of traumatic brain injury."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56c1d846ef6e39474100002e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Neuroglobin has shown rich neuroprotective effects against cerebral hypoxia, and therefore has the potential to impact outcomes after traumatic brain injury (TBI). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345238",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Neuroglobin (Ngb) is proposed to be a neuron-specific, hypoxia-responsive, neuroprotective protein. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20544857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 796,
                    "offsetInEndSection": 1081,
                    "text": "CONCLUSION: The increased expression of neuroglobin in traumatic brain injury informed us that neuroglobin had anti-apoptosis action in post-injury neuron. It could protect the neuron from traumatic stress and secondary ischemia and hypoxia insults during ultra-early and acute stages.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20476562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Neuroglobin-overexpression reduces traumatic brain lesion size in mice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "BACKGROUND: Accumulating evidence has demonstrated that over-expression of Neuroglobin (Ngb) is neuroprotective against hypoxic/ischemic brain injuries. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1201,
                    "text": "CONCLUSION: Ngb over-expression reduced traumatic lesion volume, which might partially be achieved by decreasing oxidative stress.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Neuroglobin upregulation offers neuroprotection in traumatic brain injury.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "OBJECTIVES: The aim of this study was to investigate rat neuroglobin (rNGB) expression level after traumatic brain injury (TBI) and further study its neuroprotective effects in TBI when it was overexpressed in adenoviral vector.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 955,
                    "offsetInEndSection": 1060,
                    "text": "CONCLUSIONS: NGB was upregulated in TBI and overexpressed rNGB had a significant neuroprotection in TBI. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1189,
                    "text": "This study suggested that rNGB overexpression may be a new strategy for treating of TBI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Neuroglobin has shown rich neuroprotective effects against cerebral hypoxia, and therefore has the potential to impact outcomes after traumatic brain injury (TBI).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345238",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "The aim of this study was to investigate rat neuroglobin (rNGB) expression level after traumatic brain injury (TBI) and further study its neuroprotective effects in TBI when it was overexpressed in adenoviral vector.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Accumulating evidence has demonstrated that over-expression of Neuroglobin (Ngb) is neuroprotective against hypoxic/ischemic brain injuries.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 334,
                    "text": "Various studies seem to indicate that neuroglobin is a neuroprotective agent when overexpressed, acting as a potent inhibitor of oxidative and nitrosative stress. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24491879",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are splicing speckles associated with transcription?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                "http://www.ncbi.nlm.nih.gov/pubmed/12011111",
                "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                "http://www.ncbi.nlm.nih.gov/pubmed/21086038",
                "http://www.ncbi.nlm.nih.gov/pubmed/20514231"
            ],
            "ideal_answer": [
                "Speckles contain little detectable transcriptional activity.",
                "yes"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5a8965f6fcd1d6a10c000005",
            "snippets": [
                {
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 388,
                    "text": "We show here that RNA splicing speckled domains (splicing speckles) fluctuate in constrained nuclear volumes and remodel their shapes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1339,
                    "text": "We present a model where recycling splicing factors return as part of small sub-speckles from distal sites of RNA processing to larger splicing speckles by a directed ATP-driven mechanism through interchromatin spaces.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 630,
                    "text": "Analysis of a HeLa cell line stably expressing EYFP-NHPX showed that the nucleolar accumulation of NHPX was preceded by its transient accumulation in splicing speckles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011111",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "In vivo analysis of NHPX reveals a novel nucleolar localization pathway involving a transient accumulation in splicing speckles.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011111",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 319,
                    "text": "\"Splicing speckles\" are major nuclear domains rich in components of the splicing machinery and polyA(+) RNA. Although speckles contain little detectable transcriptional activity, they are found preferentially associated with specific mRNA-coding genes and gene-rich R bands, and they accumulate some unspliced pre-mRNAs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 474,
                    "text": "RNA polymerase II transcribes mRNAs and is required for splicing, with some reports suggesting that the inactive complexes are stored in splicing speckle",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 412,
                    "offsetInEndSection": 565,
                    "text": "In normal cell growth conditions GFPeIF4A-III was mainly nucleoplasmic, but in hypoxia stress conditions it moved to the nucleolus and splicing speckles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514231",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Localization of eIF4A-III in the nucleolus and splicing speckles is an indicator of plant stress.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514231",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 618,
                    "text": " Using antibodies raised against mouse RBM6 to immunostain mammalian cell lines we found that the endogenous protein was both distributed diffusely in the nucleus and concentrated in a small number of nuclear foci that corresponded to splicing speckles/interchromatin granule clusters (IGCs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21086038",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Subnuclear targeting of the RNA-binding motif protein RBM6 to splicing speckles and nascent transcripts.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21086038",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Do all archaea possess multiple origins of DNA replication?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25309521",
                "http://www.ncbi.nlm.nih.gov/pubmed/24822028",
                "http://www.ncbi.nlm.nih.gov/pubmed/24185008",
                "http://www.ncbi.nlm.nih.gov/pubmed/14718164",
                "http://www.ncbi.nlm.nih.gov/pubmed/21364800",
                "http://www.ncbi.nlm.nih.gov/pubmed/15337158",
                "http://www.ncbi.nlm.nih.gov/pubmed/24808892"
            ],
            "ideal_answer": [
                "Origins of DNA replication differ in number and structure across the three domains of life and their properties determine the dynamics of chromosome replication. Though most archaea replicate their chromosomes using multiple origins, there are also certain archaea that possess a single origin of DNA replication (such as Pyrococcus abyssi and some archaea belonging in the hyperthermophilic order of Themococcales)."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0006260",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004261",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0003688",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018741"
            ],
            "type": "yesno",
            "id": "5547d72ef35db75526000008",
            "snippets": [
                {
                    "offsetInBeginSection": 151,
                    "offsetInEndSection": 424,
                    "text": "Origins differ in number and structure across the three domains of life and their properties determine the dynamics of chromosome replication. Bacteria and some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24185008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 508,
                    "text": "Replication starts at a single Ori site in bacteria, but in eukaryotes multiple Ori sites are used for fast copying across all chromosomes. The situation becomes complex in archaea, where some groups have single and others have multiple origins of replication.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21364800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1221,
                    "offsetInEndSection": 1322,
                    "text": "Results from this in silico analysis show that the Themococcales have a single origin of replication.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21364800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "text": "Until recently, the only archaeon for which a bona fide origin of replication was reported was Pyrococcus abyssi, where a single origin was identified. Although several in silico analyses have suggested that some archaeal species might contain more than one origin, this has only been demonstrated recently.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15337158",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 298,
                    "offsetInEndSection": 445,
                    "text": "In bacteria and eukaryotes, replication initiates from single and multiple origins, respectively, while archaea can adopt either of the two modes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24822028",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 422,
                    "text": "Bacteria and some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24185008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 423,
                    "text": "Bacteria and some archaea replicate from single origins, whereas most archaea and all eukaryotes replicate using multiple origins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24185008",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does metformin alleviate atherosclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
                "http://www.ncbi.nlm.nih.gov/pubmed/17307426",
                "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
                "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
                "http://www.ncbi.nlm.nih.gov/pubmed/29499335",
                "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
                "http://www.ncbi.nlm.nih.gov/pubmed/22672501",
                "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                "http://www.ncbi.nlm.nih.gov/pubmed/27737949"
            ],
            "ideal_answer": [
                "Yes. Metformin has been shown to decrease frequency of atherosclerosis-associated adverse effects in statin-intolerant patients and to slow the pathogenesis of type 2 diabetes mellitus.",
                "Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission.",
                "Yes. Metformin has been shown to decrease frequency of atherosclerosis-associated adverse effects in statin-intolerant patients and to slow the pathogenesis of type 2 diabetes.",
                "Coupled with their proven good safety profile these findings could translate into a significant clinical benefit. Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
                "Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
                "Yes. Metformin has been shown in a number of clinical trial to prevent and attenuate atherosclerosis.",
                "Several recently completed randomized clinical trials have reported effects of metformin on surrogate measures of atherosclerotic vascular disease. Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory response."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d38462b7bc3fee31f000012",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 184,
                    "text": "Metformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti-inflammatory and anti-atherosclerotic properties. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1407,
                    "text": "Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672501",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 27,
                    "offsetInEndSection": 95,
                    "text": "pleiotropic benefits of metformin in attenuation of atherosclerosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1056,
                    "offsetInEndSection": 1140,
                    "text": "Pleiotropic effects of metformin ameliorate atherosclerosis and vascular senescence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1408,
                    "offsetInEndSection": 1553,
                    "text": "Metformin attenuated Ang-II-induced atheromatous plaque formation and aortic aneurysm in ApoE(-/-) mice partly by reducing monocyte infiltration.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 258,
                    "text": "Metformin, an anti-diabetic drug, was reported to possess anti-atherosclerotic effects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1226,
                    "offsetInEndSection": 1598,
                    "text": " In cultured macrophages, co-treatment with metformin and atorvastatin promoted cholesterol efflux and up-regulated expression of ATP-binding cassette transporters A1 and G1. Taken together, our results suggest that atorvastatin/metformin combination therapy may achieve additional anti-atherosclerotic benefits likely through increasing cholesterol efflux in macrophages.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 366,
                    "text": "metformin abated the progression of diabetes-accelerated atherosclerosis by inhibiting mitochondrial fission in endothelial cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1681,
                    "text": "metformin attenuated the development of atherosclerosis by reducing Drp1-mediated mitochondrial fission in an AMPK-dependent manner. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 276,
                    "text": "metformin's effects on lipids and atherosclerotic vascular disease and/or provide insights into the drug's mechanisms of action on the heart and vasculature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 500,
                    "text": "Several recently completed randomized clinical trials have reported effects of metformin on surrogate measures of atherosclerotic vascular disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29499335",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1605,
                    "offsetInEndSection": 1759,
                    "text": "Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the gene DUX4 epigenetically regulated in somatic cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23969240",
                "http://www.ncbi.nlm.nih.gov/pubmed/22522912",
                "http://www.ncbi.nlm.nih.gov/pubmed/23196547",
                "http://www.ncbi.nlm.nih.gov/pubmed/23272181",
                "http://www.ncbi.nlm.nih.gov/pubmed/24278031",
                "http://www.ncbi.nlm.nih.gov/pubmed/21288772",
                "http://www.ncbi.nlm.nih.gov/pubmed/23593020",
                "http://www.ncbi.nlm.nih.gov/pubmed/24940479",
                "http://www.ncbi.nlm.nih.gov/pubmed/21734574",
                "http://www.ncbi.nlm.nih.gov/pubmed/22871573",
                "http://www.ncbi.nlm.nih.gov/pubmed/22025602",
                "http://www.ncbi.nlm.nih.gov/pubmed/21060811",
                "http://www.ncbi.nlm.nih.gov/pubmed/23143600"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16475868",
                    "o": "C532958"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2607370",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16475868"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16475868",
                    "o": "Dux4 protein, mouse"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16475868",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3832170",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1317909",
                    "o": "http://linkedlifedata.com/resource/umls/label/A3832170"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3832170",
                    "o": "DUX4 protein, human"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1317909",
                    "o": "http://linkedlifedata.com/resource/umls/label/A3840964"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3840964",
                    "o": "double homeobox, 4 protein, human"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A3840964",
                    "o": "MeSH"
                }
            ],
            "ideal_answer": [
                "The human double-homeodomain retrogene DUX4 is expressed in the testis and epigenetically repressed in somatic tissues. Recent studies provide evidence that  DUX4 is expressed in the human germline and then epigenetically silenced in somatic cells.",
                "Yes, the human double-homeodomain retrogene DUX4 is expressed in the testis and epigenetically repressed in somatic tissues.",
                "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues.   ",
                "The human double-homeodomain retrogene DUX4 is expressed in the testis and epigenetically repressed in somatic tissues.DUX4, a retrogene contained in the D4Z4 repeats, is normally epigenetically silenced in somatic cells."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063185",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044127",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0040029",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0040030",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057890",
                "http://www.uniprot.org/uniprot/DUX4_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0045858"
            ],
            "type": "yesno",
            "id": "55152c2946478f2f2c000005",
            "snippets": [
                {
                    "offsetInBeginSection": 590,
                    "offsetInEndSection": 853,
                    "text": "There are several genes on chromosome 4q35 region including DUX4 within D4Z4 repeats. Transcription of these genes is usually repressed by epigenetic modifications of this chromosomal region and also accumulation of transcriptional repressors to the repeat array.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 399,
                    "text": "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "The human double-homeodomain retrogene DUX4 is expressed in the testis and epigenetically repressed in somatic tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 685,
                    "offsetInEndSection": 1029,
                    "text": " These mice recapitulate important epigenetic and DUX4 expression attributes seen in patients and controls, respectively, including high DUX4 expression levels in the germline, (incomplete) epigenetic repression in somatic tissue, and FSHD-specific variegated DUX4 expression in sporadic muscle nuclei associated with D4Z4 chromatin relaxation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 681,
                    "text": "DUX4, a retrogene contained in the D4Z4 repeats, is normally epigenetically silenced in somatic cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1018,
                    "offsetInEndSection": 1625,
                    "text": "In contrast to control skeletal muscle and most other somatic tissues, full-length DUX4 transcript and protein is expressed at relatively abundant levels in human testis, most likely in the germ-line cells. Induced pluripotent (iPS) cells also express full-length DUX4 and differentiation of control iPS cells to embryoid bodies suppresses expression of full-length DUX4, whereas expression of full-length DUX4 persists in differentiated FSHD iPS cells. Together, these findings indicate that full-length DUX4 is normally expressed at specific developmental stages and is suppressed in most somatic tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 398,
                    "text": "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 682,
                    "text": "DUX4, a retrogene contained in the D4Z4 repeats, is normally epigenetically silenced in somatic cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 640,
                    "text": "DUX4, a retrogene contained in the D4Z4 repeats, is normally epigenetically silenced in somatic cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 396,
                    "text": "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 897,
                    "text": "Normally expressed in the testis and epigenetically repressed in somatic tissues, DUX4 expression in skeletal muscle induces expression of many germline, stem cell, and other genes that might account for the pathophysiology of FSHD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24940479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 396,
                    "text": "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "The human double-homeodomain retrogene DUX4 is expressed in the testis and epigenetically repressed in somatic tissues",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24278031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 899,
                    "text": "Normally expressed in the testis and epigenetically repressed in somatic tissues, DUX4 expression in skeletal muscle induces expression of many germline, stem cell, and other genes that might account for the pathophysiology of FSHD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24940479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 645,
                    "text": "DUX4, a retrogene contained in the D4Z4 repeats, is normally epigenetically silenced in somatic cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734574",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 397,
                    "text": "Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21288772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1755,
                    "offsetInEndSection": 2022,
                    "text": "The identification of the gene(s) and the exact epigenetic pathway underlining this disease will be mandatory to increase the rate of diagnosis for FSHD2 patients and to confirm the hypothesis of a common FSHD1 and FSHD2 pathophysiological pathway involving DUX4 gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23969240",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 594,
                    "text": "This deletion induces epigenetic modifications that affect the expression of several genes located in the vicinity. In each D4Z4 element, we identified the double homeobox 4 (DUX4) gene. DUX4 expresses a transcription factor that plays a major role in the development of FSHD through the initiation of a large gene dysregulation cascade that causes myogenic differentiation defects, atrophy and reduced response to oxidative stress. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23272181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 497,
                    "offsetInEndSection": 581,
                    "text": "decreased epigenetic repression and variegated expression of DUX4 in skeletal muscle",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 862,
                    "offsetInEndSection": 915,
                    "text": "(incomplete) epigenetic repression in somatic tissue,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23593020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 232,
                    "text": "derepression of the DUX4 retrogene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22871573",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 356,
                    "text": "The aim of our study was to identify relationships between epigenetic parameters correlating with a relaxed chromatin state of the DUX4 promoter region and clinical severity as measured by a clinical severity score or muscle pathologic changes in D4Z4 contraction-dependent (FSHD1) and -independent (FSHD2) facioscapulohumeral muscular dystrophy patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22522912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1162,
                    "text": "Specifically, abundance of RNA transcripts encoded by the DUX4 locus correlated to differential DNA methylation and H3K36me3 enrichment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22025602",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1472,
                    "offsetInEndSection": 1623,
                    "text": "Together, these findings indicate that full-length DUX4 is normally expressed at specific developmental stages and is suppressed in most somatic tissue",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21060811",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can Enlimomab improve stroke outcomes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
                "http://www.ncbi.nlm.nih.gov/pubmed/12365824",
                "http://www.ncbi.nlm.nih.gov/pubmed/9693236",
                "http://www.ncbi.nlm.nih.gov/pubmed/12038658",
                "http://www.ncbi.nlm.nih.gov/pubmed/9744839",
                "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                "http://www.ncbi.nlm.nih.gov/pubmed/11692032"
            ],
            "ideal_answer": [
                "No. Anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke and, indeed, may significantly worsen stroke outcome."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e44c33a48dab47f26000020",
            "snippets": [
                {
                    "offsetInBeginSection": 1772,
                    "offsetInEndSection": 2068,
                    "text": "Treatment with a murine anti-ICAM-1 antibody (enlimomab) has been investigated in patients with acute ischemic stroke in the Enlimomab Acute Stroke Trial (EAST). Unfortunately, the case fatality rate in this trial was significantly higher in the enlimomab patient group than in the placebo group.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 351,
                    "text": "The two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12365824",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 696,
                    "text": "en classes of neuroprotective agents have reached phase III efficacy trials but have shown mixed results. They included calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilazad and ebselen, enlimomab, GABA agonist clomethiazole, the sodium channel antagonist fosphenytoin, magnesium, glycine site antagonist GV150526 and piracetam. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12038658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "BACKGROUND AND PURPOSE: Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 907,
                    "offsetInEndSection": 1358,
                    "text": "ESULTS: At day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004). Fewer patients had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%). The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005). There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1434,
                    "offsetInEndSection": 1630,
                    "text": "CONCLUSIONS: The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1440,
                    "offsetInEndSection": 1636,
                    "text": "CONCLUSIONS\n\nThe authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1247,
                    "offsetInEndSection": 1362,
                    "text": "There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 910,
                    "offsetInEndSection": 1037,
                    "text": "RESULTS\n\nAt day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1246,
                    "text": "The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1441,
                    "offsetInEndSection": 1524,
                    "text": "However, this treatment failed to show benefit in the Enlimomab Acute Stroke Trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9744839",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1242,
                    "offsetInEndSection": 1357,
                    "text": "There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1797,
                    "offsetInEndSection": 1974,
                    "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 910,
                    "offsetInEndSection": 1037,
                    "text": "RESULTS\nAt day 90, the Modified Rankin Scale score was worse in patients treated with enlimomab than with placebo (p = 0.004).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1934,
                    "offsetInEndSection": 2069,
                    "text": "Unfortunately, the case fatality rate in this trial was significantly higher in the enlimomab patient group than in the placebo group.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19849665",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1505,
                    "text": "CONCLUSIONS\nDoses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 +/- 10 days.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9693236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 15,
                    "offsetInEndSection": 176,
                    "text": "PURPOSE: Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1791,
                    "offsetInEndSection": 1968,
                    "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1739,
                    "offsetInEndSection": 1916,
                    "text": "These observations provide several possible mechanisms for central nervous system-related clinical deterioration that occurred when Enlimomab was given in acute ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11692032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1407,
                    "offsetInEndSection": 1590,
                    "text": "The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11673584",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}